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Abstract 
P2X4 is a ligand-gated cation channel that is widely expressed amongst immune 
cells, especially in monocytes and macrophages. Despite its expression profile, the 
functional role of P2X4 in human macrophages has not been elucidated. This study 
aimed to (i) investigate the contribution of P2X4 towards ATP-evoked Ca2+ 
responses and (ii) determine the role of P2X4 towards cytokine production in human 
macrophages. Here, human THP-1-differentiated macrophages (TDM) and primary 
monocyte-derived macrophages (MDMs) were utilized as human macrophage 
models to investigate the contribution of P2X4 by means of Ca2+ measurements, 
mRNA expression analysis and cytokine secretion assays. A side-by-side 
comparison study of MDM generated through stimulation with either GM-CSF (GM-
MDM) or M-CSF (M-MDM) illustrated that P2X4 has a bigger contribution towards 
ATP-evoked Ca2+ responses in GM-MDM cells. In GM-MDM cells, P2Y11 and P2Y13 
activation both contributed towards the amplitude and sustained phase of response, 
while P2X4, but not P2X1 or P2X7, activation contributed towards the sustained 
phase of ATP-evoked Ca2+ response. Employment of a cytokine and chemokine 
mRNA profiler array in GM-MDM revealed that 100 µM ATP induced transforming 
growth factor-b2 (TGF-b2) and C-X-C motif chemokine 5 (CXCL5). Selective 
antagonism of P2X4 with PSB-12062 positively modulated ATP-mediated induction 
of TGF-b2 gene expression while it inhibited ATP-mediated induction of CXCL5 
gene expression. Although the effect on TGF-b2 was not translated at a protein 
level, PSB-12062 inhibited ATP-mediated induction of CXCL5 protein synthesis and 
secretion. Reciprocally, positive allosteric modulation of P2X4 with ivermectin 
augmented ATP-mediated CXCL5 secretion. Inhibition of P2X7, P2Y11 or P2Y13 had 
no effect on CXCL5 secretion. Altogether, we have identified a role for P2X4 
activation in determining the duration of ATP-evoked intracellular Ca2+ response 
and stimulating induction and secretion of CXCL5 in human primary macrophage. 
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Chapter 1: Introduction 
1.1 Innate immune system  
The immune system is a complex network involving various cellular and molecular 
components with specialized roles in defending the host against foreign materials. It 
can be categorized into two fundamentally different responses: the innate ‘natural’ 
response and the acquired ‘adaptive’ response. The innate response provide 
immediate host defense through involvement of various cells in combination with its 
molecular components such as complement, cytokines and acute phase proteins 
(Delves and Roitt, 2000). Cells involved in the innate response include natural killer 
cells, phagocytic cells such as neutrophils, monocytes and macrophages and cells 
that release inflammatory mediators such as basophils, eosinophils and mast cells. 
Though rapid in its actions, innate response can damage normal tissues due to the 
lack of specificity. On the other hand, acquired responses often take several days to 
weeks to develop and involve a series of key reactions such as antigen-specific 
responses achieved through activity of T- and B-lymphocytes in driving effector 
responses (Parkin and Cohen, 2001).  
 
The innate immune response is initiated upon the recognition of danger signals by 
pattern recognition receptors (PRRs) found either on the cell surface or internally in 
host immune cells (Mogensen, 2009). These danger signals include pathogen-
associated molecular patterns (PAMPs) such as foreign microbial challenge, or 
damage-associated molecular patterns (DAMPs) resulting from cellular damage or 
death (Mogensen, 2009, Janeway et al., 2001). The recognition of PAMPs and 
DAMPs by PRRs initiate a cascade of responses within the host that leads to the 
activation of intracellular signaling pathways such as kinases, transcription factors 
and adaptor molecules. These ultimately activate gene expression and synthesis of 
a broad range of molecules such as cytokines, chemokines, cell adhesion 
molecules and immunoreceptors, all of which are important in initiating early host 
response against infection and provide an important link towards adaptive immune 
response (Janeway et al., 2001, Mogensen, 2009). The first part of this chapter will 
focus on one type of cell crucial for the immune system, macrophages – their origin, 
different phenotypes resulting from polarization as well as their functions. This will 
be followed by an introduction on calcium signaling and the purinergic receptors, 
specifically how they relate to macrophages. Finally, the aims of the project will be 
discussed.   
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1.2 Macrophages  
 
1.2.1 Development and Differentiation Theories  
Since first introduced by Metchnikoff in 1892 as large phagocytic cells 
‘macrophages’, the origin and differentiation of macrophages have been studied 
and debated significantly. Various theories have been proposed regarding their 
origin however, two theories raised major attention: the reticuloendothelial system 
(RES) proposed by Aschoff (1924) and one described much later, the mononuclear 
phagocyte system developed by van Furth et al. (1972).  
 
1.2.1.1 Reticuloendothelial system (RES) theory  
The RES theory detailed that macrophages belong to a system of reticulum cells, 
categorized as a single cell system of local tissue origin and properties (Aschoff, 
1924). Studies using lithium carmine allowed the categorization of reticulum cells 
into reticuloendothelial (phagocytic endothelia) and histocytes (tissue 
macrophages). This concept was widely accepted initially until the end of 1960s, 
following several contradicting issues. First, Aschoff had no confirmation from his 
own research to back up the statement that all reticulum cells were related in terms 
of origin. Following 20 years of research by a different group, it was identified that 
histocytes and reticulum cells differed significantly in terms of cell morphology, 
function and origin (Akazaki, 1962, Takahashi et al., 1996). The second issue was 
that the proposal of the RES theory relied heavily on the use of lithium carmine 
which Aschoff believed to be taken up by reticulum cells through phagocytosis. 
However, studies by Lewis et al., (1931) illustrated that all living cells can take up 
materials by pinocytosis and de Duve (1969) demonstrated the ability of lithium 
carmine to accumulate in large lysosomal granules of reticulum cells which 
appeared to be mistaken for any evidence of phagocytosis observed in 
macrophages. These evidences, together with advances in technology post 1960s, 
allowed further confirmation that macrophages were in fact distinct from reticulum 
cells and endothelial cells.  
 
1.2.1.2 Mononuclear phagocyte system (MPS) theory  
The second and more accepted theory of macrophage origin and differentiation was 
described by van Furth in 1972. The MPS theory defined that all macrophages, 
including those appearing in inflammatory foci and those residing in tissues under 
normal quiescent conditions, are derived from monocytes. These monocytes are 
 
21 
	
differentiated from promonocytes and monoblasts originating in the bone marrow 
(Figure 1.1) (Takahashi et al., 1996). In addition to this, van Furth also described 
that all macrophages have no proliferative capacity and to be short-lived terminal 
cells of the MPS. Since the establishment of MPS theory however, various 
conflicting data have been raised. First, phylogenetic observations of macrophages 
illustrated that they emerge before the development of monocytic cells contradicting 
the idea that all macrophages are derived from monocytes (Dzierzak and 
Medvinsky, 1995, Takahashi et al., 1996). Secondly, studies by several groups 
challenged the idea that all macrophages are short-lived and non-dividing. In a 
study of parabiosis by Parwaresch and Wacker (1984), they found that half of 
peritoneal macrophages can survive by cell division while a study by Volkman 
(1976) identified that tissue macrophages such as peritoneal and pulmonary 
alveolar can survive a long time by self-renewal, without a supply of circulating 
monocytes. These findings illustrated that while monocyte-derived macrophages 
can last in peripheral tissues for approximately two weeks, tissue macrophages (i.e. 
Kupffer cells) can last up to five weeks. Therefore, although MPS theory has helped 
to define the differentiation of monocytic cells into macrophages in the context of 
inflammatory lesions, it is still unclear if under quiescent state, all tissue 
macrophages are derived from monocytes alone. Despite these contradictions, 
MPS remain to be the leading theory describing the origin of macrophages.  
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Figure 1.1. The mononuclear phagocyte system (MPS). Illustration describing 
suggested origin of macrophages from monocytes as described by van Furth 
(1972). This model describes that monocytes are differentiated from promonocytes 
and monoblasts that originate within the bone marrow. These monocytes can then 
differentiate into macrophages with the help of colony stimulating factors such as 
macrophage colony-stimulating factor (M-CSF) or granulocyte macrophage-colony 
stimulating factor (GM-CSF). Adapted from van Furth (1980).  
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1.2.2 Macrophage subpopulations and development  
Two major macrophage populations have been described in literature, participating 
at different stages of inflammation: tissue-resident macrophages and monocyte-
derived macrophages (Daems et al., 1976, Davies and Taylor, 2015, Lahmar et al., 
2016). Although the majority of our knowledge on the development of macrophages 
comes from research in mouse models, the human embryonic hematopoietic 
system is thought to be organized in a similar manner to mice (Tavian and Peault, 
2005). Initially, tissue-resident macrophages are thought to solely be derived from 
circulating monocytes, which are supplied by bone marrow hematopoietic stem cells 
(HSC) (Geissmann et al., 2010). However, further studies illustrated that in humans, 
macrophages could arise in the embryo through a process independent of the bone 
marrow progenitors. The current knowledge describes that macrophages in fetal 
and adult tissues are derived from three possible sources which includes the yolk 
sac, the fetal liver and the bone marrow. The bone marrow is thought to give rise to 
tissue resident bone marrow derived macrophages and inflammatory bone marrow 
monocyte-derived macrophages. 
 
1.2.2.1 Tissue-resident macrophage 
Tissue-resident macrophages are heterogeneous cells, which represents up to 10-
15% of total cell number in steady-state conditions (Italiani and Boraschi, 2014). 
They are found in every tissue of an adult mammal and display unique location-
specific phenotypes and gene expression profiles. Macrophages have been 
described to play critical roles in innate immune system as well as development and 
homeostasis of the tissue in which they reside (Haldar and Murphy, 2014). 
Specialization of macrophages in different microenvironments means that they are 
defined with different names according to their location within tissue (Table 1.1). 
Examples of this include: microglia (CNS), osteoclasts (bone), alveolar (lung), 
histocytes (connective tissue), Kupffer cells (liver) and Langerhans cells (skin) 
(Italiani and Boraschi, 2014). Although displaying highly different transcriptional 
profiles, macrophages of different tissue origin possess similar basic functions such 
as phagocytosis, antigen presentation and wound-healing, all of which will be 
described in greater detail in section 1.2.3 (Gautier et al., 2012). It is thought that 
unlike monocyte-derived macrophages, tissue-resident macrophages in most 
tissues do not require an ongoing supply from circulating monocytes and instead, 
they can be maintained through a self-renewal process. In steady-state conditions, 
tissue-resident macrophages can proliferate at low levels; however, in situations 
where macrophages are depleted or during an inflammatory challenge, this 
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proliferation rate greatly increase (Hashimoto et al., 2013, Sieweke and Allen, 
2013). Despite much effort to increase understanding on tissue-resident 
macrophage development, it is still poorly understood and awaits further work.  
 
1.2.2.2 Monocyte-derived macrophages  
In response to an inflammatory reaction, an increase in effector cell number is 
observed within the tissue. These effector cells are also known as monocyte-
derived macrophages (Italiani and Boraschi, 2014). The increase in monocyte-
derived macrophages at inflammatory sites is usually a result of the drastic loss of 
resident macrophages due to tissue adherence, emigration and death (Barth et al., 
1995, Italiani and Boraschi, 2014). Hence, two strategies are recruited as a 
mechanism to cope with the reduced number of effector cells within tissues. The 
first includes blood monocytes recruitment into tissue, which is driven by resident 
macrophages in combination with other cells within the tissue. These recruited 
monocytes are a source of inflammatory macrophages or also known as monocyte 
derived macrophages. The second mechanism is to increase the number of tissue 
resident macrophages proliferation, which is achieved through the enhancement of 
their self-renewal properties (Italiani and Boraschi, 2014).  
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Table 1.1 Types of tissue-resident macrophages depending on their 
localization and their specialized function. Different names are allocated for the 
different macrophages depending on tissue locations. Despite having specialized 
functions within the tissues, these macrophages in general possess similarities in 
their function which will be described in greater detail in section 1.2.1.3. Adapted 
from Italiani and Boraschi (2014).  
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1.2.3 Macrophage Function 
Macrophages are a heterogeneous population of cells widely and ubiquitously 
distributed throughout various tissues and organs of vertebrates. They possess 
different cell morphology and variable functions depending on which tissue they 
reside in, as described in Table 1.1. In addition to specific roles of tissue-resident 
macrophages, they share a series of common functions that include phagocytosis, 
immune surveillance, antigen presentation, cytokine secretion and wound healing 
(Arango Duque and Descoteaux, 2014). Each of these functions will be discussed 
further below.  
 
1.2.3.1 Phagocytosis  
Macrophages are specialized cells involved in phagocytosis within the immune 
system – a process that involves the internalization of large particles such as 
pathogens, apoptotic cells and debris into phagosomes. Phagocytosis is considered 
the first step in triggering host defense and inflammation and is required for the 
removal of enormous numbers of apoptotic cells (Aderem, 2003). The removal of 
particles through phagocytosis is thought to involve four basic steps: 1) pathogen is 
recognized by receptors present on the surface of macrophages, 2) signaling 
pathway is activated resulting in polymerization of actin, 3) actin-rich membrane is 
extended to reach out to particles and pull them towards the center of the cell, and 
finally 4) phagosomes mature into phagolysosome (Aderem, 2003). Phagolysosome 
is an acidic and hydrolytic compartment that can kill and digests pathogens in 
preparation for antigen presentation. 
 
1.2.3.2 Immune Surveillance and Initiation of Inflammation 
Macrophages are key immune cells involved in maintaining homeostasis and 
performing immune surveillance. In quiescent state, macrophages secrete very low 
levels of pro-inflammatory mediators, which is insufficient to initiate inflammation. 
However, upon exposure to pro-inflammatory mediators (i.e. cytokines, interferons), 
microbial products and DAMPs, macrophages acquire a pro-inflammatory 
phenotype resulting in the secretion of a vast array of mediators and cytokines 
(Arango Duque and Descoteaux, 2014). These cytokines include IL-1, IL-6, IL-12, 
TNF-a and inducible nitric oxide synthase (Figure 1.2). In addition to this, 
macrophages also produce chemoattractants (i.e. chemokines) that can recruit 
additional leukocytes to participate in the resolution of inflammation (Arango Duque 
and Descoteaux, 2014).  
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Figure 1.2. Monocytes can differentiate to become phenotypically distinct 
macrophages. Upon exposure to different stimuli, monocytes differentiate into 
either pro-inflammatory (M1), or anti-inflammatory (M2) macrophages. These stimuli 
include microbial substances as well as biochemical signals present in the 
microenvironment. Macrophage polarization depends on the presence of various 
cytokines, which are provided by lymphocytes, and other non-immune cells. 
Following polarization towards M1/M2, macrophages secrete vast array of cytokines 
and chemokines that can either promote inflammation or wound healing/tissue 
repair. Adapted from Duque and Descoteaux (2014). 
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1.2.3.3 Antigen Presentation  
In the innate immune system, some immune cells can act as professional antigen-
presenting cells (APCs) with a main role in presenting antigen to T cells to induce 
their activation during inflammatory responses. To activate T cells, APC must first 
degrade native proteins into peptides which can then be fed onto major 
histocompatibility complex (MHC) molecules. Two MHC molecules exist: class 1 for 
CD8-expressing T cells and class II for CD4-expressing T cells (Sprent, 1995). 
Once on the surface, the peptide-bound MHC molecules on APC are recognized by 
T cells via specific ab T-cell receptors. These are then able to manifest effector 
function of activated T cells within the adaptive immune system. 
 
The taking up and presentation of antigen is a process that links together the innate 
and adaptive immune system and is therefore considered one of the most crucial 
features of tissue macrophages (Ley, 2014). Many studies have revealed the ability 
of tissue-resident macrophages in participating as APCs. This includes a recent 
study by Morris et al. (2013) illustrating the ability of adipose tissue macrophages as 
APCs to regulate adipose tissue CD4+ T cells in mice. In addition to this, it has also 
been speculated that inflammatory monocyte-derived cells with M1-like functional 
phenotype act as APC that activate/polarize effector Th1 and Th17 cells upon 
generation of IL-12 and IL-23, respectively. In a similar manner, M2-like tissue 
macrophages are likely to be involved in the polarization of iTreg cells, while their 
role in Th2 polarization is not as clearly understood (Ley, 2014, Mills and Ley, 2014).  
 
1.2.3.4 Cytokine Secretion  
Cytokines are a group of small proteins that play an important role in cell signaling. 
They are produced mainly by macrophages and lymphocytes, although other cells 
such as endothelial cells, epithelial cells and adipocytes are also capable of 
cytokine production (Arango Duque and Descoteaux, 2014). In macrophages, 
cytokines are crucial in determining their polarization and mediating their transition 
from innate to adaptive immunity (Unanue et al., 1976). Depending on the origin 
and the microenvironment that they reside in, macrophages can be categorized into 
several subsets which include either ‘classically’ M1 or ‘alternatively’ M2 activated. 
Each of the two subsets of macrophages secretes different cytokines: pro-
inflammatory (M1) or anti-inflammatory (M2) (Figure 1.2). The release of cytokines 
involves an orchestrated pathway that is spatiotemporally regulated. The 
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dysregulation of cytokine secretion is often implicated with disease states that range 
from allergy to chronic inflammation (Arango Duque and Descoteaux, 2014).  
 
1.2.3.5 Wound healing  
One of the more interesting roles of macrophage in the immune system is their 
ability to promote wound healing. In fact, macrophages play such an important role 
in this process that Mosser & Edwards (2008) attempted to classify macrophages 
into three categories based on their homeostatic function: host defence, immune 
regulation and wound healing. In vitro studies revealed that macrophages can 
transition from a pro-inflammatory phenotype towards an anti-inflammatory or 
reparative phenotype (Fadok et al., 1998). This transition is a requisite for the switch 
from inflammation to proliferation in the wound healing process (Fadok et al., 1998). 
Although it was initially assumed that IL-4/IL-13 are the canonical factors 
responsible for the generation of anti-inflammatory macrophage phenotype, recent 
studies suggest that it may involve an IL-4/IL-13 independent pathway (Daley et al., 
2010). It is speculated that this alternative pathway involves the activation of TLRs 
which induces the activation of adenosine 2A receptor giving rise to an M2 
phenotype.  
 
Macrophages play a key role in wound healing as they retain the ability to remove 
neutrophils, which are often abundant in early wounds (Koh and DiPietro, 2011). 
This is an essential process as excessive number of neutrophils can negatively 
influence repair, causing damage to normal tissue (Dovi et al., 2003). Removal of 
neutrophils from sites of injuries by macrophages can be performed in several 
ways: 1) inducing apoptosis in neutrophils (Meszaros et al., 2000), and 2) 
recognizing and ingesting apoptotic neutrophils through phagocytosis to resolve 
wound inflammation (Khanna et al., 2010, Meszaros et al., 1999). This latter 
mechanism of removal is thought to drive phenotypic change of macrophages from 
pro-inflammatory to the reparative phenotype (Fadok et al., 1998).  
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1.2.4 Macrophage polarization and functional phenotypes  
Macrophages are remarkably plastic and flexible cells that are able to alter their 
physiological characteristics following the exposure to varying environmental cues, 
hence giving rise to different populations of cells with distinct functions. The process 
describing perturbation of macrophages with endogenous danger signals (such as 
debris of necrotic cells or ATP) and exogenous agents (such as cytokines, microbes 
or microbial products) is known as macrophage activation or polarization. The 
polarization of macrophages is a crucial process involved in the outcome of many 
diseases and various macrophage taxonomy has been described in an attempt to 
classify the different populations of macrophages. Two taxonomy have been 
discussed thoroughly within the literature: 1) the M1/M2 classification which imitate 
the Th cell nomenclature (Martinez and Gordon, 2014) and 2) classification by 
Mosser and Edwards (2008) based on macrophage functions (wound healing, host-
defense and immune regulation). Here, only the M1/M2 classifications of 
macrophage phenotype will be described in greater detail.  
 
1.2.4.1 M1  
In vitro, macrophages are activated towards an M1 functional program upon 
exposure to infectious microorganism such as the Gram-negative product 
lipopolysaccharide (Suresh and Sodhi, 1991) and by inflammation-related cytokines 
TNF-a or IFN-g (Arango Duque and Descoteaux, 2014) (Figure 1.3). A few of the 
main characteristics of M1 macrophages, also known as classically-activated 
macrophages, include their participation as inducers in Th1 responses, their ability 
to mediate resistance against intracellular parasites and finally, their ability to 
produce effector molecules (i.e. nitric oxide, reactive oxygen species and 
inflammatory cytokines (IL-1b, TNF, IL-6, IL-8 and IL-12)). In vitro, they are 
characterized by an IL-12hiIL-23hiIL-10lo phenotype (Gordon and Taylor, 2005). For 
this reason, M1 macrophages are described as pro-inflammatory accompanied with 
killing/inhibitory functional capacity. It is thought that monocyte-derived 
macrophages from circulating inflammatory monocytes tend to polarize towards M1 
phenotype although they can polarize towards both M1 or M2 phenotype, 
depending on tissue condition (Figure 1.3) (Davies et al., 2011, Hashimoto et al., 
2013). 
 
 
 
 
31 
	
1.2.4.2 M2  
In contrast to M1 macrophages, M2 macrophages are described as anti-
inflammatory, involved in healing/growth promoting functions (Mills, 2012, Mills et 
al., 2000). The activation of M2 macrophage phenotype in vitro can be categorized 
further into M2a (alternative inflammation), M2b and M2c (deactivation) 
macrophages, depending on their stimuli exposure. Exposure towards Th2-related 
cytokines IL-4 or IL-13 leads to the polarization towards M2a which expresses a 
series of chemokines to promote the local increase of Th2 cells, basophils and 
eosinophils. Polarization towards M2b phenotype are achieved by a combination of 
immune complexes, LPS, apoptotic cells and IL-1Ra, all of which results in the 
secretion of anti-inflammatory cytokines such as IL-10 as well as pro-inflammatory 
cytokines TNF and IL-6. Finally, exposure to anti-inflammatory molecules such as 
IL-10, TGF-b and glucocorticoids leads to the polarization towards M2c, which 
causes the secretion of immunosuppressive cytokines such as IL-10 and TGF-b  
(Figure 1.2). Cytokines secreted by M2c macrophages have the ability to promote 
the development of Th2 lymphocytes and Tregs, making them competent cells to 
protect organs from injury resulting from inflammatory insults (Gordon, 2003, 
Martinez et al., 2008). Further characteristics of M2 macrophages in vitro involved 
their high expression level of mannose, scavenger and galactose-type receptors, 
their ability to take part in polarized Th2 responses and finally, possessing an IL-
12loIL-23loIL-10hiTGF-bhi phenotype (Italiani and Boraschi, 2014).  
 
1.2.4.3 Current hypothesis on macrophage polarization  
Although activation of macrophages towards M1 and M2 phenotype has been 
described in greater detail in vitro, it is still unclear whether this phenotypic and 
functional evolution occurs in vivo. Studies in mice revealed that the switch from M1 
to M2 macrophages in the context of inflammatory response allows macrophages to 
perform different activities at the different stages of the process. However, whether 
M1 and M2 macrophages belong to two phenotypically distinct populations 
performing different functions, or whether they are the same cells that shift from one 
phenotype to another depending on microenvironment signals, remain a 
controversy (Italiani and Boraschi, 2014).  
 
Three hypotheses have been generated to attempt to explain this issue. The first 
described that different subsets of monocytes or macrophages can adopt different 
functional phenotype, with monocyte-derived macrophages in tissues adopting M1 
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phenotype and tissue-resident macrophages adopting a cytoprotective and 
reparative M2 macrophage phenotype (Auffray et al., 2007). The second hypothesis 
described that an inflammatory reaction involves a sequential recruitment of 
monocytes into the tissue. Monocytes recruited at the early phase are exposed to 
signals that polarize them towards M1 phenotype while those recruited at a late 
phase are exposed to signals polarizing them towards an M2 phenotype (Arnold et 
al., 2007). Finally, the third hypothesis described that depending on the 
environmental condition, polarized macrophages can switch from one phenotype to 
another. This was evident from in vitro studies illustrating the ability of polarized M1 
macrophages to switch to M2 macrophages in culture (Italiani et al., 2014, Mylonas 
et al., 2009, Stout et al., 2005). Despite our increasing understanding for 
macrophage activation and polarization, the current knowledge on the mechanistic 
basis of macrophage diversity in different tissues or in response to changing 
environment is still lacking.  
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1.2.5 Disease implication of macrophages  
Tissue damage resulting from infection or injury initiates the recruitment of 
inflammatory monocytes from the circulation into tissue which then differentiate into 
macrophages (Geissmann et al., 2010). Due to the nature of the microenvironment 
of damaged tissue, these recruited macrophages exhibit a pro-inflammatory 
phenotype and secrete a range of pro-inflammatory factors as well as ROS and NO 
to activate anti-microbial defense mechanisms (Murray and Wynn, 2011b). Although 
inflammatory macrophages are beneficial in facilitating the clearance of invading 
organisms, uncontrolled regulation may result in substantial tissue damage due to 
excessive cytotoxic activity that is induced by ROS and nitrogen species (Nathan 
and Ding, 2010). This can potentially lead to the progression of chronic 
inflammatory and autoimmune diseases (Krausgruber et al., 2011, Sindrilaru et al., 
2011). To limit this damage, pro-inflammatory macrophages must undergo 
apoptosis or switch towards an anti-inflammatory phenotype. Here, the involvement 
of macrophages in inflammatory disease is described in greater detail.  
 
1.2.5.1 Macrophages in inflammatory disease 
Macrophages are known to contribute to the pathogenesis of many chronic 
inflammatory conditions that include asthma, rheumatoid arthritis, fibrosis and 
atherosclerosis (Hansson and Hermansson, 2011, Murray and Wynn, 2011b). For 
example, the inflammatory response in allergic asthma is accompanied by the 
recruitment of Th2 lymphocytes, mast cells, eosinophils and macrophages to the 
lung as well as the presence of a macrophage-like APC within the airway lumen 
(Julia et al., 2002). Additional studies also revealed that the severity of allergen-
induced disease is worsened by IL-4R+ macrophages (Ford et al., 2012), while 
protection is associated with a reduction in IL-4R+ macrophages (Moreira et al., 
2010). Increased number of IL-4R+ macrophages have also been associated with 
reduced lung function (Melgert et al., 2011).  
 
The role of monocyte-derived macrophage in atherogenesis has been a topic of 
interest. Recruitment of monocytes into the intima layer of the artery marks the 
earliest event in atherosclerosis. Following their infiltration to the intima, monocytes 
differentiate into macrophages, which can ingest lipoproteins transforming them into 
lipid-rich foam cells and giving rise to the atherosclerotic plaque (Moore et al., 2013, 
Liu et al., 2014). As the disease progresses, the atherosclerotic plaque can increase 
in size, becoming vulnerable and eventually rupturing resulting in a heart attack, 
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stroke or even sudden cardiac arrest (Moore and Tabas, 2011). In vivo studies in a 
mouse model of atherosclerosis identified that targeting chemokines to inhibit 
monocyte recruitment resulted in the inhibition or reduction of atherogenesis, 
confirming the essential role of macrophages in atherosclerosis development 
(Mestas and Ley, 2008). Different subsets of macrophages are observed in 
atherosclerotic plaques. In the early stages, infiltration of M2 phenotype 
macrophages was observed, however, as the plaque development progressed, M1 
phenotype macrophages increased and eventually become dominant, promoting 
acute atherothrombotic vascular accident (Leitinger and Schulman, 2013, Moore 
and Tabas, 2011). Although usually associated with negative impact towards 
atherosclerosis, macrophages have also been associated with anti-atherosclerotic 
function. For example, macrophages as professional phagocytes, remove 
pathogens, small debris and damaged cells from atherosclerotic tissue through the 
process of phagocytosis (Schrijvers et al., 2007). Additionally, TGF-b secreted by 
M2 macrophages has been shown to inhibit the recruitment of inflammatory cells 
and has been associated with protection against atherosclerosis (Mallat et al., 
2001).  
 
Upon activation by endogenous danger signals and PAMPs, macrophages are 
activated and secrete various anti-microbial mediators, inflammatory cytokines and 
chemokines that include TNFa, IL-1, IL-6 and CCL2 (Wynn and Barron, 2010). If not 
tightly controlled, these cytokines and chemokines drive inflammatory responses 
and can exacerbate tissue injury, even leading to abnormal wound healing and 
ultimately causing scarring, also known as fibrosis (Duffield et al., 2005). Hence, 
macrophages are primary producers of various cytokines implicated in the 
pathogenesis of inflammatory conditions. 
 
In addition to chronic inflammatory conditions, macrophages have also been 
implicated in the pathogenesis of autoimmune diseases. They are regarded as an 
important source of many key inflammatory cytokines (IL-12, IL-18, IL-23 and 
TNFa) acting as important drivers of autoimmune inflammation (Murray and Wynn, 
2011a). Studies in mice revealed that macrophage production of IL-23 promotes 
end-stage joint autoimmune inflammation (Wynn et al., 2013). In addition to this, 
pro-inflammatory phenotype macrophages have also been attributed with the 
pathogenesis of chronic demyelinating diseases of the central nervous system 
(CNS) by contributing to axon demyelination in a mouse model of multiple sclerosis 
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(Ponomarev et al., 2011). Finally, secretion of IL-23 and TNF by CD14+ 
macrophages has been detected in Crohn’s disease patients (Kamada et al., 2008).  
 
Although the majority of studies reported macrophages as a contributor towards 
inflammatory conditions, a few have also reported suppressive roles. The 
suppressive role of macrophages is evident from a study which illustrated ROS 
produced by macrophages can limit arthritis in mice through inhibition of T cell 
activation (Gelderman et al., 2007) and the ability of resident tissue macrophages to 
maintain homeostasis of the gut through the production of suppressive cytokine IL-
10 and antagonizing pro-inflammatory macrophages (Murai et al., 2009, Smith et 
al., 2009). Taken together, it is apparent that macrophage differentiation in the local 
environment can affect the pathogenesis of various inflammatory conditions.  
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1.3 Calcium signaling  
Calcium ions (Ca2+) play a vital role in every aspect of cellular life as an intracellular 
messenger participating in cellular processes which include gene transcription, 
contraction and differentiation (Bootman, 2012). Cells invest much of their energy to 
control changes in Ca2+ concentration with a gradient maintained between their 
intracellular (approximately 100 nM free) and extracellular (~1 mM) concentrations 
(Clapham, 2007). Ca2+ concentration gradients in cells are controlled through three 
methods: 1) chelation, 2) compartmentalization, or 3) extrusion. To control Ca2+ 
levels within a cell, an array of channels, pumps and cytosolic buffers are involved.  
 
In macrophages, Ca2+ signaling plays a critical role and regulates various cellular 
processes such as regulating pro-inflammatory gene expression and cytokine 
secretion (Desai and Leitinger, 2014). LPS-activated macrophages have been 
shown to increase cytosolic calcium level, which is crucial for the production of TNF-
a (Watanabe et al., 1996) and reduced IL-12 production (Liu et al., 2016). Another 
important role for Ca2+ signaling in macrophages is their contribution towards 
phagosome maturation, engulfment of apoptotic cells and subsequent anti-
inflammatory response as well as their contribution to maintaining leading-edge 
structure of migrating macrophages (Evans and Falke, 2007; Gronski et al., 2009). 
Studies have revealed that the process of phagocytosis is also tightly regulated by 
level of intracellular Ca2+ (Nunes and Demaurex, 2010). This was demonstrated in a 
study by Cuttell et al. (2008) whereby mutations in genes linked to Ca2+ flux resulted 
in defects in the clearance of apoptotic cells.  
 
1.3.1 ON and OFF mechanisms  
The Ca2+ signalling pathway is a complex network that involves several steps. The 
activation of signalling pathways requires a stimulus which results the in the 
activation of an ‘ON’ mechanism that feed Ca2+ into the cytoplasm, stimulating Ca2+-
sensitive processes. The final step of the Ca2+ signalling pathway involves an ‘OFF’ 
mechanism that is made up of pumps and exchangers to extrude Ca2+ from the 
cytoplasm to restore the resting state of a cell (Berridge et al., 2000).  
 
The first stage of the Ca2+ network involves the generation of Ca2+-mobilizing 
signals from both internal and external sources resulting in the activation of the ‘ON’ 
mechanism. While internal sources are controlled by channels found on 
endoplasmic reticulum (ER) or sarcoplasmic reticulum in muscles (SR), external 
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sources are controlled by channels found within the plasma membrane of cells 
(Berridge et al., 2000). The entry of Ca2+ from extracellular space to the cytoplasm 
is governed by voltage-operated channels (VOCs) and receptor-operated channels 
(ROCs) (Berridge et al., 2000). The release of Ca2+ from internal stores is a tightly 
controlled mechanism triggered by a variety of second messengers which include 
inositol 1,4,5-triphosphate (IP3), cyclic ADP ribose (cADPr) or, significantly Ca2+ 
itself. The increase in intracellular Ca2+ level can act on channels such as IP3 and 
ryanodine receptors (RyR), to promote further release of Ca2+ from intracellular 
stores. This process is known as Ca2+-induced Ca2+ release (Berridge, 1993). The 
emptying of internal stores can also then result in the activation of store-operated 
channels (SOCs) found on the plasma membrane of cells.  
 
The final part of the Ca2+ signaling network involves the OFF mechanism in which 
Ca2+ is rapidly removed from the cytoplasm by numerous pumps and exchangers 
(Blaustein and Lederer, 1999, Pozzan et al., 1994). Removal of Ca2+ involves the 
extrusion of Ca2+ out of cells through plasma membrane Ca2+-ATPase (PMCA) 
pumps and Na+/Ca2+-exchangers as well as the uptake of Ca2+ back into internal 
stores through sarco-endoplasmic reticulum ATPase (SERCA) (Berridge et al., 
2000). The mitochondrion is also responsible for sequestering Ca2+ rapidly during 
the development of Ca2+ signal.  
 
1.3.2 Calcium channels in macrophages  
Macrophages are non-excitable cells and rely on Ca2+ permeable channels that are 
not gated by voltage. These cell surface receptors in macrophages include ROCs 
such as purinergic receptor (P2 receptors; discussed in section 1.4), SOCs (Orai 
channels) and transient receptor potential (TRP) channel (Desai and Leitinger, 
2014).  
 
1.3.2.1 Orai channels 
Orai channels, also known as CRAC channels, are activated upon the emptying of 
ER stores (Hogan et al., 2010). Although studies have revealed their regulatory 
mechanisms, their functional role in macrophage biology remains unclear. 
Previously, they have been linked with the production of ROS and with the 
engulfment of apoptotic cells in macrophages. In addition to this, it is also thought 
that the opening of Orai channels requires the activation of Gq-coupled P2Y 
receptors which leads to the subsequent depletion of Ca2+ stores (Desai and 
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Leitinger, 2014). This led to the speculation that activation of Orai channels may be 
critical for the cellular processes downstream of P2Y receptors. However, further 
work is still required to confirm this hypothesis. 
  
1.3.2.2 TRP channels  
TRP channels are a family of cation-selective channels that are gated by 
temperature, mechanical force, ligands and internal cues such as pH. TRP 
channels play an important role in macrophages and this is evident from a study 
which illustrated that a lack of TRPM2 in mice impaired their ability to induce Ca2+ 
influx upon ROS stimulation, resulting in the inability to produce chemokines. These 
chemokines are crucial for the recruitment of cells and the attenuation of neutrophil 
infiltration (Yamamoto et al., 2008). In addition to this, TRP channels have been 
shown to play a role in phagocytosis and chemotaxis with macrophages lacking 
TRPV2 showing deficiency in triggering of phagocytosis when exposed to zymosan 
and IgG opsonized particles (Link et al., 2010). Most recently, TRPC1 has been 
associated with a role in restraining the secretion of IL-1b in response to 
inflammatory stimuli (Py et al., 2014).  
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1.4 Purinergic signaling  
Adenosine 5-triphosphate (ATP) was identified as a co-transmitter in nerves 
supplying the gut and bladder in the early 1970s (Burnstock, 1972). This discovery, 
together with various studies by Drury and Szent-Gyorgyi (1929), Buchthal and 
Folkow (1948) and Emmelin and Feldberg (1948) relating to purines in heart and 
peripheral ganglia, allowed the proposal of the purinergic signaling concept by 
Geoffrey Burnstock in 1972. It is now well accepted that ATP is a cotransmitter in all 
nerves of the peripheral and central nervous system (Verkhratsky et al., 2009). 
Purinergic signaling is the extracellular signaling pathway mediated by purine 
nucleotides and nucleosides and involves the activation of purinergic receptors. 
These extracellular mediators include purine nucleoside (adenosine), its nucleotides 
(ATP, adenosine diphosphate (ADP), and adenosine monophosphate (AMP)) and 
pyrimidine nucleotides (uridine diphosphate (UDP), uridine diphosphate glucose 
(UDP-Glu) and uridine triphosphate (UTP)), all of which are key extracellular 
messengers in the central and peripheral nervous system, regulating cell function 
(Williams, 2002). 
 
1.4.1 Purinergic receptors  
In 1978, the discovery of two families of purinergic receptors, P1 and P2 receptors, 
was made (Burnstock, 1978). While P1 receptors are described to be sensitive to 
adenosine, P2 receptors are sensitive to ATP and ADP (Verkhratsky et al., 2009). 
Pharmacological characterization of P2 receptors were reported in 1985 allowing 
their categorization into ligand-gated ion channel P2X receptors and G protein-
coupled P2Y receptors (GPCRs) (Burnstock and Kennedy, 1985). However, it was 
not until the successful cloning of these receptors in early 1990’s that the purinergic 
signaling hypothesis was finally accepted. Currently, there are 4 subtypes of P1 
receptors, 7 subtypes of P2X receptors and 8 subtypes of P2Y receptors. The 
activation of purinergic receptors leads to various major cellular signaling pathways 
that are evident by reports demonstrating short-term signaling in neurosecretion, 
neuromodulation and neurotransmission. In addition to this, their activation also 
mediates long-term signaling  involved in cell proliferation, differentiation and death 
(Verkhratsky et al., 2009).  
 
1.4.1.1 P1 receptors 
P1 receptors all couple to G proteins which have seven putative transmembrane 
(TM) domains with the NH2 terminus lying on the extracellular side and the COOH 
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terminus lying on the cytoplasmic side of the membrane (King and Burnstock, 
2002). So far, four subtypes of P1 receptors have been successfully cloned and are 
denoted as A1, A2A, A2B and A3 receptors. While A1 and A2A receptors possess high 
affinity for adenosine, A2B and A3 receptors possess relatively lower affinity for the 
agonist (Fredholm et al., 2011). In addition to this, A1 and A3 receptors are coupled 
to Gi/o proteins while A2A and A2B are coupled to Gs protein (Fredholm et al., 2011). 
P1 receptors are widely distributed in the mammalian system with A1 receptors 
being widely distributed in the CNS, adrenal glands, skeletal muscle and adipose 
tissue (Dixon et al., 1996, Fredholm et al., 2011), A2A receptors being widely 
distributed in spleen, immune cells, platelets and the heart (Fredholm et al., 2011), 
A2B receptors being ubiquitously distributed in the brain (Dixon et al., 1996) and A3 
receptors being widely expressed in rat testis (Meyerhof et al., 1991) and mast cells 
as well as low levels in the brain (Dixon et al., 1996). In vitro and in vivo studies 
have illustrated potent anti-inflammatory function of all adenosine receptors in 
inflammatory cells. Pro-inflammatory function has also been associated with some 
adenosine receptors (King and Burnstock, 2002). 
 
1.4.1.2 P2X receptors  
P2X receptors (P2XR) are ligand gated ion channels permeable to sodium, 
potassium and calcium that open upon the binding of ATP. P2X receptors are found 
in all vertebrate species (Burnstock, 2007) and in many invertebrate marine species 
(Fountain and Burnstock, 2009, Fountain, 2013). In vertebrates, they are implicated 
in various physiological processes, which range from synaptic transmission to 
inflammation as well as pain and taste. P2XR can be categorized into 7 different 
subtypes (P2X1-7), showing 30 – 50% sequence identity at the amino acid level 
(Burnstock, 2006). The formation of trimeric P2XR can involve homo- and hetero-
multimers. While all P2XR, except for P2X6, can form a functional receptor as a 
homomultimer, heteromultimers have only been described in a few instances. 
These include the formation of P2X2/3 in nodose ganglia, P2X4/6 in CNS neurons and 
P2X1/5 in blood vessels (Burnstock, 2006). The main difference between receptor 
subtypes lies in their agonist sensitivities as well as their rates of activation and 
deactivation (Table 1.2) (Coddou et al., 2011). While P2X1 and P2X3 have been 
shown to be rapidly activating and desensitizing, P2X2 and P2X4 are slowly 
desensitizing (North, 2002, North, 2016). 
 
 
 
41 
	
1.4.1.3 P2Y receptors  
P2Y receptors (P2YR) are a family of metabotropic G-protein coupled receptors, 
which can be activated by various nucleotides such as ATP, ADP, UTP, UDP and 
UDP-glucose (Table 1.3) (Burnstock and Knight, 2004). There are 8 subtypes of 
P2YR which are known as P2Y1, P2Y2, P2Y4, P2Y6, P2Y11 – P2Y14. P2YR share 21 
– 48 % sequence homology, with the greatest similarity observed between P2Y12 
and P2Y13 (Abbracchio et al., 2003, Abbracchio and Burnstock, 1994, Khakh et al., 
2001). They are characterized by seven TM spanning regions, an extracellular NH2- 
and intracellular COOH-termini and structural diversity of intracellular loops and the 
C termini which determines the coupling to either Gaq/11, Gas or Gai proteins (Figure 
1.3) (Burnstock and Knight, 2004).  
 
In response to nucleotide activation, recombinant P2YR either activate 
phospholipase C (PLC) which causes the release of intracellular Ca2+ or affect 
adenylate cyclase (AC) which in turn results in the alteration of cyclic AMP (cAMP) 
levels (Table 1.3) (Abbracchio et al., 2003). While P2Y1, P2Y2, P2Y4, P2Y6 and 
P2Y11 have been shown to mainly signal through Gaq/11 activating PLC, P2Y12 – 
P2Y14 signal through Gai to inhibit AC (Abbracchio et al., 2006). In addition to being 
coupled to the Gaq/11 subunit, P2Y11 is also coupled to Gas which leads to the 
activation of AC and increase in cAMP levels. P2YR has also been suggested to 
form homomultimeric and heteromultimeric assemblies under certain conditions and 
it is also known that many cells express multiple subtypes of P2YRs (Abbracchio et 
al., 2006, Burnstock and Knight, 2004).  
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Figure 1.3 Structure of P2 receptors and second messengers associated with 
their activation. A) Diagram illustrating the transmembrane topology of P2XR 
protein showing both N-terminus and C-terminus within the cytoplasm. Two putative 
membrane-spanning segments (TM1 and TM2) traverse the lipid bilayer of the 
plasma membrane and are connected by a long extracellular loop containing the 
ATP binding site. B) Illustration of G-protein coupled P2YR. P2Y1,2,4,6 are coupled to 
Gaq subunit activating PLCb and mobilization of intracellular Ca2+. P2Y12,13,14 are 
coupled to the Gai subunit inhibiting adenylyl cyclase (AC). P2Y11 is coupled to both 
Gaq and Gas subunit activating Ca2+ mobilization and cAMP, respectively. Adapted 
from Burnstock and King (2004).  
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P2XR      
subtype   
Downstream 
signaling 
pathway 
  Agonist   Antagonist   Primary distribution 
P2X1*  LIC  
ATP = ab-
meATP = 2-
meSATP   
MRS2220, MRS2159, NF449, 
NF279, Ro-0437626, Suramin, 
PPADS, TNP-ATP  
Platelets, cerebellum, smooth muscle 
and dorsal horn spinal neurons 
P2X2**  LIC  
ATP > ATPgS 
>2-meSATP > 
a.b-meATP 
 
RB-2, NF279, NF770, NF776, 
NF778, PSB-12011, PSB-
10211, Suramin, PPADS  
CNS, smooth muscle, retina, 
chromaffin cells, autonomic and 
sensory ganglia 
P2X3*  LIC  
2-meSATP > 
ATP > a,b-
meATP   
A-317491, NF023, NF279, 
NF449, RO-85, MRS2159, 
MRS2257, Suramin, PPADS  
Sensory neurons and sympathetic 
neurons 
P2X4**  LIC  
ATP > a,b-
meATP > 
BzATP   
5-BDBD, BBG, Paroxetine, 
PSB-12062, BX430, Suramin, 
PPADS, TNP-ATP   
CNS, immune cells, testis, colon 
P2X5  LIC  
ATP > 2-
meSATP > 
ATPgS  
BBG, Suramin, PPADS, TNP-
ATP   Skin, gut, bladder, spinal cord  
P2X6***  LIC  
ATP > 2-
meSATP  TNP-ATP, PPADS  CNS and spinal cord  
P2X7  LIC  BzATP > ATP   
MRS2159, KN-62, BBG, 
suramin, A438079, 
AZ11645373, PPADS  
Immune cells, pancreas, skin 
 
Table 1.2 Characteristics of P2XR. P2XR have a widespread tissue distribution with each receptor having different agonist sensitivity. *P2X1 
and P2X3 are fast desensitizing, **P2X2 and P2X4 are slow desensitizing, ***P2X6 do not form a functional receptor as a homotrimer. LIC: 
Ligand gated ion channel. Table adapted from Burnstock and Knight (2004). 
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P2YR      
subtype   
Downstream signaling 
pathways   Agonist   Antagonist   Primary distribution 
P2Y1  
GPCR: Gaq - PLCb 
activation, ↑[Ca2+]i  
2-MeSADP > 2-
MeSATP = ADP 
> ATP   
MRS2279, MRS2179, 
MRS2500  
Epithelial and endothelial 
cells, platelets, immune cells 
and brain 
P2Y2  
GPCR: Gaq and Gai - 
PLCb activation, ↑[Ca2+]i  UTP = ATP   Suramin, AR-C118925XX  
Epithelial and endothelial cells 
and immune cells  
P2Y4  
GPCR: Gaq - PLCb 
activation, ↑[Ca2+]i  UTP > ATP   
ATP (human), Reactive 
blue 2, PPADS  Endothelial cells, placenta 
P2Y6  
GPCR: Gaq - PLCb 
activation, ↑[Ca2+]i  
UDP > UTP >> 
ATP  
MRS2578, Reactive blue 
2, PPADS, suramin  
Epithelial cells, placenta, T 
cells, thymus 
P2Y11  
GPCR: Gaq and Gas - 
PLCb activation, AC 
activation, ↑[Ca2+]i  
AR-C67085MX 
> Bz-ATP > 
ATP   
Suramin, Reactive Blue 2, 
NF340, NF157  
Spleen, intestins, 
granulocytes 
P2Y12  
GPCR: Gai - inhibition of 
AC  
ADP = 2-
MeSADP  
PSB-0739, Ticagrelor, 
Clopidogrel, AR-
C69931MX  
Platelets, glial and microglial 
cells of the brain 
P2Y13  
GPCR: Gaq and Gai - 
inhibition of AC, PLCb 
activation  
ADP = 2-
MeSADP > ATP 
= 2-MeSATP  
ARC-69931MX, ARC-
67085MX, MRS-2211  
brain, bone marrow, spleen 
and lymph nodes  
P2Y14 
 
GPCR: Gai - inhibition of 
AC 
 
UDP-glucose = 
UDP 
 
N/A 
 
Adipose tissue, stomach, 
intestine, brain, mast cells 
 
Table 1.3 Characteristics of P2YR. P2YR have a widespread tissue distribution and each receptor are coupled to either Gaq, Gas or Gai 
subunit leading to various downstream signaling pathways. GPCR: G protein coupled receptor. Table adapted from Burnstock and Knight 
(2004). 
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1.4.2 P2X4 receptors 
P2X receptors have been described briefly in section 1.4.1.2. However, as the focus 
of this thesis is to study P2X4 receptors, a thorough overview discussing 
pharmacology, structure and composition as well as localization of this receptor will 
be discussed below. 
 
1.4.2.1 Structure and Composition  
All P2X receptor subtypes have been described to consist of intracellular NH2 and 
COOH termini and form two functional domains, the extracellular domain and the 
transmembrane (TM) domain. All subunits are made up of two TM-spanning 
domains, one responsible for channel gating and the other responsible for lining of 
the ion conducting pore, joined by a large extracellular loop (ectodomain). This 
ectodomain is known to consist of 10 conserved cysteine residues forming the ATP 
binding site (North, 2016, Marquez-Klaka et al., 2007) (Figure 1.3). Biophysical 
characterization of native and recombinant P2XRs informed the hypothesis that 
these channels form as trimeric homomers or heteromers (Coddou et al., 2011) and 
whole-cell and single-cell recordings illustrated that three molecules of ATP were 
required for the activation of the channel (Jiang et al., 2003, Ding and Sachs, 1999, 
Bean et al., 1990). Evidence that P2XR are organized as either homotrimers or 
heterotrimers initially came from studies co-expressing slowly desensitizing P2X2 
with fast desensitizing P2X3 (Lewis et al., 1995). Immunoprecipitation studies 
allowed the prediction of 11 different forms of heteromers (Torres et al., 1999) 
although only six functional P2XR heteromers have been characterized and these 
include P2X1/4 (Nicke et al., 2005) and P2X4/6 (Le et al., 1998).   
 
The crystal structure of P2X4 zebrafish by Kawate et al. (2009) confirmed the 
hypothesis that the receptor forms a trimer and since then, there has been a 
significant advancement to the understanding of this ligand-gated ion channel. 
Crystallization studies illustrated each subunit rises from the plasma membrane, 
resembling the structure of a dolphin surfacing from the ocean, with its tail 
submerged within the lipid bilayer (Figure 1.4A and B). With this, the body regions of 
the three subunits intertwine to form one central vertical cavity (Kawate et al., 2009). 
Upon the binding of ATP, it is thought that the subunits flex together within the 
ectodomain and separate in the membrane-spanning region to form an open 
channel state (North, 2002, North, 2016).  
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Figure 1.4 Crystal structure of P2X4 receptor. A and B) Stereo-view of 
homotrimeric zebrafish P2X4 receptor views parallel to the membrane and from the 
extracellular side of the membrane, respectively. Each trimer subunit is depicted in 
different colors. Image taken from Kawate et al., 2009.  
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1.4.2.2 Pharmacology  
 
1.4.2.2.1 Agonist 
ATP acts as the main agonist for all homomeric and heteromeric P2XR although 
activation is done in a receptor-specific manner with EC50 values ranging from 
nanomolar to milimolar concentrations (Coddou et al., 2011). Early 
electrophysiological studies by Soto et al. (1996a) in rat P2X4 expressed in Xenopus 
oocytes reported the agonist profile as ATP > 2-methylthio-ATP > CTP > a,b-
meATP > dATP. The same order of agonists efficacy was demonstrated in human 
P2X4 expressed in Xenopus oocytes (Garcia-Guzman et al., 1997). Reported EC50 
values for ATP in rat and human P2X4 was illustrated to be 6.9 ± 0.8 µM and 7.4 ± 
0.5 µM, respectively (Soto et al., 1996a, Garcia-Guzman et al., 1997). Further 
characterization of P2X4 orthologues in mammalian HEK293 cells illustrated EC50 
values for ATP in mouse, human and rat P2X4 to be 2.3 µM, 1.4 µM and 5.5 µM, 
respectively (Jones et al., 2000). 
 
1.4.2.2.2 Positive modulators  
There are currently two well-described positive modulators for P2X4. The first 
positive modulator is cibacron blue, an isomer of reactive blue 2 that possess an 
inhibitory action at all P2X receptors, except for P2X4. Application of low 
concentrations (3 – 30 µM) of cibacron blue has been shown to potentiate rat P2X4 
responses in HEK293 cells by increasing the potency of ATP agonist towards P2X4 
(Miller et al., 1998).  
 
The second known positive modulator is ivermectin (IVM), a derivative of 
Streptomyces avermitilis. IVM is a member of lipophilic compounds known as 
avermectins and is used widely in human medicine for the treatment of river 
blindness, and in veterinary medicine for the treatment of a range of ento- and ecto-
parasites (Burkhart, 2000). It has been described to act as positive allosteric 
modulator of vertebrate GABAA and nicotinic a7 receptor (Zemkova et al., 2014) 
and P2XR. Amongst the P2XR, IVM has been shown to be capable of acting as a 
positive modulator for both P2X4 and P2X7, although P2X4 has been shown to be 
the most sensitive towards IVM (Khakh et al., 1999). Extracellular application of IVM 
potentiated P2X4 currents and delayed channel deactivation (Khakh et al., 1999, 
Fountain and North, 2006) while IVM potentiated only the magnitude of human P2X7 
responses while not affecting channel deactivation (Norenberg et al., 2012). 
	 48 
Although IVM binding to invertebrate glutamate-activate chloride channels has been 
studied (Hibbs and Gouaux, 2011), the IVM binding site on P2X4 remains to be 
elucidated. It has been speculated by Priel and Silberberg (2004) that IVM is likely 
to bind to separate sites on P2X4 with a high affinity IVM binding site which results in 
an increase in maximal current activated by saturating agonist concentration and a 
second low affinity binding site which causes a delay to the deactivation of the 
channel.  
 
1.4.2.2.3 Non-selective antagonists of P2X4 
The study of P2X4 has been hampered mainly due to the lack of selective 
antagonists available commercially. Up until recently, researchers had to rely on the 
use of broad-spectrum antagonists such as suramin, blue brilliant G (BBG) dye and 
PPADS, as well as other inhibitory methods such as divalent cations, pH and 
several drugs (anti-depressants and statins). Each of these will be described below.  
 
1.4.2.2.3.1 Broad-spectrum antagonists 
Suramin is a broad-spectrum purinergic receptor antagonist that shows very weak 
activity at mouse, rat and human P2X4 orthologues. Maximal inhibition of currents 
varies between 11-35% with pIC50 > 4 displayed for all orthologues (Jones et al., 
2000). In addition to this, another broad-spectrum antagonist pyridoxalphosphate-6-
azophenyl-2’,4’-disulfonic acid (PPADS) has been illustrated to fully inhibit human 
and mouse, but not rat, P2X4 with pIC50 of approximately 5 for both. Lastly, 2’,3’-O-
(2,4,6-trinitrophenyl) ATP (TNP-ATP) displayed a weak inhibitory action at P2X4 with 
a competitive nature (Hernandez-Olmos et al., 2012, Balazs et al., 2013a). 
 
1.4.2.2.3.2 Ethanol 
The P2X4 has been shown to be the most abundant P2XR subtype in mammalian 
CNS and the most sensitive towards ATP. Ethanol has been shown to inhibit ATP-
gated currents in P2X4 in HEK293 cells through whole-cell patch-clamp 
(Ostrovskaya et al., 2011). IVM has also been shown to antagonize the inhibitory 
action of ethanol at P2X4 by interfering with ethanol binding to the channel 
(Asatryan et al., 2010). 
 
1.4.2.2.3.3 Divalent cations 
Several divalent cations have been associated with having an inhibitory effect 
towards ATP-gated currents in P2X4. Extracellular Zn2+ at high concentrations (>100 
mM) and Cd2+ was shown to inhibit P2X4 currents in a voltage-dependent manner 
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(Garcia-Guzman et al., 1997). Extracellular Cu2+ was also shown to inhibit P2X4 
current but in a non-competitive and voltage-independent manner (Acuna-Castillo et 
al., 2000). 
 
1.4.2.2.3.4 pH  
Studies have revealed that extracellular H+ negatively modulates P2X4 with acidic 
environments (pH<6) completely abolishing channel activity while a pH above 
physiological levels potentiates channel activity (Clarke et al., 2000). P2X4 has been 
shown to be predominantly found within the intracellular lysosomal compartment 
and the inhibition of channel activity at low pH may be an important physiological 
regulator for this receptor (Qureshi et al., 2007).  
 
1.4.2.2.3.5 Antidepressants 
The majority of research surrounding P2X4 has been focused on neuropathic pain 
within the CNS. Several clinically used antidepressants such as paroxetine, 
fluoxetine and clomipramine have been illustrated to have an inhibitory effect 
towards P2X4 (Nagata et al., 2009). It was hypothesized that these drugs mediate 
analgesic effects for the treatment of neuropathic pain through P2X4 inhibition. 
Amongst them, paroxetine has been shown to be the most potent P2X4 inhibitor 
with a non-competitive nature and a pIC50 of 5.7, although it is much more potent as 
a serotonin reuptake inhibitor (Nagata et al., 2009). In addition to this, the inhibitory 
effect of paroxetine appears to be non-selective as studies by Dao-Ung et al. (2015) 
illustrated their ability to block human P2X7. The antidepressant amitriptyline was 
also studied further but was revealed to inhibit mouse and rat P2X4, but not the 
human isoform (Sim and North, 2010). 
 
1.4.2.2.3.6 Statins and cholesterol depleting agents 
More recently, HMG-CoA reductase inhibitor, fluvastatin has been reported to have 
an inhibitory activity on heterologously expressed human P2X4 and native P2X4 in 
human THP-1 monocytes as assessed through intracellular Ca2+ measurements (Li 
and Fountain, 2012). It was speculated that the inhibitory effect of fluvastatin on the 
P2X4-mediated Ca2+ response was due to depletion of cellular cholesterol (Li and 
Fountain, 2012). 
 
1.4.2.2.4 Selective antagonists 
For a long time, researchers had to rely on non-selective P2XR antagonists such as 
TNP-ATP, BBG) and paroxetine, to study P2X4. However, these agents possess low 
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affinity for P2X4 and are significantly more potent at other targets (Gum et al., 2012). 
Recently, growing evidence that highlights the importance of P2X4 in health and 
disease has triggered interest in the development of selective receptor antagonists. 
The discovery of selective P2X4 antagonists will, therefore, present a new avenue 
for scientific research to selectively target P2X4 therapeutically.  
 
1.4.2.2.4.1 5-BDBD 
Benzodiazepine derivative 5-BDBD is one of the first selective P2X4 antagonists to 
be described in the literature that has become commercially available (Fisher et al., 
2005). It has been reported as a moderately potent and selective P2X4 antagonist 
with an IC50 value of 0.5 µM in CHO cells. The application of two different 
concentrations of 5-BDBD resulted in a rightward shift in the ATP dose-response 
curve indicating that 5-BDBD acts as a competitive antagonist to the P2X4 receptor 
(Balazs et al., 2013b). However, radio-ligand binding assays illustrated that 5-BDBD 
was unable to displace [35S]ATPgS binding to P2X4 indicating that rather than acting 
as a competitive antagonist, it has an allosteric nature towards P2X4 (Muller, 2015).  
 
1.4.2.2.4.2 N-substituted phenoxazine derivative 
More recently, two compounds derived from N-substituted phenoxazine were 
identified as potent and selective allosteric P2X4 antagonists. One of the derivatives 
is N-(Benzyloxycarbonyl)phenoxazine (PSB-12054), a potent antagonist of the 
human P2X4 receptor (IC50 value of 0.189 µM), but less potent towards rat (IC50 
value of 2.1 µM) and mouse (IC50 value of 1.77 µM) P2X4. It has been reported to 
possess high selectivity for human P2X4 with over 50-fold against P2X2, P2X3 and 
P2X7 and over 30-fold against P2X1 (Hernandez-Olmos et al., 2012).   
 
The second less potent, but more water-soluble, of the two derivatives is N-(p-
methylphenylsulfonyl)phenoxazine (PSB-12062). PSB-12062 was shown to have 
similar potency in all three species: human (IC50 value of 1.38 µM), rat (IC50 value of 
0.928 µM) and mouse (IC50 value of 1.76 µM) P2X4 (Hernandez-Olmos et al., 2012). 
It has been shown to be allosteric in nature with 35-fold selectivity towards P2X4 
versus P2X1, P2X2, P2X3, and P2X7 (Hernandez-Olmos et al., 2012). However, 
PSB-12062 was unable to completely block ATP-induced P2X4-mediated Ca2+ influx 
even when used at high concentrations (>30 µM).  
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1.4.2.2.4.3 Carbamazepine derivatives 
Several carbamazepine derivatives were recently investigated as potential P2X4 
receptor antagonists, with N,N-diisopropyl-5H-dibenz[b,f]azepine-5-carboxamide 
being found to be the most potent towards human P2X4 (IC50 of 3.44 µM). However, 
this compound was found to be less potent at mouse and rat P2X4 (Tian et al., 
2014). Despite its potency towards human P2X4, it appeared to lack selectivity 
against two other P2X subtypes (P2X1 and P2X3) but was selective versus P2X2 
and P2X7. Further optimization will be required to improve the selectivity of this 
compound.  
 
1.4.2.2.4.4 BX430 
Phenylurea BX430 (1-(2,6-dibromo-4-isopropyl-phenyl)-3-(3-pyriudyl)urea is a 
recently discovered P2X4 antagonist. Patch-clamp studies illustrated BX430 to have 
a sub-micromolar potency with IC50 value of 0.54 µM, and 10 – 100 fold selectivity 
toward P2X4 receptor versus other P2XR subtypes (Ase et al., 2015). Acting 
through a noncompetitive allosteric route, BX430 has been shown to potently 
antagonize the zebrafish P2X4 receptor but has no effect on rat and mouse P2X4 
orthologs (Ase et al., 2015).  
 
1.4.2.3 Subcellular localization, trafficking and regulation  
The subcellular distribution of P2XR subunits are all different because of their 
varying trafficking properties. While some are localized within the endoplasmic 
reticulum (ER), others are predominantly found at the cell surface or within 
endosomes and lysosomes (Robinson and Murrell-Lagnado, 2013). It is thought that 
the trafficking of receptors to and from the plasma membrane serves as a means to 
rapidly up- or down-regulate cellular responses mediated by ATP.  
 
1.4.2.3.1 Subcellular Localization  
P2X4 have been described to undergo rapid constitutive internalization from the 
plasma membrane and to be predominantly expressed within late endosomes and 
intracellular lysosomal compartments (Bobanovic et al., 2002, Qureshi et al., 2007, 
Robinson and Murrell-Lagnado, 2013, Vacca et al., 2009) (Figure 1.5). They resist 
degradation within the lysosome by their N-linked glycans which can be found within 
the intra-luminal loop of the receptor (Boumechache et al., 2009). The localization of 
P2X4 to endolysosomes was demonstrated in immune and endothelial cells 
(Bobanovic et al., 2002, Qureshi et al., 2007, Royle et al., 2002). Various studies 
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have revealed that the constitutive endocytosis of P2X4 receptor is a process that is 
regulated by clathrin and can be inhibited by a pharmacological compound known 
as dynasore. The inhibition of P2X4 endocytosis results in the accumulation of P2X4 
receptor at the cell membrane of cells (Bobanovic et al., 2002, Boumechache et al., 
2009, Qureshi et al., 2007, Royle et al., 2002). Two examples include the 
contradicting effect of dynasore in cultured microglial cells and bone marrow derived 
macrophages. In vitro studies of microglial cells treated with LPS showed an 
upregulation of P2X4 expression indicating that they relied on the continuous cycling 
of the receptors to and from the cell surface. However, treatment of BMDM cells 
with LPS had a significantly different effect and did not result in an increase in cell 
surface P2X4 expression. Despite various studies, the regulation of plasma 
membrane expression of P2X4 is not well understood.  
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Figure 1.5. Subcellular distribution of P2X4 receptor. P2X4 are constitutively 
recycled between the plasma membrane and late endosomes and lysosomes. 
Within the lysosomes, P2X4 remain stable and are not degraded. Endocytosis of 
P2X4 involves a clathrin- and dynamin-dependent process. Adapted from Robinson 
and Murrell-Lagnado (2013). 
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1.4.2.3.2 Receptor Trafficking and Regulation 
Trafficking of P2XR is determined by a common motif YXXXK in the C-terminus 
(Chaumont et al., 2004). P2X4 has two tyrosine-based endocytic motifs found in the 
C-terminus and one dileucine-like motif within the N terminus (Royle et al., 2005, 
Royle et al., 2002, Qureshi et al., 2007). Mutations of one of the tyrosine-based 
endocytic motifs resulted in slowing down of receptor endocytosis while mutation of 
the leucine motif within the N terminal resulted in failure of receptor targeting to 
lysosomes (Royle et al., 2005, Royle et al., 2002).  
 
The trafficking of P2XR to and from the cell surface is regulated by their activation in 
a Ca2+-dependent manner (Robinson and Murrell-Lagnado, 2013). For P2X4 that is 
predominantly intracellular, enhanced translocation of intracellular receptors to the 
cell surface as a mechanism of up-regulating receptor function. In macrophages, 
P2X4 surface expression has been shown to be increased following stimulation that 
promotes lysosome exocytosis via alkalinazation of lysosomes or increasing 
cytosolic Ca2+ level (Qureshi et al., 2007). In addition to their activation, the 
trafficking and targeting of P2XR is also regulated by their interactions with other 
proteins and lipids which can vary from cell to cell (Robinson and Murrell-Lagnado, 
2013, Pike, 2004). P2X4 expressed in HEK293 cells have been illustrated to 
associate with lipid rafts generated using a detergent-free approach (Allsopp et al., 
2010). The exact mechanism to which P2X4 target rafts has not been determined.  
 
1.4.2.4 Single nucleotide polymorphism  
Single nucleotide polymorphisms (SNPs) are common in the genes encoding 
human P2XR (Caseley et al., 2014). Although P2X7 present the highest number of 
polymorphisms and contain a large set of SNPs, reports within the literature 
identified four nonsynonymous polymorphisms in the human P2X4 gene (Stokes et 
al., 2011). Genotyping of two Australian cohorts by Stokes et al. (2011) illustrated 
polymorphism of P2X4 as a potential risk factor for high pulse pressure. It was 
identified that this SNP caused substitution of tyrosine315 with cysteine in the 
human P2X4 causing impairment of the receptor function. Electrophysiological 
analysis revealed that this mutation caused a significant reduction of ATP-induced 
peak current amplitude when compared to wild-type P2X4 (Stokes et al., 2011). It 
was speculated that this mutation resulted in the disruption of the agonist binding 
site of the receptor, hence impairing receptor function.   
	 55 
1.4.2.5 Expression in immune cells 
Amongst the P2XR, P2X4, along with P2X7, are the predominant receptors found 
within immune cells (Boumechache et al., 2009, de Rivero Vaccari et al., 2012, 
Jacob et al., 2013). The expression of P2X4 has been described in almost all 
immune cells including lymphocytes (B, T lymphocytes and NK cells), 
monocytes/macrophages, mast cells and eosinophils. Despite its widespread 
distribution in immune cells, no studies have reported the expression of P2X4 in 
neutrophils. A thorough quantitative mRNA analysis by Wang et al. (2004) identified 
mRNA expression of P2X4 to be the highest in lymphocytes and monocytes. The 
high expression of P2X4 in T lymphocytes and B lymphocytes was also elaborated 
further in studies reported by Di Virgilio et al. (2001) and Sluyter et al. (2001), 
respectively. mRNA expression of P2X4 was also detected in NK cells by Gorini et 
al. (2010). Corroborating with reports by Wang et al. (2004), various other studies 
have also illustrated the expression of P2X4 in monocytes, macrophages and 
microglia where it plays a role in the release of inflammatory mediators (Ulmann et 
al., 2010, Tsuda et al., 2003, Raouf et al., 2007, Bowler et al., 2003). Following 
peripheral nerve injury, the expression of P2X4 on the surface of spinal microglia 
was described to be upregulated which results in the release of brain-derived 
neurotrophic factor (BDNF) contributing to chronic neuropathic pain (Tsuda et al., 
2003, Trang and Salter, 2012). Whole-cell recordings of mouse peritoneal 
macrophages further illustrated functional P2X4 through ATP-evoked inward 
currents (Sim et al., 2007) and co-expression of P2X4 and P2X6 subunits was also 
identified in subpopulations of rat Kupffer cells (the liver macrophage). All murine 
and rat macrophage cell lines have been shown to express P2X4 subtypes which 
have also been demonstrated to be functionally implicated in evoking ATP-mediated 
increase in cytosolic Ca2+ levels (Coutinho-Silva et al., 2005, Bowler et al., 2003). In 
humans, the expression of P2X4 has been reported in alveolar macrophages 
(Myrtek et al., 2008) and monocyte derived macrophages (Stokes et al., 2011, de 
Rivero Vaccari et al., 2012). However, no functional implications through induction 
of intracellular Ca2+ elevation have been demonstrated in alveolar macrophages.  
 
In addition to monocytes, macrophages and lymphocytes, co-expression of P2X4 
and P2X7 subunits was identified in rat dendritic cells (Xiang et al., 2006). Human 
dendritic cells were found to express mRNA for P2X4 (Di Virgilio et al., 2001, 
Berchtold et al., 1999) and evidence of functional P2X4 was described in immature 
and mature dendritic cells through Ca2+ measurement studies (Ferrari et al., 2000b). 
Finally, mRNA transcripts for P2X4 have been described in human eosinophils 
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(Ferrari et al., 2000a, Ferrari et al., 2006, Idzko et al., 2001) and in human lung mast 
cells (HLMC) (Bradding et al., 2003). Despite reports of P2X4 expression in 
eosinophils and mast cells, their function remains unexplored.  
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1.4.3 ATP as DAMP signal to activate purinergic receptors in 
macrophages  
For many years, the main source of ATP acting on purinergic receptors was thought 
to be damaged or dying cells. However, it is now clear that many healthy cells can 
release ATP physiologically in response to many factors such as mechanical 
distortion, hypoxia and other agents (Bodin and Burnstock, 2001). For example, 
during acute inflammation, there is an increase in ATP release from endothelial cells 
which can act on cell surface receptors P2XR and P2YR. This extracellular ATP is 
quickly degraded by a series cell surface enzymes called ectonucleotidases into 
ADP, AMP and adenosines (Cekic and Linden, 2016). These enzymes can be 
further categorized into nucleoside triphosphate diphosphohydrolases (NTPDases 
1, 2, 3 and 8), nucleotide pyrophosphatases (NPP 1, 2 and 3), alkaline phosphatase 
and 5’ nucleotidase (Yegutkin, 2008, Robson et al., 2006). Ectonucleotidases, 
ENTPDases, like CD39 degrades ATP into ADP and ADP into AMP while 5’ 
nucleotidase, like CD73, converts AMP into adenosine (Burnstock and Boeynaems, 
2014).  
 
Macrophages are thought to be able to respond to extracellular ATP gradients at 
three basic stages. First, macrophages migrate towards increasing ATP 
concentration, second, they use the ATP gradients from apoptotic cells as a ‘find-
me’ signal to locate and phagocytose the dying cells. Lastly, in the presence of high 
concentrations of ATP, macrophages are able to robustly secrete pro-inflammatory 
cytokines (Desai and Leitinger, 2014). The presence of extracellular ATP has been 
shown to inhibit macrophage-mediated cytotoxicity of human tumour cells 
(Cameron, 1984) 
 
1.4.4 Role of P2 receptors in macrophages 
P2XR are widely distributed throughout tissues, both excitable and non-excitable, of 
the mammalian system (Zemkova et al., 2008). Despite their wide distribution, it has 
been illustrated that the mammalian brain has the highest levels of purines and the 
greatest variety of purinergic receptors (Buell et al., 1996, Seguela et al., 1996). In 
other tissues of the mammalian system, the distribution of P2XR has been 
described to be more variable with P2X4 and P2X7 being the predominant P2XR 
expressed in immune cells (Buell et al., 1996, Soto et al., 1996b). Tabulated 
information regarding the distribution of different subtypes of P2XR and P2YR in the 
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mammalian system is shown in Table 1.2 and 1.3, respectively. Table 1.4 illustrated 
the roles of P2XR and P2YR in macrophages of the immune system.  
 
Most research in immune cells like macrophages has focused on understanding the 
role of P2X7 (Table 1.4) (Griffiths et al., 1995, Perregaux and Gabel, 1994). P2X7 
has been shown to be expressed in human monocyte-derived macrophages and 
also in BAC1.2F5 mouse macrophages with their main function being to mediate 
phospholipase (PL) D activity (el-Moatassim and Dubyak, 1993, Hickman et al., 
1994). In RAW 264.7 mouse macrophages, ATP released through stimulation with 
LPS increased nitric oxide synthase (NOS) expression and production of nitric oxide 
(NO) and has been shown to induce activation and production of tissue factors that 
favors thrombosis (Sperlagh et al., 1998, Tonetti et al., 1994). P2X7 has also been 
shown to be important in mediating phagocytosis where over-expression of P2X7 
was observed during phagocytosis of non-opsonized beads and heat-inactivated 
bacteria (Gu et al., 2012, Gu et al., 2010). Loss of function polymorphisms of P2X7 
and P2X4 are associated with reduction in phagocytosis and were seen in patients 
suffering from macular degeneration (Gu et al., 2013). 
 
Although P2X7 have been illustrated to play a dominant role in macrophages of the 
immune system, evidence of the involvement of other receptors has slowly 
accumulated. Studies in the spleen and peritoneal macrophages of mouse J774 
allowed the identification of multiple P2XR and P2YR subtypes (Coutinho-Silva et 
al., 2005). In human alveolar macrophages, mRNA expression of multiple P2XR 
(P2X1, P2X4, P2X5 and P2X7) and multiple P2YR (P2Y2, P2Y4, P2Y6, P2Y11, P2Y13 
and P2Y14) were observed (Myrtek et al., 2008). The potential roles of P2X4 in 
macrophages, often working together with P2X7, have also been slowly emerging. 
Examples of this include the possible involvement of P2X4 in the ATP-mediated 
current of human macrophages as slowly desensitizing ATP-induced currents were 
abolished in P2X4 knockout mice (Brone et al., 2007). Studies using siRNA against 
P2X4 illustrated a potential role of P2X4 in regulating P2X7-induced cell death 
(Kawano et al., 2012a, Kawano et al., 2012b).  
 
In addition to P2XR, P2YR have also been illustrated to be expressed and found to 
be functional in macrophages of the immune system. Knockout studies showed that 
P2Y2 and P2Y4 are the dominant P2YR subtypes in mouse peritoneal macrophages 
(del Rey et al., 2006). Out of the P2YR, involvement of P2Y2 has been studied the 
most in macrophages. DAMP signals such as nucleotides, are released by apoptotic 
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cells and promote P2Y2-dependent recruitment of phagocytic macrophages. This 
recruitment of phagocytic macrophages was shown to be reduced in P2Y2-deficient 
mice (Elliott et al., 2009).  
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Purinergic receptors Potential function  
 
P2Y1, P2Y2, P2Y4, P2Y11, 
P2X1, P2X4, P2X7 
 
 
Increase in intracellular Ca2+  
 
P2X7 
 
Release of IL-1b 
Release of cathepsins  
 
 
P2X4, P2X7 
 
Regulation of autophagy 
Release of PGE2  
 
 
P2Y2, P2Y12, P2X1, P2X3 
 
 
Promotion of chemotaxis and phagocytosis 
 
P2Y4, P2Y6, P2Y11-14, P2X1-6 
 
 
Undefined roles 
 
Table 1.4. Role of purinergic receptors in human macrophages. Potential roles 
of P2XR and P2YR in macrophages of the immune system. Adapted from Jacobson 
et al., 2013. 
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1.4.4.1 Role of P2 receptors in control of cytokines of immune cells  
The production of cytokines in the immune system is a tightly regulated process as 
dysregulation can act as a contributor to disease pathologies. Studies have 
revealed that the modulation of P2 receptors can affect production of cytokines. 
 
1.4.4.1.1 P2X receptors 
The most well studied P2 receptor that has been associated with cytokine secretion 
is P2X7. In macrophages, P2X7 have been associated with roles such as mediating 
pro-inflammatory response achieved through the secretion of IL-1b and bacterial 
killing. It has been described in several cellular systems that a rise in intracellular 
Ca2+ level promoted by P2X7 activation is required for IL-1b posttranslational 
processing (Brough et al., 2003, Gudipaty et al., 2003). The involvement of P2X7 in 
IL-1b secretion is evident from studies illustrating that high ATP concentrations (>1 
mM) is an effective stimuli for posttranslational processing of IL-1b and that this high 
agonist concentration is a requirement consistent with activation of P2X7. This was 
confirmed with studies using P2X7-deficient mice where ATP-induced secretion of 
IL-1b was abolished (Qu et al., 2007, Solle et al., 2001). 
 
Apart from P2X7, there is generally no association with the activation of other P2X 
receptors and cytokine modulation. However, more recently, activation of P2X4 has 
been shown to mediate prostaglandin E2 (PGE2) release by tissue-resident 
macrophages, initiating inflammatory pain (Ulmann et al., 2010). In addition to this, 
P2X4 knockdown studies in mouse macrophages RAW264.7 showed that P2X4 
modulates P2X7-dependent inflammatory functions such as release of high mobility 
group box 1 (HMGB1) and IL-1b production (Kawano et al., 2012a). Further study 
by Chen et al. (2013) illustrated that P2X4 expression was co-localized with NLRP3 
inflammasome, IL-1b and IL-18 expression and that ATP-P2X4 signaling regulates 
IL-1 family cytokine secretion.  
 
1.4.4.1.2 P2Y receptors 
P2Y6 is a P2YR subtype that has been well-studied in macrophages and has gained 
much interest. P2Y6 expression has been shown to be upregulated following 
macrophage activation (del Rey et al., 2006) and that knocking out P2Y6 in mice 
impaired their ability to secrete cytokine IL-6 and macrophage inflammatory protein 
2 (MIP-2) (Bar et al., 2008). Several reports have also linked P2Y6 function to the 
expression of IL-8, which is important for the recruitment of neutrophils to sites of 
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infection (Luster, 1998, Mukaida, 2003). Although the mechanism by which P2Y6 
mediates cytokine production is still not clear, it is speculated that it may involve the 
activation of PLC and the involvement of intracellular Ca2+. The rise in intracellular 
Ca2+ is thought to be coupled to an ERK-activated signaling pathway which 
ultimately leads to the expression of IL-8 (Warny et al., 2001). Another speculation 
is that a rise in intracellular Ca2+ concentrations is linked to NF-kb transcription 
factor which has been associated with expression of cytokine genes (Korcok et al., 
2005). 
 
Amongst the P2Y receptors, P2Y11 is another subtype that has been studied for 
their role in modulating cytokine secretion, especially in human dendritic cells. In 
dendritic cells, P2Y11 has been associated with IL-12 and IL-23 production, both of 
which are key cytokines for the activation of Th1 state (Trinchieri, 2003b, Trinchieri, 
2003a, Langrish et al., 2004). P2Y11 has also been reported as a functional receptor 
in macrophages with its activation speculated to induce polarization of macrophages 
towards M1 phenotype, characterized by an increase in the production of IL-12 
cytokines (Sakaki et al., 2013b). Further to this, the regulation of IL-12 and IL-23 
expression by P2Y11 is thought to be achieved through the activation of Gas-type G 
protein which leads to the activation of adenylate cyclase and a rise in cAMP level 
(Wilkin et al., 2002, Gabel, 2007). Finally, P2Y2 has also been shown to mediate 
potentiation of PGE2 release which is involved in the induction of NOS resulting in 
the stimulation of chemokine CCL2 production (Stokes and Surprenant, 2007).  
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1.4.5 Therapeutic exploitation 
In the past decade, P2XR and P2YR have gained significant interest as potential 
therapeutic targets as various studies have illustrated their link with diseases such 
as atherosclerosis, thrombosis, diabetes and neuropathic pain (Burnstock and 
Williams, 2000, Balasubramanian et al., 2010, Kaczmarek-Hajek et al., 2012). Many 
efforts have been invested in designing selective and potent agonists and 
antagonists, small molecules and antibodies to target these receptors. Despite 
continued efforts, few examples of therapeutically useful compounds exist. This is 
mainly because P2 receptors display a wide tissue distribution making it difficult to 
target them specifically. In addition to this, P2 receptors are tightly regulated by 
enzymes such as ectonucleotidases and may be co-activated with other receptors 
(purinergic and non-purinergic). For these reasons, developing novel drugs to target 
P2 receptors for the treatment of macrophage-associated pathologies remain a 
challenging area for the pharmaceutical industry.  
 
Amongst the P2XRs, P2X3 has been targeted for visceral pain due to its limited 
distribution on primary afferent fibers and more recently, it has also been targeted 
for treatment of chronic cough (Abdulqawi et al., 2015). P2X7 have been studied 
extensively leading to the development of many potent small molecules and 
selective blockers by pharmaceutical companies. P2X7 were initially identified as a 
potential target for the treatment of rheumatoid arthritis but trials only reached phase 
IIb before being terminated (Keystone et al., 2012, North and Jarvis, 2013). In 
addition to this, P2X4 has gained significant interest as a target for the treatment of 
chronic pain. This was derived from several studies illustrating that following spinal 
cord injury or peripheral nerve injury, P2X4 expression is upregulated in activated 
microglia and that P2X4 knockout mice, tactile allodynia was significantly reduced 
compared with wild-type mice (Tsuda et al., 2003). Therapeutic exploitation of P2YR 
have been more successful with P2Y2 agonist and antagonist being used as a 
treatment for dry eye disease and antimicrobial treatment, respectively (Jacobson et 
al., 2012, Lau et al., 2014), and P2Y12 antagonists (i.e. clopidogrel and ticagrelor) 
being used clinically for the treatment of acute coronary syndrome (ACS) (Fuller and 
Chavez, 2012, Jacobson et al., 2012, Chua and Ignaszewski, 2009).  
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1.5 Key aims and outline of project 
It is apparent from the current literature that human macrophages express various 
P2XRs and P2YRs. There is a clear understanding to what the role of P2X7 is in 
human macrophages allowing it to be exploited therapeutically with several drugs 
being developed to target this receptor. However, even though P2X4 is highly 
expressed in immune cells, the lack of selective antagonists and agonists for this 
receptor mean that our understanding of the functional role of P2X4 in human 
macrophages is still lacking. Many recent studies have proposed potential roles of 
P2X4 in the context of inflammatory responses within the immune system, which can 
be associated with inflammatory diseases. Therefore, this project hopes to study the 
contribution of P2X4 towards ATP-evoked Ca2+ response in human macrophages 
using various pharmacological tools while also elucidating a functional role of P2X4. 
To achieve this, three key aims were set during this project:  
 
1) To identify key pharmacological tools which can be used to selectively isolate 
P2X4-mediated Ca2+ influx in human cell lines. This will be discussed in chapter 3 of 
the thesis where I performed a side-by-side comparison of human THP-1 monocytic 
cell line vs. human THP-1 differentiated macrophages cell line. 
 
2) To identify and characterize the contribution of P2X4 activation towards 
intracellular Ca2+ level in human primary macrophages using the limited 
pharmacological tools available for P2X4. As there are two main ways to generate 
human monocyte-derived macrophages (MDM); either through stimulation with 
recombinant human GM-CSF (GM-MDM) or M-CSF (M-MDM), chapter 4 will 
discuss a side-by-side comparison to identify which of the two, is a better model to 
study P2X4-mediated Ca2+ response. 
 
3) To elucidate a functional role of P2X4 in human macrophages, mainly in the 
context of cytokine and chemokine secretion in response to ATP stimulation. This 
will be discussed in chapter 5 of the thesis focusing on the approaches used to 
select candidate genes that may be affected by P2X4 activation.  
 
Overall, this project hopes to increase the current understanding of the usefulness 
of some of the pharmacological tools commercially available for P2X4 and expand 
our knowledge on the role of P2X4 activation in human macrophages. 
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Chapter 2: Materials and Methods 
 
2.1 Materials and reagents  
A comprehensive list of all ligands, modulators and inhibitors used throughout the 
study are presented in tables 2.1 to 2.5.    
 
Table 2.1: Extracellular nucleotides 
Nucleotide Supplier Purity Final conc. 
ATP Sigma ≥ 99% 0.01 – 1000 µM 
a,b-meATP Sigma ≥ 93% 1 – 100 µM 
BzATP Sigma ≥ 93% 1 – 500 µM 
 
 
Table 2.2: Purinergic receptor modulator 
Compound Function Supplier Final conc. Ref 
Ivermectin P2X4 positive allosteric 
modulator 
Tocris 3 µM Li & Fountain, 
(2012) 
 
 
Table 2.3: Purinergic receptor antagonists 
Compound Receptor target Supplier Final conc. Ref 
PSB-12062 P2X4 Sigma 10 µM Hernandez-Olmos et 
al. (2012) 
5-BDBD P2X4 Tocris 10 µM Fischer et al. (2004) 
Balazs et al. (2013) 
A438079 P2X7 Abcam 10 µM Bhaskaracharya et al. 
(2014) 
Ro0437626 P2X1 Tocris 30 µM Jaime-Figueroa et al. 
(2005) 
MRS2211 P2Y13 Tocris 10 µM Kim et al. (2005) 
NF340 P2Y11 Tocris 10 µM Kim et al. (2005) 
AR-
C118925xx 
P2Y2 Tocris 10 µM Kemp et al. (2004) 
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MRS2578 P2Y6 Tocris 10 µM Mamedova et al. 
(2004) 
Koizumi et al. (2007) 
MRS2500 P2Y1 Tocris 1 µM Kim et al. (2003) 
Hechler et al. (2006) 
 
Table 2.4: Inhibitors and modulators 
Compound Function Supplier Final conc. Ref 
Thapsigargin SERCA pump 
inhibitor 
Santa-
Cruz 
5 µM Robinson et al. (1992) 
Shima et al. (1992) 
U-73122 PLC inhibitor Tocris 10 µM Hollywood et al. (2010) 
McMillan & McCarron 
(2010) 
Dynasore Dynamin 
inhibitor 
Sigma 80 µM Macia et al. (2006) 
Kirchhausen et al. 
(2008) 
Vacuolin-1 Ca2+-dependent 
lysosomal 
fusion inhibitor 
Santa-
Cruz 
1 µM Cerny et al. (2004) 
Huynh et al. (2005)  
 
Table 2.5: Differentiation and stimulating factors 
Compound Function Supplier Final conc. Ref 
PMA PKC activator Abcam 320 nM Ke et al. (2015) 
Park et al. (2007) 
Zhang et al. (2014) 
rhuGM-CSF Differentiation factor Peprotech 10 ng/ml Dabritz et al. (2015) 
Buttari et al. (2014) 
Castiello et al. 
(2011) 
rhuM-CSF Differentiation factor Peprotech 10 ng/ml Buttari et al. (2014) 
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2.2 Cell culture 
 
2.2.1 THP-1 cells 
2.2.1.1 General maintenance  
THP-1 cells are a human cell line originally derived from a patient with acute 
monocytic leukemia. They have become one of the most widely used cell lines to 
study function and regulation of monocytes and macrophages (Qin, 2012). Cells 
were obtained from European Collection of Cell Cultures (ECACC) and cultured in 
Roswell Park Memorial Institute (RPMI)-1640 media containing 0.3 g/L L-Glutamine 
(Lonza), supplemented with 10% (v/v) heat-inactivated foetal bovine serum (FBS; 
PAA Laboratories) and 1% (v/v) penicillin-streptomycin solution containing 50 
units/ml penicillin and 50 µg/ml streptomycin (Life Technologies).  
 
2.2.1.2 Cell passage  
THP-1 cells were cultured in suspension, in vented T75 flasks (Nunc) at 37oC in a 
humidified 5% CO2 incubator. Cells were routinely counted using a haemocytometer 
and passaged by diluting them to the required cell density. Cell density was 
maintained below 8x105 cells/ml to prevent spontaneous differentiation into 
macrophages.  
 
 2.2.1.3 Cryopreservation and Thawing 
For cryopreservation, cells were stored at a density of 1x106/ml in THP-1 cell culture 
media supplemented with 10% (v/v) glycerol. Cells were added into cryovials (Nunc) 
and stored in a Mr Frosty™ freezing container (Thermo Scientific) for overnight 
storage at -80oC before being transferred into a liquid nitrogen tank (-196oC). To 
thaw, cells were removed from liquid nitrogen and gently warmed at 37oC in a water 
bath until 70% thawed. Cells were then diluted in 10 ml of THP-1 culture media in a 
gentle manner to dilute the cryopreservant. Cells were centrifuged at 805 x g for 7 
minutes at room temperature and supernatant was removed. The resulting cell 
pellet was resuspended in 5 ml of THP-1 culture media and transferred to a vented 
T25 flask for incubation at 37oC in a humidified 5% CO2 incubator.  
 
 2.2.1.4 P2X4 Knockdown THP-1 cells 
P2X4 knockdown (P2X4-KD) THP-1 cells were generated by infecting THP-1 cells 
with lentiviral pLKO.1-puro shRNA constructs that target the human P2X4 receptor. 
Alongside this, THP-1 cells with non-target control vectors were also prepared. 
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These cells were cultured in THP-1 cell culture media and stable expression was 
maintained by puromycin supplementation at a final concentration of 1 µg/ml 
(InvivoGen). 
 
 2.2.1.5 THP-1-differentiated macrophages 
THP-1-differentiated macrophages were generated by stimulating THP-1 cells with 
320 nM of phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich) for 48 hours at 
37oC in a humidified 5% CO2 incubator. To check for differentiation, a change in cell 
morphology with increasing granularity was observed through an inverted 
microscope.   
 
2.2.2 1321N1 astrocytoma cells 
 2.2.2.1 General maintenance  
1321N1 is a human astrocytoma cell line derived from the parent line U-118 MG 
that originates from malignant gliomas (Pontén and Macintyre, 1968). 1321N1 cells 
was a kind gift from Professor Jens George Leipziger (Aarhus University) and were 
cultured in Dulbecco’s Modified Eagle Media containing L-Glutamine (0.6g/L) 
(DMEM) supplemented with 10% (v/v) heat-inactivated FBS and 1% (v/v) penicillin-
streptomycin solution containing 50 units/ml penicillin and 50µg/ml of streptomycin.  
 
 2.2.2.2 Cell passage 
Human 1321N1 cells are adherent and were cultured in vented T75 flasks (Nunc) at 
37oC in a humidified 5% CO2 incubator. Cells were passaged once they reached 
approximately 70% confluency. This was achieved by rinsing cells with 5 ml 
Dulbecco’s phosphate buffered saline (dPBS) followed by treatment with 3 ml of 
Trypsin solution (Lonza) at 37oC for 2-3 minutes. To detach the adherent cells, 
gentle agitation was applied to the flask and the enzymatic reaction was terminated 
by diluting trypsin with 1321N1 cell culture media in a 1:1 ratio. Cells were 
centrifuged at 805 x g for 7 minutes at room temperature and the supernatant was 
discarded. The cell pellet was resuspended in 1321N1 culture media and used or 
re-seeded into fresh T75 flasks for culture.  
 
 2.2.2.3 Cryopreservation and Thawing  
Cryopreservation of cells was performed as described for THP-1 cells (Section 
2.2.1.3), substituting THP-1 cell culture media for 1321N1 culture media. In addition 
to this, cells were resuspended in 45% (v/v) 1321N1 culture media, 45% (v/v) FBS 
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and 10% (v/v) dimethyl sulfoxide (DMSO). DMSO was used in cryopreservation of 
1321N1 cells in substitution of glycerol in THP-1 cells.  
 
 2.2.2.4 hP2X4 pLVX-IRES-mCherry 1321N1 astrocytoma cells  
hP2X4 pLVX-IRES mCherry 1321N1 were cultured in 1321N1 culture media and 
stable expression of mCherry was maintained by regular confirmation using the 
fluorescence microscope and re-sorting for highly expressing mCherry cells. To limit 
heterogeneity of hP2X4 mCherry 1321N1 cells within experiments, cells from the 
same passage were cryopreserved following sorting and were thawed out when 
necessary to perform an experiment.  
 
2.2.3 HEK293T/17 cells 
 2.2.3.1 General maintenance  
HEK293 is a cell line isolated from human embryonic kidney cells (Thomas and 
Smart, 2005). HEK293T/17 cells are derived from HEK293 cells that have been 
transfected with a gene encoding large T antigen, with clone 17 being selected 
specifically for its high transfectability. These cells were obtained from ECACC and 
were cultured in DMEM containing L-Glutamine (0.6 g/L) supplemented 10% (v/v) 
heat-inactivated FBS and 1% (v/v) penicillin-streptomycin solution containing 50 
units/ml of penicillin and 50 µg/ml of streptomycin.  
 
 2.2.3.2 Cell passage 
HEK293T/17 cells are adherent and were cultured in vented T75 flasks at 37oC in a 
humidified 5% CO2 incubator. HEK293T cells were passaged in a similar manner to 
1321N1 cells (Section 2.2.2.2), replacing 1321N1 cell culture media with 
HEK293T/17 culture media.  
 
 2.2.3.3 Cryopreservation and Thawing 
HEK293T/17 cells were cryopreserved and thawed in a similar manner to 1321N1 
cells (Section 2.2.2.3), replacing 1321N1 cells culture media with HEK293T/17 
culture media.  
 
 2.2.3.4 Generation of lentiviral particles   
For the generation of lentiviral particles, HEK293T/17 cells were plated in 150-mm2 
petri dishes (Nunc) at a density of 45x105 cells/ml. Cells were incubated overnight at 
37oC in a humidified 5% CO2 incubator (described in greater detail in section 2.6.3).   
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2.3  Primary Cell Isolation 
Human whole blood was obtained from healthy volunteers through the NHS blood 
and transplant service.  
 
2.3.1 Peripheral blood mononuclear cells (PBMC) isolation 
Whole blood was centrifuged at 1000 x g for 10 minutes with no brake to isolate 
plasma. To inactivate complement, the collected plasma was heat-inactivated at 
56oC for 30 minutes and centrifuged at 1000 x g for 20 minutes and supernatant 
was collected. Whole blood was diluted with RPMI in a 1:1 ratio and layered onto 15 
ml of Histopaque-1077 density gradient media before centrifuging at 1000 x g for 25 
minutes at room temperature with no brake. Following centrifugation, mononuclear 
cells were collected by gently transferring the opaque interface into a fresh 
centrifuge tube. Cells were washed with RPMI and sedimented at 300 x g for 10 
minutes at room temperature. Once supernatant was discarded, cells were washed 
twice with dPBS. The resultant PBMC pellet was resuspended in RPMI before 
counting the number of PBMCs using trypan blue exclusion on a haemocytometer. 
 
2.3.2 Monocyte adherence  
PBMCs were seeded into vented T75 flasks (Nunc) in RPMI at a density of 1.5x106 
cells for every cm2 and incubated at 37oC in a humidified 5% CO2 incubator for 2 
hours. Following incubation, adhered monocytes were washed thoroughly 6 – 8 
times with dPBS and cultured with tissue culture media (TCM). TCM were prepared 
by supplementing RPMI-1640 media containing 0.3 g/L L-Glutamine (Lonza) with 
2.5% (v/v) heat-inactivated autologous serum and 1% (v/v) penicillin-streptomycin 
solution containing 50 units/ml penicillin and 50 µg/ml streptomycin (Lonza).  
 
2.3.3 Generation of monocyte-derived macrophages 
To allow complete differentiation of monocytes into macrophages, monocytes were 
cultured in TCM supplemented with a colony-stimulating factor (CSF): 10 ng/ml of 
recombinant human macrophage colony stimulating factor (rhuM-CSF) or 
recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) 
(both from Peprotech). Cells were cultured with the desired CSF over a period of 6 
days at 37oC in a humidified 5% CO2 incubator. Cells were washed with dPBS and 
fresh CSF was added to the culture every 3 days.  
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Following 6 days culture, cells were detached from the flasks by treating each T75 
flasks with 5 ml of TrypLE Express solution (Life Technologies) and incubating for 
20 minutes at 37oC. Following gentle agitation to dislodge adherent cells, cells were 
centrifuged at 300 x g for 10 minutes at room temperature and the supernatant was 
discarded. The cell pellet was resuspended in TCM and used for experimentations.  
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2.4  Polymerase Chain Reaction (PCR) 
 
2.4.1 Total RNA extraction 
To obtain a cell lysate for RNA extraction, 1x106 cells were centrifuged at 805 x g for 
7 minutes at room temperature to obtain a pellet. Supernatant was removed and cell 
pellet was resuspended in 1 ml of TRI Reagent® (Sigma) to allow complete cell 
lysis and vortexed for 1 minute. TRI Reagent® is a single-step total RNA isolation 
reagent that was adapted from Chomczynski and Sacchi (1987). For every 1 ml of 
TRI Reagent®, 100 µl of 1-bromo-3-chloropropane was added to allow complete 
separation of homogenate into aqueous and organic phases. Samples were 
thoroughly vortexed and allowed to stand at room temperature for 15 minutes 
before centrifuging at 14,800 x g for 15 minutes at 4oC. Centrifugation resulted in 
the formation of three phases, which included a lower red organic phase containing 
protein, a cloudy interphase containing denatured proteins and genomic DNA, and 
an upper aqueous clear phase which contain RNA. This upper phase containing 
RNA was transferred to a fresh 1.5 ml microcentrifuge tube and 0.5 ml of propan-2-
ol (Fisher) was added to the RNA, vortexed and allowed to stand at room 
temperature for 15 minutes. Precipitation of the RNA was achieved by centrifuging 
the sample at 14,800 x g for 15 minutes at 4oC. Supernatant was discarded and the 
pellet was washed in 1 ml of ice-cold 75% (v/v) ethanol. The sample was 
centrifuged at 14,800 x g for 10 minutes at 4oC. Ethanol was gently removed from 
the tube, leaving the pellet to air-dry for up to 30 minutes. Rehydration of RNA was 
achieved through the addition of 20 µl of nuclease-free water followed by heating at 
65oC for 5 minutes.  
 
2.4.2 Elimination of genomic DNA using DNase I  
To remove contaminating DNA from purified RNA and remove divalent cations to 
limit RNA degradation, Ambion® DNA-free™ Kit (Life Technologies) was used. To 
each RNA sample 0.1 volume of 10X DNase I Buffer and 1 µl of rDNase was added 
and mixed gently before incubation at 37oC for 30 minutes. DNase inactivation 
reagent was added to each RNA sample at 0.1 volume and was left to incubate at 
room temperature, for 2 minutes. Lastly, RNA samples were centrifuged at 10,000 x 
g for 90 seconds and supernatant was transferred to a fresh tube without agitating 
pellet. RNA samples were kept at -80oC for long-term storage. 
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2.4.3 Total RNA quantification  
Total RNA (tRNA) concentration was quantified by adding 1 µl of the RNA sample to 
a NanoDrop 2000c UV-Vis spectrophotometer instrument (Thermo Scientific) and 
NanoDrop 2000c software. The absorbance was read at A260 (nm) and A280 (nm), 
with the ratio of the absorbance at 260 and 280 nm (A260/280) being used to assess 
the purity of nucleic acids. Samples with the A260/280 ratio value close to 2.00 were 
considered pure. RNA samples were kept at -80oC for long-term storage.  
 
2.4.4 Complementary DNA synthesis  
The isolated tRNA from section 2.4.1.2 was reverse transcribed into complementary 
DNA (cDNA). Reactions were prepared in duplicates where one reaction contained 
reverse transcriptase (RT) enzyme to allow the production of cDNA from target RNA 
sequence and a second sample contained no reverse transcriptase (RT’) enzyme 
and was used as a negative control to confirm that any PCR amplicon was derived 
from synthesized cDNA rather than genomic DNA.  
 
For each reaction, 1 µg of tRNA was randomly primed with 200 ng of random 
hexamers (Invitrogen) in a total volume of 11 µl and incubated at 70oC for 10 
minutes. Following RNA priming, each reaction was added into a 1.5 ml centrifuge 
tubes containing 4 µl of 5x first strand buffer (Invitrogen), 2 µl (0.1 M) of DTT 
(Invitrogen), 1 µl (200 U) of Superscript II Reverse transcriptase (Invitrogen) enzyme 
(to RT samples only), 0.5 µl (5 µM) dNTPs (Bioline) and 0.75 µl (30 U) of RNasin® 
ribonuclease inhibitor (Promega) to limit RNA degradation. Each reaction was made 
up to a total volume of 20 µl with nuclease-free water. Reactions were incubated in 
a 42oC water bath for 1 hour followed by heat inactivation at 70oC for 10 minutes. 
cDNA samples were stored at -20oC until required.  
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2.4.5 Non-quantitative reverse transcription-PCR 
Non-quantitative reverse transcription PCR (RT-PCR) technique was employed to 
detect gene expression of either functional or non-functional P2X5 in THP-1 cells, 
THP-1 differentiated macrophages (TDM) or monocyte-derived macrophages 
(MDM).  
 
2.4.5.1 Primers  
All primers were supplied lypholised from Sigma-Aldrich and were reconstituted to 
100 µM in nuclease-free water and stored at -20oC for long term storage. Working 
solutions of 10 µM concentration were prepared. ACTB primer pair serves as a 
positive control while P2X5 primer pair was used to distinguish between functional 
and non-functional isoforms of the receptor. Amplification of functional (containing 
exon 10) P2X5 will yield a band at 461 bp while amplification of non-functional (exon 
10-less) P2X5 will yield a band at 395 bp (Kotnis et al., 2010) (Table 2.6). 
 
 
 
Table 2.6: Primer sequences for b-actin and P2X5 
 
 
  
Gene Accession Number Sequence Direction 
Size 
(bp) 
ACTB 
NM_001101.
3 
CACAGAGCCTCGCCTTTGCC 
CGATGCCGTGCTCGATGGGG 
Sense 
Antisense 
282 
 
P2X5 
 
NM_001204
520.1 
CACTATTCTTTTAGCCGTCTGGAC 
TTCTGACTGCTGCTTCCACGCTTC 
Sense 
Antisense 
395 / 
461 
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2.4.5.2 PCR 
To investigate P2X receptor gene expression, prepared cDNA samples were used 
as a template for PCR amplification. Reactions for each primer were prepared in 0.2 
ml thin-walled nuclease-free microcentrifuge tubes with b-actin serving as a 
housekeeping gene. To each reaction, 1 µl of cDNA (either RT or RT‘), 1 µl (200 
nM) of forward primer, 1 µl (200 nM) of reverse primer, and 25 µl of ReadyMix™ 
Taq PCR Reaction Mix (Sigma-Aldrich) were added. Reactions were made up to a 
final volume of 50 µl with nuclease-free water and mixed gently and briefly 
centrifuged. To allow selective amplification, each sample reaction was thermally 
cycled. The following cycle conditions were used: initial denaturation of DNA helix at 
94oC for 1 minute, followed by 35 cycles of denaturation at 94oC for 30 seconds, 
annealing of primers to the DNA template at 55oC for 30 seconds and finally, 
extension of the cDNA strand by dNTPs addition at 72oC for 1 minute. The last step 
included extension at 72oC for 5 minutes to allow any single-stranded DNA to be 
fully extended. Amplified samples were stored at -20oC until further use.  
 
2.4.5.3 Agarose gel electrophoresis  
Agarose gel electrophoresis is one of the most common ways to separate DNA 
fragments by their size and allows visualization on a gel by the addition of ethidium 
bromide. DNA fragments are separated on the basis of charge with smaller 
fragments migrating faster than larger fragments. Agarose gel (Melford 
Laboratories) was prepared as a 1.5% (w/v) solution in 1x Tris-acetate-EDTA buffer 
(TAE, Thermo Scientific) and heated in a microwave until fully dissolved. To every 
100 ml of agarose gel made, 4 µl of ethidium bromide solution was added. The gel 
was poured onto a cast and allowed to set at room temperature for 30 minutes, 
before being transferred to an electrophoresis chamber containing 1 x TAE buffer. 
Samples were prepared by mixing 40 µl of PCR reaction with 8 µl of 6x purple 
loading dye (New England Biolabs) and were loaded into the wells of the gel. 
Alongside the samples, a 100 base-pair (bp) DNA ladder (New England Biolabs) 
was used as a molecular weight marker reference. DNA electrophoresis was carried 
out at 90V (volts) for 75 minutes. Gel visualization was performed under ultra violet 
(UV) light using a ChemiDoc™ XRS visualizer (Bio-Rad).  
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2.4.6 Quantitative real time-PCR 
Quantitative real-time PCR (qRT-PCR) combines PCR amplification and detection 
into a single step allowing quantification by labeling PCR products with fluorescent 
dyes during thermal cycling. qRT-PCR was performed using the TaqMan®-based 
detection using a fluorogenic probe specific to a target gene, which is detected as it 
accumulates during PCR. 
  
2.4.6.1 Primers 
All Taqman gene expression assays (primers and probes) were purchased from 
Applied Biosystems (Life Technologies) (Table 2.7 to 2.9) . All gene expression 
assays have FAM™ reporter dyes at the 5’ end of the Taqman® MGB probe and a 
non-fluorescent quencher (NFQ) at the 3’ end of the probe, with the MGB moiety 
attached to the quencher molecule. NFQ are advantageous in that it provides lower 
background signal giving more precise quantitation while the MGB moiety stabilizes 
the hybridized probe and effectively raises Tm. All TaqMan® MGB probes and 
primers were provided pre-mixed to a concentration of 18 µM for each primer and 5 
µM for the probe at a 20X mix. The housekeeping genes used in the qRT-PCR 
reactions were either ACTB, RPLP0 or GAPDH, depending on the cell type being 
investigated.   
 
2.4.6.2 Taqman RT-PCR assay 
cDNA samples were diluted to 10 ng using nuclease-free water. Samples (5 µl) 
alongside Taqman probes (15 µl) were added, to duplicate wells for each gene 
tested, to wells of a 96-well MicroAmp® fast optical plate (Applied Biosystems). 
Negative control wells were prepared for each gene tested by substituting cDNA 
samples with nuclease-free water in separate wells. For each gene of interest, a 
reaction mix was prepared by adding 10 µl TaqMan® PCR master mix (Applied 
Biosystems), 1 µl TaqMan® Gene Expression assay mix (Applied Biosystems) and 
4 µl nuclease-free water onto the diluted cDNA samples. The plate was then sealed 
with an optical adhesive cover (Applied Biosystems) and centrifuged briefly at 300 x 
g. Plates were loaded onto a 7500 fast real-time PCR machine (Applied 
Biosystems) and ran for 20 seconds at 50oC, 10 minutes at 95oC, followed by 40 
cycles of 15 seconds at 95oC and 1 minute at 60oC and a lastly, a dissociation step 
to assess for primer dimers and target specificity. Data was analysed using 7500 
software v.2.0.5 by recording the threshold cycle (Ct) value for each set of samples. 
Values were normalised against the geometric mean of housekeeping genes and 
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analysed using DDCt method to calculate the relative quantification values (2-DDCt), 
which measures the fold-change in gene expression to control cells. Gene 
expression that appears above Ct value of 35 were considered to be absent. 
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Table 2.7: Endogenous control Taqman probes 
Gene name Assay ID 
Reporter 
Dye 
Reporter 
Quencher 
Amplicon 
Length 
ACTB Hs01060665_g1 FAM NFQ 63 
RPLP0 Hs99999902_m1 FAM NFQ 105 
GAPDH Hs02758991_g1 FAM NFQ 93 
 
Table 2.8: P2X and P2Y receptor Taqman probes 
Gene name Assay ID 
Reporter 
Dye 
Reporter 
Quencher 
Amplicon 
Length 
P2X1 Hs00175686_m1 FAM NFQ 73 
P2X2 Hs04176268_g1 FAM NFQ 88 
P2X3 Hs01125554_m1 FAM NFQ 84 
P2X4 Hs00602442_m1 FAM NFQ 91 
P2X5 Hs01112471_m1 FAM NFQ 83 
P2X6 Hs01003997_m1 FAM NFQ 105 
P2X7 Hs00175721_m1 FAM NFQ 89 
P2Y1 Hs00704965_s1 FAM NFQ 73 
P2Y2 Hs04176264_s1 FAM NFQ 82 
P2Y4 Hs00267404_s1 FAM NFQ 91 
P2Y6 Hs00366312_m1 FAM NFQ 70 
P2Y11 Hs01038858_m1 FAM NFQ 72 
P2Y12 Hs01881698_s1 FAM NFQ 136 
P2Y13 Hs03043902_s1 FAM NFQ 63 
P2Y14 Hs01848195_s1 FAM NFQ 155 
 
Table 2.9: Cytokine and Chemokines Taqman probes 
Gene name Assay ID 
Reporter 
Dye 
Reporter 
Quencher 
Amplicon 
Length 
CXCL5 Hs01099660_g1 FAM NFQ 93 
TGFb2 Hs00234244_m1 FAM NFQ 92 
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2.5  Immunocytochemistry  
Immunocytochemistry was employed to determine the presence of P2X receptor 
proteins in cells. Cells were seeded at a density of 2.5x104/ml in each well of a 6-
well tissue culture plate (Nunc) lined with a sterile coverslip and were left to culture 
at 37oC in a humidified 5% CO2 incubator. Media was aspirated from each well and 
cells were gently rinsed twice with PBS (pH 7.4) at room temperature. Cells were 
fixed with 4% (w/v) paraformaldehyde in PBS for 15 minutes at room temperature. 
Once fixed, cells were washed twice with PBS and permeabilized with 0.25% (v/v) 
Triton X-100 (in PBS) for 10 minutes at room temperature. Following 
permeabilization, cells were washed three times with PBS and blocked with 1% 
(w/v) bovine serum albumin (BSA) (in PBS) for 30 minutes at room temperature to 
prevent non-specific binding of the antibodies. Following the blocking step, cells 
were sufficiently washed with PBS to remove excess protein that may prevent 
detection of the target antigen. Cells were incubated overnight at 4oC with primary 
antibody diluted in 1% (w/v) BSA (in PBS) (Table 2.10).  
 
Following overnight incubation with primary antibody, cells were washed thoroughly 
with PBS and incubated with secondary antibody in 1% (w/v) BSA (in PBS) for 1 
hour at room temperature, away from light (Table 2.10). To confirm that the 
secondary antibodies do not bind non-specifically, negative controls were prepared 
in which cells were stained only with secondary antibody and no primary antibody. 
Finally, cells were washed thoroughly with PBS and were placed on to glass slides 
that contained 20 µl Vectashield Antifade mounting media with DAPI (Vectorlabs). 
This mounting media was used to prevent photobleaching while DAPI was used to 
detect nuclear staining. The coverslips containing cells were then sealed on to the 
glass slides using nail varnish and were dried completely at room temperature away 
from light. For long term storage, the slides were kept at 4oC in the dark.   
 
2.5.1 Confocal microscopy 
Laser-scanning confocal microscope Zeiss LSM510 META (Zeiss) at the Henry 
Welcome Laboratory for Cell Imaging was used to visualize fixed cells following 
immunocytochemistry described in section 2.5. Images for each sample were 
standardized to corresponding negative control, which was stained only with 
secondary antibody.  
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Table 2.10: Primary and Secondary Antibodies for immunocytochemistry and 
flow cytometry (FACS) 
Target 
1o/2o
Ab 
Reactivity Host Clonality 
Dilution/ 
Conc. 
Supplier 
P2X1 1o Human Goat Polyclonal 1:200 Santa-Cruz 
P2X4 1o Human Rabbit Polyclonal 
1:200 (IC); 
0.8mg/ml 
(FACS) 
Alomone 
P2X4 (ext) 1o Human Rabbit Polyclonal 
0.8mg/ml 
(FACS) 
Alomone 
P2X5 1o Human Goat Polyclonal 1:200 Santa-Cruz 
P2X7 1o Human Goat Polyclonal 1:200 Santa-Cruz 
P2Y1 1o Human Rabbit Polyclonal 1:200 Santa-Cruz 
P2Y2 1o Human Goat Polyclonal 1:200 Santa-Cruz 
P2Y6 1o Human Rabbit Polyclonal 1:200 Alomone 
P2Y12 1o Human Goat Polyclonal 1:200 Santa-Cruz 
P2Y13 1o Human Goat Polyclonal 1:200 Santa-Cruz 
Alexa Fluor 
488 (AF488) 
2o Goat Rabbit Polyclonal 1:1000 Invitrogen 
Alexa Fluor 
488 (AF488) 
2o Rabbit Goat Polyclonal 1:1000 Invitrogen 
IgG Isotype 
Control (IC) 
1o Human Rabbit Polyclonal 
0.8mg/ml 
(FACS) 
Cell 
Signaling 
Technology 
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2.6  Generation of P2X4-knockdown THP-1 cells  
To better understand the functional role of P2X4 receptor, P2X4-knockdown THP-1 
cells were generated through a gene silencing strategy. The method selected was 
the delivery of short-hairpin ribonucleic acid (shRNA) sequences carried by lentiviral 
pLKO.1 puro (puromycin-resistant) vector (Moffat et al., 2006; Figure 2.1). This 
method was chosen as it enables the generation of long-term stable knockdown cell 
lines with the antibiotic used for selection maintenance. To generate the knockdown 
cell line, three components were required: a lentiviral vector (pLKO.1 puro vector) 
containing the shRNA or transgene, a packaging vector (psPAX2) and an envelope 
vector (pMD2.G). psPAX2 is a second-generation packaging plasmid containing a 
robust CAG promoter for efficient expression of packaging proteins. Meanwhile, 
pMD2.G envelope plasmid encodes for glycoproteins of vesicular stomatitis virus 
(VSV-G) that stabilise the viral particles.  
 
2.6.1 Preparation of plasmid DNA for transfection 
Bacterial glycerol stocks for pLKO.1 puro vectors carrying shRNA sequences 
targeting P2X4 were selected from the RNA interference (RNAi) consortium (TRC) 
and purchased from MISSION™ shRNA library (Sigma-Aldrich, Table 2.11). Serving 
as a negative control, pLKO.1 puro non-target shRNA control plasmid DNA was 
also purchased (Sigma-Aldrich). Bacterial stocks of psPAX2 and pMD2.G were 
purchased from Addgene.  
 
Bacterial glycerol stocks were streaked onto Luria Bertani agar plates (LB agar; 35 
g of LB agar in 1 L distilled water and sterilized by autoclaving) supplemented with 
100 µg/ml ampicillin. Plates were incubated facing down overnight at 37oC. A single 
colony from each plate was then transferred to 10 ml of LB broth (20 g of LB broth in 
1 L of distilled water and sterilized by autoclaving), supplemented with 100 µg/ml 
ampicillin. Colonies were left shaking at 220 revolutions per minute (rpm) overnight 
at 37oC. Following growth of bacteria, colonies were centrifuged at 805 x g for 10 
minutes and supernatant was discarded. Plasmid DNA was extracted using an 
E.Z.N.A Plasmid Mini Kit II (Omega Bio-Tek) following manufacturer’s instructions. 
Quantification of DNA in the samples was carried out using the Nanodrop system as 
described in 2.4.1.2. A260/A280 ratio of 1.8 is usually regarded as pure for DNA 
samples.   
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Figure 2.1 TRC1.5 vector map (pLKO.1-puro) with an shRNA insert. The length 
of the pLKO.1-puro plasmid including the shRNA insert is 7,086 bp. Image taken 
from sigma-aldrich website, accessed on 12th August 2015 
 
 
 
Table 2.11: Sequence of shRNA P2X4 plasmid DNA 
TRC No. Clone ID Sequence 
44962 NM_002560.2- 
563s1c1 
CCGGGCGGATTATGTGATACCAGCTCTCG 
AGAGCTGGTATCACATAATCCGCTTTTTG 
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2.6.2 Puromycin kill curve 
To determine the concentration of puromycin required to kill THP-1 cells, a 
puromycin kill curve was generated. A range of puromycin (InvivoGen) 
concentrations (0.1, 1 and 10 µg/ml) was tested over 5 days in triplicates. On day 0, 
in a 96-well black plate (Fisher Scientific), THP-1 cells were seeded at 200 µl per 
well with a density of 1x106 cells/ml in THP-1 culture media. Ranging concentrations 
of puromycin, or media alone as a blank, were added to the corresponding wells in 
the plate and cultured at 37oC in a humidified 5% CO2 incubator. Cell viability was 
tested every day for a total of 5-days period using CellTiter 96® AQueous One 
solution cell proliferation assay (Promega), a colorimetric assay that measures 
mitochondrial function through the ability of the cells to convert MTT into formazan. 
For each well 10 µl of CellTiter 96® AQueous One solution were added and 
incubated for 4 hours at 37oC in a humidified 5% CO2 incubator.  Quantity of 
formazan product was then measured by performing absorbance reading using the 
Flex Station III plate reader (Molecular Devices) at 490 nm, which is directly 
proportional to the number of live cells in the culture. Cell viability was then 
measured by taking away the absorbance value of media alone from individual 
samples. Based on this data, the optimal puromycin concentration sufficient to kill 
THP-1 cells was 1 µg/ml over 5 days (Figure 2.2).  
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Figure 2.2 Puromycin kill curve on THP-1 cells. The effect of varying 
concentrations of puromycin (0.1, 1 and 10 µg/ml) to THP-1 cells was investigated 
over 5 days period (n=3). THP-1 cells were seeded at a density of 1 x 106 cells/ml 
and cell viability was tested upon exposure of varying concentrations of puromycin 
across different time points using CellTiter 96® AQueous One solution cell 
proliferation assay.  
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2.6.3 Lentivirus production in HEK293T/17 
Lentivirus production was performed in HEK293T/17 cells (Section 2.2.3). For every 
pLKO.1 puro shRNA or non-target plasmid to be transfected, 9x106 HEK293T/17 
cells were seeded on a 150 mm petri dish (Thermo Scientific) in HEK293T/17 cell 
culture media without penicillin-streptomycin antibiotic. The cells were allowed to 
adhere overnight at 37oC in a humidified 5% CO2 incubator.  
 
Following the overnight incubation, 1.2 ml of serum free OPTIMEM media (Life 
Technologies) was added to two sterile 1.5 ml centrifuge tubes designated as tube 1 
and tube 2. To tube 1, 36 µl of lipofectamine 2000 transfection reagent (Life 
Technologies) was added. To tube 2, the following concentrations of plasmid DNA 
and lentivirus vectors were added: 9 µg lentiviral vector containing transgene 
(pLKO.1 puro P2RX4 or pLKO.1 puro non-target shRNA DNA), 12 µg psPAX2 
packaging vector and 3 µg pMD2.G envelope vector. Both reaction tubes were 
allowed to incubate for 5 minutes at room temperature followed by the addition of 
tube 1 contents to tube 2 and a further incubation for 20 minutes at room 
temperature. The reaction mix was added to the HEK293T/17 cells in a drop-wise 
manner and incubated at 37oC in a humidified 5% CO2 incubator for 6 hours. After 6 
hours, the transfection reagent was removed, replaced with fresh 20 ml HEK293T 
cell culture media containing penicillin-streptomycin antibiotics and allowed to 
culture for a further 24 hours. For the next 3 days, 20 ml of media (virus) was 
collected from the cells and passed through a 0.45 µm polyethersulfone (PES) filter 
(GE Healthcare) to remove cells or debris followed by addition of 20 ml fresh 
HEK293T/17 cell culture media. At the end of third day, 10 ml of Lenti-X™ 
Concentrator (ClonTech Laboratory Inc.) to every 30 ml virus-containing media and 
mixed by gentle inversion. This reaction was left to incubate overnight at 4oC. The 
following day, the virus was centrifuged at 1,000 x g for 45 minutes at 4oC and pellet 
was gently resuspended in 0.5 ml DMEM media with no additives. Viral samples 
were immediately aliquoted and stored at -80oC.  
 
2.6.4 p24 ELISA and determining viral titre 
To quantify lentivirus associated HIV-1 p24 core protein, QuickTiter™ Titer Kit 
(Lentivirus Associated HIV p24) was performed following the manufacturer’s 
protocol (Cell Biolabs, Inc). In brief, after forming complexes with ViraBind™ 
lentivirus reagent (patented technology), while free p24 remains in supernatant, the 
amount of lentivirus associated p24 is measured by a HIV p24 ELISA. The kit has 
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detection sensitivity limit of 1 ng/ml HIV p24, or about 10,000 to 100,000 TU/ml 
VSVG-pseudotyped lentivirus samples (Li et al., 2015, Xu et al., 2015). Detection 
was performed using FITC-conjugated anti-HIV p24 monoclonal antibody and HRP-
conjugated anti-FITC monoclonal antibody.  Absorbance was read for each well 
using FlexStation III plate reader at 450 nm. The results are shown in Figure 2.3.  
 
2.6.5 Transduction of lentiviral particles 
Prior to transduction of lentiviral particles into THP-1 cells, it was necessary to 
optimize lentiviral particles titre based on survival of cells against puromycin 
antibiotic selection. Cells were transduced with varying titre of scrambled or shRNA 
P2X4 lentiviral particles (0.5 – 50 µl) in the presence of 8 µg/ml hexadimethrine 
bromide for 24h at 37oC in a humidified 5% CO2 incubator and media was changed 
the following day. At day 3, 1 µg/ml of puromycin was added to all cells and cell 
viability was assessed using MTT method (as described in Section 2.6.2) and 
absorbance recorded at 490nm. The lentiviral particle titre that offers the cells with 
the most resistance towards puromycin was selected for transduction. Figure 2.4A 
and B illustrated that for both scrambled and shRNA P2X4 lentiviral particles, 5 µl 
served as the optimal titre for cell survival against antibiotic selection.  
 
Following identification of optimal lentiviral particle titre for transduction, THP-1 cells 
were seeded into 24-well tissue culture plates at 2x104 cells per well in 2 ml THP-1 
culture media. Several conditions were prepared: control well (cells alone with no 
treatment), scrambled shRNA well (5 µl of non-target shRNA transduction particles), 
P2X4 shRNA well (5 µl of virus generated as described in section 2.6.3). To promote 
transduction, a final concentration of 8 µg/ml hexadimethrine bromide was added 
into each well. Plates were incubated at 37oC in a humidified 5% CO2 incubator and 
media was changed the following day. At day 3, 1 µg/ml of puromycin was added to 
the non-control wells to select for cells stably incorporating the viral genome for a 
total of 5 days. Viability of cells was checked using the inverted microscope on a 
daily basis. Following 5 days, cells were removed from wells and centrifuged at 805 
x g for 7 minutes at room temperature. Supernatant was discarded and cell pellet 
was resuspended in THP-1 culture media before transferring into a vented T25 
flasks supplemented with 1 µg/ml puromycin.  
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Figure 2.3 HIV p24 ELISA standard curve of recombinant HIV-1 p24 antigen in 
the concentration range of 1 – 100 ng/ml. Lentivirus associated p24 amount in 
the supernatant was calculated per manufacturer’s guideline. The amount of virus-
associated p24 titer (ng/ml) in each sample was calculated based on standard curve 
fitting. To calculate the amount of lentiviral particle (LP) in each sample, p24 titre 
was multiplied by a value of 1.25 x 107, with the assumption that 1ng p24 = 1.24 x 
107 LPs. 
 
  
0 50 100
0
1
2
3
O
D
 4
50
nm
p24 (ng/ml)
	 88 
 
 
 
Figure 2.4 Identifying lentiviral particle titre for THP-1 transduction. THP-1 
cells were seeded at a density of 1 x 106 cells/ml and transduced with varying 
amounts of lentiviral particles before exposure to 1 µM puromycin selection over 5 
days. The optimal titre (0.5 – 50 µl) for lentiviral particle transduction was measured 
using CellTiter 96® AQueous One solution cell proliferation assay. 
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2.6.6 Flow cytometry   
To determine surface expression of P2X4 receptor in scrambled shRNA vs. P2X4 
shRNA cells, surface and total staining of P2X4 receptor was performed on flow 
cytometry. 1x106 scrambled shRNA or P2X4 shRNA TDM cells were prepared for 
surface staining. Cells were resuspended at a density of 1x106 cells/ml. For each 
staining, a negative control of 1) unstained cells, and 2) isotype control with 
secondary antibody were prepared. Cells were incubated with 1 µl Fc block for 10 
minutes at room temperature prior to staining. Cells were then stained with primary 
antibody of either 1 µl of rabbit polyclonal aP2RX4 (extracellular), 1 µl of rabbit 
polyclonal aP2RX4 (intracellular) antibody or 1 µl of mouse IgG polyclonal antibody 
(isotype control) (Table 2.10) and left to incubate at room temperature for 60 
minutes. Cells were washed with 3 ml of PBS once at 200 x g for 5 minutes and 
resuspended in 100 µl secondary antibody goat a-rabbit AF488, diluted in PBS 
(Table 2.9). Cells were incubated at room temperature for 60 minutes away from 
light. Finally, cells were washed with PBS at 200 x g for 5 minutes and transferred 
into 5 ml FACS tubes. Fluorescence intensity was read for AF488 using Cytoflex 
instrument (Beckman Coulter) and gates were set based on isotype control staining.  
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2.7  Generation of hP2X4 pLVX-IRES-mCherry over-
expressing 1321N1 cells  
pLVX-IRES-mCherry (Figure 2.5) is an HIV-1 based, lentiviral vector expressing two 
proteins from a bicistronic mRNA transcript, allowing mCherry to be expressed 
simultaneously with a protein of interest in any mammalian cell type. Additionally, 
the vector allows mCherry to be used as an indicator of transduction efficiency as 
well as a marker for selection by flow cytometry.  
 
2.7.1 Preparation of plasmid DNA for transfection 
P2X4 pLVX-IRES-mCherry construct was previously made in-house and was used 
to generate P2X4 overexpressing 1321N1 cell line. Briefly, BamHI restriction was 
performed on pLVX-IRES mCherry vector and P2X4-pcDNA3.1 construct (Figure 
2.6). Ligation of equal amounts of P2X4 insert with pLVX-IRES-mCherry vector was 
performed overnight at 16oC (T4 DNA ligase; New England Biolabs). Ligation 
product was transformed into Stbl3 chemically competent cells and plasmid DNA 
was isolated using E.Z.N.A Plasmid Mini Kit II (Omega Bio-Tek) following 
manufacturer’s instructions. 
 
2.7.2 Lentivirus production in HEK293T/17 
Production of lentivirus was performed as described previously in section 2.6.2 with 
lentiviral vector containing transgene being either empty pLVX-IRES-mCherry or 
hP2X4 pLVX-IRES-mCherry.  
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Figure 2.5 pLVX-IRES-mCherry vector map and multiple cloning site (MCS). 
Total length of the vector is 8,172 bp. Image was taken from Clontech website, 
accessed on the 12th August 2015.  
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Figure 2.6 pcDNA™ 3.1(+) and pcDNA™ 3.1(-) vector map. The total length of 
the vector is 5428 bp and 5427 bp for pcDNA™ 3.1 (+) and pcDNA™ 3.1 (-), 
respectively. The vector consists of ampicillin and neomycin resistance genes. 
Image was taken from Invitrogen website, accessed on 12th August 2015.     
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2.7.3 Viral transduction through spinoculation 
1321N1 cells are anecdotally known to not express any P2X receptors (Communi et 
al., 1996). P2X4 over-expressing stable 1321N1 cell line was generated by 
spinoculating hP2X4 pLVX-IRES-mCherry lentiviral particles into 1321N1 cells. A 
control of empty pLVX-IRES-mCherry 1321N1 cells was also generated. To perform 
spinoculation, 10 µl of lentiviral particles was added into every 1x105 1321N1 cells, 
supplemented with final concentration of 8 µg/ml of hexadimethrine bromide in a 15 
ml falcon tube. The tube was centrifuged at 1,400 x g for 60 minutes at room 
temperature. Virus-containing media was gently aspirated and pellet was very 
gently resuspended in 1 ml 1321N1 cell culture media and transferred into a vented 
T25 flask incubated at 37oC in a humidified 5% CO2 incubator.   
 
2.7.4 Cell sorting  
Highly expressing pLVX-IRES-mCherry 1321N1 cells (P4 population as shown in 
Figure 2.7A to C) were sorted using BD FACSAria™ III cell sorter (Becton 
Dickinson, BD) using standard FITC filter sets (Excitation: 587 nm; Emission: 610 
nm) and put back into a vented T75 for culture. Successful transduction of hP2X4 
pLVX-IRES-mCherry into 1321N1 astrocytoma cells was also confirmed using 
fluorescence microscopy (Figure 2.7D). 
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Figure 2.7 Sorting of mCherry-expressing 1321N1 astrocytoma cells. A) 
Histogram illustrating mCherry-expressing 1321N1 cells pre-sorting. P2 gating was 
set for low-expressing mCherry while P4 gating was set for highly-expressing 
mCherry. B) Histogram illustrating P2X4-mCherry expressing 1321N1 cells pre-
sorting. P2 and P4 gating was set as described above. C) Histogram illustrating 
P2X4-mCherry expressing 1321N1 cells post-gating. As can be seen, a much higher 
proportion of the cells are found to be positive within the P4 gating. Cells were 
sorted using the BD FACS Aria instrument at a density of 1x106 cells/ml. D) P2X4-
mCherry 1321N1 cells as seen under the fluorescence microscope post-sorting 
(Left: brightfield image; Right: fluorescence image under FITC laser). Images are 
representative of n=3.  
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2.8  Calcium mobilization  
Detection of intracellular calcium signals was performed using fluorescent Ca2+ 
indicator known as Fura-2 AM (Life Technologies), a ratiometric Ca2+ indicator. 
Fura-2 AM is a membrane-permeable indicator that can cross the cell membrane. 
Once inside the cell, their acetoxymethyl (AM) group is removed by cellular 
esterases resulting in the release of an ion-sensitive indicator that remains within 
the cell. Measurement of Ca2+-induced fluorescence at both 340 nm and 380 nm 
allows for calcium quantification based on 340/380 ratios. The use of ratio 
minimizes effects of photobleaching and eliminates variables such as local 
differences in fura-2 concentration as well as cell thickness, resulting in more 
accurate and reproducible results. Fura-2 AM was used in all calcium mobilization 
assays in all cell types.  
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Figure 2.8 Fura-2AM calcium indicator dye. (A) Hydrolysis of AM ester to allow 
the formation of Fura-2 and Ca2+ complex and fluorescence detection. Image was 
adapted from Dojindo Europe website, accessed on 12th August 2015. (B) 
Fluorescence excitation spectra of Fura-2 AM in solutions containing 0-39.8 µM free 
Ca2+. Image was taken from Life Technologies website, accessed on 12th August 
2015.  
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2.8.1 Calcium mobilization buffers  
Buffers required for the Ca2+ mobilization assay are shown in tables 2.12 and 2.13. 
Ca2+ loading buffer was prepared as described above in Table 2.12 with the addition 
of 0.01% (w/v) pluronic acid.  
 
 
Table 2.12: Ca2+ Salt-Buffered Solution (SBS) – pH 7.4 
Reagents Concentration (mM) 
Sodium chloride 130 
Potassium chloride 5 
Magnesium chloride 1.2 
Calcium chloride 1.5 
D-Glucose 8 
HEPES 10 
 
Table 2.13: Ca2+-free SBS – pH 7.4 
Reagents Concentration (mM) 
Sodium chloride 130 
Potassium chloride 5 
Magnesium chloride 1.2 
EGTA 2 
D-Glucose 8 
HEPES 10 
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2.8.2 Intracellular Ca2+ measurements on cells in suspension  
THP-1 cells were counted and harvested as triplicates at a density of 1x106 cells/ml. 
The required number of cells was centrifuged at 805 x g for 7 minutes at room 
temperature and supernatant was discarded. The resultant cell pellet was 
resuspended and loaded with a final concentration of 2 µM of Fura-2 AM in Ca2+ 
loading buffer (section 2.8.1) to a final cell density of 1x106 cells/ml. Cells were 
incubated in the dark for 1 hour at 37oC with gentle inversion every 15 minutes to 
prevent cells pelleting. Cells were washed twice with either Ca2+-SBS or Ca2+-free 
SBS at 805 x g for 7 minutes at room temperature. Cells were resuspended in SBS 
to a final concentration of 1x106 cells/ml and were plated into sterile black 96-well, 
clear-bottomed plate (Corning) at a final volume of 200 µl per well and allowed to 
settle for 1 hour at 37oC. Halfway through the incubation, if the effect of antagonists 
or modulators need to be investigated, the relevant compounds were added into the 
corresponding wells and were left to incubate for the rest of the 30 minutes at 37oC. 
Nucleotides were added by a FlexStation III microplate reader (Molecular Devices) 
set to deliver 50 µl from 96-well U-bottomed plates (Thermo Scientific). 
Fluorescence measurements were taken at lem = 510 nm, lex = 340 nm and lex = 
380 nm. Fluorescence at 340 nm and 380 nm were used to quantify the change in 
intracellular calcium levels, represented as F-ratio, following subtraction of baseline 
response.     
 
2.8.3 Intracellular Ca2+ measurements on adherent cell lines  
Adherent cells (human astrocytoma 1321N1 or HEK293T/17 cells) were diluted with 
their designated cell culture media to 1.25x105 cells/ml and added to wells (200 µl) 
of a sterile black 96-well, clear-bottomed plate (Corning) such that each well 
contained 2.5x104 cells. For primary cells (human MDM), cells were diluted in TCM 
to 1x106 cells/ml and each well consisted of 2x105 cells. Plates were incubated at 
37oC in a humidified 5% CO2 incubator overnight to allow cells to adhere and form a 
monolayer. The following day, media was carefully aspirated and replaced with 200 
µl of 2 µM Fura-2 AM diluted in Ca2+ loading buffer (section 2.8.1) followed by 
incubation for 1 hour at 37oC. After cells were loaded, the wells were washed twice 
in either Ca2+ containing or Ca2+ free SBS buffer. It is important to note, however, 
that leaving the cells with Ca2+ free SBS buffer is likely to affect intracellular store 
size by depleting them of intracellular Ca2+. To test the effect of various antagonists 
or modulators, compounds were added to the corresponding wells and left to 
incubate for another 30 minutes at 37oC in the dark. For all experiments, agonist 
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ATP was added by a FlexStation III microplate reader (Molecular Devices) set to 
deliver 50 µl from 96-well U-bottomed plates (Thermo Scientific). As described in 
section 2.8.2, fluorescence measurements were taken at lem = 510 nm, lex = 340 
nm and lex = 380 nm. Fluorescence at 340 nm and 380 nm were used to quantify 
the change in intracellular calcium levels, represented as F-ratio, following 
subtraction of baseline response.  
 
  
	 100 
2.9  Quantification of mRNA expression, secretion and 
synthesis of cytokines and chemokines 
 
2.9.1  human MDM stimulation  
GM-MDM cells were differentiated from monocytes following 6 days stimulation with 
rhuGM-CSF as described in section 2.3.3. Cells were seeded into sterile 24 well 
plates (Nunc) at a final amount of 0.5x106 cells per condition and allowed to settle 
for 24 hours at 37oC in a humidified 5% CO2 incubator. Following settling period, 
cells were washed once with sterile PBS and fresh TCM was added into each well. 
For the purpose of initial study to identify candidate genes using the profiler array, 
cells were stimulated for 6 hours with 100 µM ATP, with or without 30 minutes pre-
treatment of 10 µM PSB-12062. Unstimulated cells treated with vehicle (0.5% final 
DMSO concentration) served as negative control while 100 ng/ml 
lipopolysaccharide was used as positive control. For qRT-PCR time point studies, 
stimulation was performed at 6h, 9h, 18h and 24h. Following each stimulation time 
points, cells were lysed with TriReagent® and stored at -80oC until further use.  
 
2.9.2 RT2 profiler PCR Array  
To investigate if P2X4 receptor could mediate cytokine and chemokine expression, 
human Cytokines & Chemokines RT2 Profiler PCR Array (Qiagen) was done as a 
screening tool for potential candidate genes. This PCR array profiles the expression 
of 84 key secreted proteins (common cytokines as well as growth factors and 
hormones) that is central to the immune response (Figure 2.9 and Table 2.14).  
 
To each well of a 96-well human cytokines & chemokines RT2 profiler PCR Array 
(Qiagen), 5 µl cDNA samples (0.5 ng) were added alongside 20 µl of PCR master 
mix (2xRT2 SYBR Green ROX Mastermix diluted in RNase-free water) were added 
using multi-channel pipette, to reduce variability. Plate was then sealed with an 
optical adhesive cover and centrifuged briefly at 300 x g. Plates were loaded onto a 
7500 fast real-time PCR machine (Applied Biosystems) and ran for 20 seconds at 
50oC, 10 minutes at 95oC, followed by 40 cycles of 15 seconds at 95oC and 1 
minute at 60oC. This was followed by a continuous melt curve stage run for 15 
seconds at 95oC, 1 minute at 60oC, 30 seconds at 95oC and a final step for 15 
seconds at 60oC.    
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Data was analysed using 7500 software v.2.0.5 by recording down the threshold 
cycle (Ct) value for each samples. Values were corrected against the geometric 
mean of 5 housekeeping genes (ACTB, B2M, GAPDH, RPLP0 and HPRT1) and 
analysed using DDCt method to calculate the relative quantification values.  
 
2.9.3 Identifying the most stable housekeeping genes  
The RT2 Profiler PCR array included 5 internal housekeeping genes: ACTB, B2M, 
GAPDH, RPLP0 and HPRT1. It was important to identify which of the housekeeping 
genes served as the most stable reference genes for normalization of gene 
expression in human primary GM-MDM cells. Using RefFinder online database tool, 
the stability of the five reference genes were evaluated and compared using four 
different computational programs (geNorm, Normfinder, BestKeeper and the 
comparative DDCt method). Data shown in Figure A1 (Appendix section) illustrated 
that GAPDH serves as the most stable housekeeping genes in GM-MDM cells 
(N=5).  
 
2.9.4 Generating Heat Map for RT2 profiler analysis  
Heat Map was generated using Matrix2png tool 
(http://www.chibi.ubc.ca/matrix2png/) and data was represented as log2 fold change 
whereby the value 0 denotes no change in fold expression. Positive value denotes 
up-regulation in gene expression and negative value denotes down-regulation in 
gene expression.  
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Figure 2.9 Genes investigated in the human cytokine and chemokine RT2 
Profiler PCR Array. Each of the 96-wells plate consisted of 84 different human 
cytokine and chemokine genes (blue; listed on Table 2.14), 5 internal reference 
genes (red; ACTB – Actin B, B2M – Beta-2-microglobulin, GAPDH – 
Glyceraldehyde-3-phosphate dehydrogenase, HPRT1 – Hypoxanthine 
phosphoribosyltransferase 1, RPLP0 – ribosomal protein, large P0), 2 internal 
negative controls (green; HGDC – human genomic DNA contamination; RTC – 
reverse transcription control) and internal positive control (orange; PPC – positive 
PCR control).  
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Table 2.14 Gene Table: RT2 Profiler PCR Array 
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2.10  Sandwich Enzyme-Linked Immunosorbent Assay 
(Sandwich ELISA) 
ELISA is a technique used commonly for detecting and quantifying substances like 
proteins, peptides, antibodies and hormones. First developed in early 1970s, 
ELISAs rely on specific interaction between an epitope on an antigen and a 
matching antibody binding site. Sandwich ELISA requires the use of two antibodies: 
the capture and detection antibody. Detection is achieved through the assessment 
of conjugated enzyme activity by incubation with a substrate that gives a 
measurable product. 
 
2.10.1 Collection of supernatant samples and protein lysates for ELISA 
quantification 
To quantify secreted CXCL5 and TGFb2 protein, supernatants were collected at 
various time points following different agonist or antagonist treatments. 
Supernatants were stored at -80oC and freeze-thawing was avoided. To quantify the 
amount of synthesized CXCL5, protein was extracted from MDM cells using RIPA 
lysis and extraction buffer (ThermoFisher, UK) using the manufacturer’s 
instructions. In brief, 0.5x106 MDM cells in a 24-well plate format were lysed using 
100 µl of RIPA buffer containing protease inhibitor (1:200 dilution) for 10 minutes at 
4oC. Lysed cells were centrifuged at 10,000 x g for 10 minutes at 4oC, supernatants 
containing extracted protein were collected and stored at -80oC. The amount of 
protein in each sample was quantified using a colorimetric-based bicinchoninic acid 
(BCA) Protein Assay (ThermoFisher, UK) as per manufacturer’s instruction. BCA 
Protein Assay relies is a two-step protein detection assay that includes an initial 
step of biuret reaction which involve the chelation of copper with protein in an 
alkaline environment followed by a second step that involves a color development 
reaction. This color development is formed when BCA encounters reduced cation 
generated in the initial first step.  
 
2.10.2 Human CXCL5 ELISA 
The amount of secreted CXCL5 protein in conditioned supernatants or synthesized 
CXCL5 in protein lysates were quantified using the human CXCL5 ELISA Max™ 
Deluxe Set (Biolegend) as described per manufacturer’s protocol. In brief, 96-well 
Nunc™ Maxisorp™ ELISA plate was coated with Capture Antibody overnight at 
4oC. Plate was blocked with assay diluent A for 1h at RT followed by the addition of 
standards (1.9 – 125 pg/ml human CXCL5), supernatant samples (diluted 1:1), or 
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protein lysate samples (diluted 1:10) and left to incubate at RT for 2h. Detection 
antibody was added for 1h at RT followed by addition of avidin-HRP solution for a 
further 30 minutes. Finally, substrate solution was added to each well and left for 10 
minutes before stop solution was added to stop the reaction. Absorbance was 
recorded at 450 nm and 570 nm within 15 minutes of reaction. In between each step 
described above, plate was washed 4 times with wash buffer (PBS + 0.05% Tween) 
and complete removal of wash buffer was achieved by firmly tapping plate on clean 
absorbent paper.  
 
2.10.3 Human TGF-b2 ELISA 
The amount of secreted TGF-b2 protein in conditioned supernatants of MDM 
stimulation studies were performed using the human TGF-b2 DuoSet ELISA (R&D 
Systems) as described in the manufacturer’s protocol. In brief, 96-well microplate 
was coated with Capture Antibody overnight at RT. Plate was blocked with assay 
diluent for 1h at RT followed by the addition of standards (31.3 – 2000 pg/ml human 
TGF-b2) or supernatant samples (diluted 1:1) and left to incubate at RT for 2h. Prior 
to addition of supernatant samples to the plate, activation of latent TGF-b2 was 
performed using sample activation kit 1 (R&D systems), as per manufacturer’s 
protocol. Detection antibody was added for 2h at RT followed by addition of 
Streptavidin-HRP solution for a further 20 minutes. Finally, substrate solution was 
added to each well and left for 20 minutes before stop solution was added to stop 
the reaction. Absorbance was recorded at 450 nm and 570 nm. In between each 
step described above, plate was washed 3 times with wash buffer and complete 
removal of wash buffer was achieved by firmly tapping plate on clean absorbent 
paper.  
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2.11 Lactate Dehydrogenase (LDH) Cytotoxicity Assay 
LDH cytotoxicity assay (CaymanChem, UK) quantitates cell death in response to 
either chemical compounds or environmental factors. LDH is a soluble enzyme that 
is found within the cytosol of cells and it is released upon cell damage or lysis into 
the surrounding culture medium. The kit relies on measuring LDH activity in the 
culture medium as an indicator of cell membrane integrity, and therefore 
cytotoxicity. This assay was performed to identify if incubation with the P2X4 
antagonist, PSB-12062, over various time points were able to induce cytotoxicity to 
cells. Experiments were performed according to manufacturer’s protocol. In brief, 
conditioned supernatants collected from primary MDM stimulation experiments were 
centrifuged at 400 x g for 5 minutes to eliminate debris. Into a 96-well tissue culture 
plate, 100 µl of LDH standard or 100 µl of conditioned supernatants was incubated 
with 100 µl of LDH reaction solution with gentle shaking on an orbital shaker for 30 
minutes, at room temperature. Absorbance was read at 490 nm with a plate reader.  
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2.12 Data and Statistical Analysis  
All data were analyzed using Origin Pro 9.1 software (Origin Lab Corporation, USA) 
or Excel (Microsoft Corporation, USA). Data are represented as mean ± SEM 
(standard error of the mean), with n representing the number of experiments or 
replicates. For all experiments involving cell lines, ‘n’ number represents technical 
replicates while all experiments involving primary macrophages, ‘N’ number 
represents biological replicates as obtained from human donors. Statistical analysis 
between paired data was performed by means of Student’s paired t-tests while 
unpaired data was performed by means of Student’s unpaired t-tests statistical 
analysis. Statistical significance at the 5% (p<0.05), 1% levels (p<0.01) and 0.1% 
levels (p<0.001) has been indicated by the asterisks *, ** and *** respectively.  
 
2.12.1 Analysis of intracellular Ca2+ measurements   
Concentration response curves were fitted with Hill1 equation as described below, 
where start and end refers to lowest and highest point of the y-axis peak, 
respectively. If the value of (end – start) is greater than 0, n can be defined as 5 and 
k can be defined as 1.  ! = #$%&$ + ()*+ − #$%&$) ./0/ + ./ 
 
Analysis of peak magnitude was performed on SoftmaxPro software by deducting 
baseline Ca2+ level (lowest point of y-axis) from highest point of y-axis denoting the 
peak in F ratio unit (Figure 2.10). Analysis of decay kinetics (t) and area under the 
curve was performed using ExpDecay1 function and Integrate function in OriginPro 
9.1 software (Figure 2.10), respectively. ExpDecay1 function quantifies decay 
kinetics using the formula shown below, whereby y0, A1, and t1 represents Y offset, 
amplitude, and ‘time’ constant, respectively.  ! = !0 + 21	×	exp	 − . − .9$: 	 
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Figure 2.10 Representative time-trace response to illustrate analysis of Ca2+ 
response data. Peak magnitude response of Ca2+ response was quantified as the 
difference between the highest y-axis value minus the lowest y-axis value 
(represented as blue arrow). Decay kinetics (t) of Ca2+ response is quantified using 
the exponential decay function in OriginPro 9.1 software (represented as fitted red 
line). Net calcium movement within cell is quantified as area under the curve using 
integration function in OriginPro 9.1 (represented as grey shaded area).  
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Chapter 3: Investigating contribution 
of P2X4-mediated Ca2+ response in 
THP-1 monocyte/macrophage system 
3.1. Introduction 
P2X receptor family (P2X1-7) is widely distributed in both neuronal and non-neuronal 
tissues (Knight and Burnstock, 2004). Two receptors belonging to this family, P2X4 
and P2X7, are highly expressed in immune cells such as monocytes and 
macrophages and have generated increasing interest as potential anti-inflammatory 
drug targets (Bowler et al., 2003, Tsuda et al., 2003, Raouf et al., 2007, Li et al., 
2008, Ulmann et al., 2010). Due to the early identification of highly selective and 
potent P2X7 receptor antagonists, research development focusing on mechanism to 
which P2X7 could be targeted therapeutically have grown rapidly (Donnelly-Roberts 
and Jarvis, 2007). However, the case for P2X4 receptor remains tentative. This is 
mainly due to two reasons: the lack of selective P2X4 receptor antagonists and the 
complicating presence of P2X7, which is generally co-expressed with P2X4 in 
macrophages and microglia (Knight and Burnstock, 2004, Surprenant and North, 
2009).  
 
More recently, two selective P2X4 receptor antagonists have been made 
commercially available: 5-BDBD and PSB-12062. 5-BDBD, a derivative of 
benzodiazepine, was the first P2X4 antagonist to be described in a patent (Fisher et 
al., 2005) and has been shown to have a competitive nature (Balazs et al., 2013a). 
Therefore, most current studies involving P2X4 receptor have utilized 5-BDBD as a 
tool to block the receptor. The second and less known P2X4 antagonist is a 
derivative of N-substituted phenoxazine known as PSB-12062 (Hernandez-Olmos et 
al., 2012). It has been described to possess an allosteric nature with equal potency 
in three species: human, mouse and rat (IC50: 0.928 – 1.76 µM) (Hernandez-Olmos 
et al., 2012). With the development of selective P2X4 antagonists, research on the 
P2X4 receptor has slowly progressed.  
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The lack of available selective pharmacological tools to manipulate P2X4 has 
hampered research to identify its functional roles in immune cells. Despite reports 
that P2X4 is highly expressed in monocytes and macrophages, very little evidence 
has shown its relevance in these cells (Boumechache et al., 2009). So far, P2X4 has 
only been shown to play a secondary role in facilitating P2X7 in mouse 
macrophages with their co-expression illustrating enhanced P2X7-mediated cell 
death via Ca2+ influx (Kawano et al., 2012b). Further evidence showed that mice 
lacking P2X4 had reduced IL-1b production and M1 monocyte-derived macrophages 
(de Rivero Vaccari et al., 2012, Kawano et al., 2012b, Kawano et al., 2012a). These 
preliminary studies demonstrate the urgent need to explore P2X4 function in 
monocytes and macrophages and the prospect of identifying this receptor as 
therapeutic target for treatments of inflammatory conditions.  
 
One of the main sources of cells to study the monocyte/macrophage system comes 
from freshly isolated human monocytes. However, this remains technically 
challenging due to low availability of human samples, low cell yields and a high 
degree of variability due to their heterogeneous nature. The human monocytic THP-
1 cell line is a well-established in vitro model for studying monocyte function (Qin, 
2012). THP-1 cells have been shown to share a similar cell morphology and 
molecular marker expression as human monocytes (Auwerx, 1991). In addition to 
this, they can differentiate into cells that highly resemble macrophages following 
stimulation with low concentrations of phorbol 12-myristate 13-acetate (PMA) to 
allow in vitro study of macrophage function (Daigneault et al., 2010, Park et al., 
2007).   
 
3.2. Aims  
THP-1 cells and THP-1-differentiated macrophages (TDM) were employed as in 
vitro models to investigate the P2X4-mediated Ca2+ response. To address this aim, 
several pharmacological tools were employed to help characterize P2X4 through 
quantification of intracellular Ca2+ release. In addition to this, this chapter also aims 
to discuss which of the two is a better model to study the contribution of P2X4 
towards ATP-evoked Ca2+ responses.   
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3.3. Results  
3.3.1. Expression of P2X receptors in THP-1 monocytes vs. TDM   
Although THP-1 cells and TDM cells have been used widely to study P2X receptor 
functions, the expression of P2XR in these cells is not well documented. Therefore, 
mRNA and protein expression studies using qRT-PCR and confocal microscopy, 
respectively, was initially performed.  
 
mRNA expression of P2XR in THP-1 cells and TDM cells are described in Figure 
3.1. Quantitative comparison of the expression of each receptor was observed 
through the cycle threshold (Ct) values. Genes with Ct values greater than 35 were 
considered absent. As can be seen (Figure 3.1A), mRNA of P2X1, P2X4, P2X5, 
P2X6 and P2X7 was found to be expressed in both THP-1 cells and TDM cells. P2X2 
mRNA expression was only observed in THP-1 cells while P2X3 mRNA expression 
was absent in both cell types. With these Ct values, it was possible to quantitatively 
measure the fold change of each receptor in TDM cells vs. THP-1 cells. Figure 3.1B 
illustrated a significant down regulation of P2X1 and P2X2 mRNA expression (P2X1: 
0.38 ± 0.058 fold and P2X2: 0.13 ± 0.074 fold; n=5; P<0.001) in TDM cells 
compared to THP-1 cells. Interestingly, mRNA expression of P2X4 in TDM was 
significantly up regulated when compared to THP-1 cells (2.61 ± 0.52 fold; n=5; 
P<0.0.5; Figure 3.1B). No significant changes in mRNA expression of P2X5, P2X6 
and P2X7 were observed in the two cell types. In addition to this, non-quantitative 
reverse transcription (RT)-PCR was also performed to investigate if THP-1 and 
TDM cells express the functional or non-functional isoform of P2X5. Studies showed 
that a single-nucleotide polymorphism (SNP) at the 3’ splice end of exon 10 of 
human P2X5 gene can result in an exon 10-deleted isoform of P2X5 yielding a non-
functional and cytoplasmic distributed P2X5. A study investigated by Kotnis et al. 
(2010) showed that genotyping of human samples revealed predominance of the 
non-functional P2X5. Figure 3.1C and D illustrated that representative of n=3 
replicates, both THP-1 cells and TDM cells, respectively, express the non-functional 
(exon 10-less) P2X5 as observed with a band size of 395 bp.  
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Figure 3.1. Expression of P2X receptor genes in THP-1 differentiated 
macrophages. A) Table showing qRT-PCR Ct values to identify which P2X genes 
are expressed in THP-1 cells and TDM cells. Ct values that appear >35 were 
considered absent (n=3). Undetected genes are represented as N/A. B) Fold 
change in mRNA expression of P2X receptor genes in TDM cells, normalised to 
housekeeping gene and THP-1 cells (n=3). Asterisks include significant changes 
towards control (*** p<0.001, * p<0.05, Student’s t-test). C and D) Non-quantitative 
RT-PCR analysis of P2X5 mRNA expression to distinguish non-functional (395 bp) 
and functional isoform (461 bp) of the receptor in THP-1 and TDM, respectively. b-
Actin was used as a positive control. Images are representative of n=3 donors. 
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Expression of P2XR in the two cell types was also studied at protein level using 
confocal microscopy. All P2XR antibodies employed in this study detect the 
intracellular epitope of each receptor, which required the cells to be fixed and 
permeabilized prior to staining with the antibodies. Staining with secondary antibody 
(goat AF488 and rabbit AF488) alone was performed as a negative control to 
ensure no false positive staining was detected. As shown in Figure 3.2, protein 
expression of P2X1, P2X4, P2X5 and P2X7 was found present in both THP-1 cells 
and TDM cells and appear to have a punctate distribution throughout the cell. 
However, it was not possible to differentiate whether the expression is found 
predominantly within the surface of the cell, in the cytoplasm, perinuclear or within 
the nucleus of the cells. Despite the inability to describe receptor localization within 
the two types of cells, these data collectively illustrate that P2X1, P2X4, P2X5 and 
P2X7 receptors are expressed at the mRNA and protein level in both cell types.  
	 	
	 114 
	
	
Figure 3.2. Expression of P2X receptor in THP-1 and TDM. Immunocytochemistry of P2X receptor expression in: A) THP-1 cells and B) 
TDM cells, as seen under confocal microscopy. Blue represents DAPI nuclear stain while green represents human P2X receptor conjugated 
with AF488. Scale bar represents 10 µm. Images represent n=3 replicates. 
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3.3.2. Investigating the selectivity of P2XR antagonists on over expressing cell 
lines  
As the main aim of this chapter is to identify the contribution of P2X4 to ATP-evoked 
Ca2+ response, various pharmacological tools such as receptor antagonists were 
utilized. To confirm the selectivity of each of the antagonists, each compound was 
initially tested on either hP2X1, hP2X4 or hP2X7 recombinant over expressing cell 
lines. P2X4 antagonists were tested on both hP2X4 (for identification of IC50) and 
hP2X7 (for selectivity study) recombinant over-expressing cell line, while P2X1 and 
P2X7 antagonists were tested for inhibitory effects on hP2X1, hP2X4 and hP2X7 
recombinant over-expressing cell line. In addition to this, the compound IVM was 
also tested in both hP2X1 and hP2X7 over expressing cell lines to test for selectivity.  
 
3.3.2.1. Selectivity of IVM and P2X1 antagonist on hP2X1 over expressing cell 
line 
Ivermectin (IVM) has been accepted widely as a selective positive allosteric 
modulator for P2X4. However, studies by Norenberg et al. (2012) illustrated that IVM 
can potentiate currents of human monocyte-derived macrophages that 
endogenously express hP2X7 without influencing the decay kinetics. These findings 
indicated that effect of IVM is not selective for hP2X4. There has been no further 
evidence that IVM can act on any other hP2XR. As hP2X1 recombinant over 
expressing cell lines is available in-house, the effect of 3 µM IVM was tested.   
 
A dose response curve for a,b me-ATP was initially performed to identify the 
maximal concentration required for activation of P2X1. As shown (Figure 3.3A), 
a,b me-ATP elicited a concentration-dependent increase in intracellular Ca2+ level in 
hP2X1 over expressing cell line (EC50= 0.21 ± 0.022 µM, n=3). Maximal Ca2+ 
response was obtained from application of 1 µM of a,b me-ATP with representative 
time-response traces being shown in Figure 3.3B. 1 µM a,bme-ATP was used to 
investigate the effect of IVM and P2X1 antagonist, Ro0437626. Pre-treatment of 
hP2X1 over expressing cells with 3 µM IVM resulted in a significant inhibition of the 
magnitude of a,b me-ATP-evoked Ca2+ response (0.31 ± 0.04 F ratio vs. 0.15 ± 0.03 
F ratio, n=3, P<0.05) (Figure 3.3C). This finding indicated that while IVM has been 
reported to have a positive modulatory effect on hP2X4 and hP2X7, it does not affect 
hP2X1 in a similar manner. Pre-treatment of cells with 30 µM Ro0437626 resulted in 
	 116 
a significant reduction of the magnitude of a,b me-ATP-evoked Ca2+ response (0.33 
± 0.045 F ratio vs. 0.13 ± 0.011 F ratio) (Figure 3.3D). Unfortunately, a dose 
response of the effect of Ro0437626 as well as the effect of P2X4 antagonists was 
not performed due to difficulty in getting a stable and consistent a,b me-ATP-evoked 
Ca2+ response in these over expressing cell line. 
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Figure 3.3. hP2X1 mCherry HEK 293F cells as a tool to test selectivity of 
compounds. A) a, b me-ATP dose-response curve on hP2X1 mCherry HEK 293F 
cells (n=3). B) Representative time-response curve at 1 µM a,b me-ATP on the 
hP2X1 mCh HEKF 293F cells (n=3). Representative time-response curve on the 
effect of compounds on a, b me-ATP-mediated Ca2+ response: C) 3 µM IVM (n=3) 
and D) 30 µM Ro0437626 (n=3). 
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3.3.2.2.  Testing the selectivity of P2XR antagonists on hP2X4 over expressing 
cell line 
As various P2XR antagonists were used throughout this study, it is important to 
ensure that the P2X1 and P2X7 antagonist were selective towards their reported 
receptor target and not act on P2X4. In addition to this, it is also important to identify 
the IC50 values for P2X4 antagonists (5-BDBD and PSB-12062) that were used 
throughout this study. To achieve this, the effect of each compounds was tested on 
ATP-evoked Ca2+ response in hP2X4 over expressing cell line.  
 
As shown (Figure 3.4A), ATP elicited a dose-dependent increase in intracellular 
Ca2+ level in hP2X4 over expressing cells (EC50 = 0.12 ± 0.0031 µM; n=3), with 
maximal response observed at 1 µM ATP. Application of higher concentrations of 
ATP (300 µM and 1 mM) resulted in the reduction of intracellular Ca2+ response 
which may suggests receptor desensitization. Representative time response traces 
(Figure 3.4B) illustrated a rise in intracellular Ca2+ level following application of 100 
µM ATP, which is then followed by a sustained elevated phase. Here, a dose 
response of P2X4 antagonists: 5-BDBD and PSB-12062 was performed to identify 
the IC50 values. IC50 values of 5-BDBD and PSB-12062 were quantified to be 9.42 ± 
1.09 µM (n=3) and 3.06 ± 0.57 µM (n=3), respectively (Figure 3.4C and D, 
respectively). At the highest concentration of 30 µM, 5-BDBD was only able to 
induce a 52.37 ± 6.40 % (n=3, P<0.001) inhibition on the hP2X4 over expressing 
cell line, while PSB-12062 was able to induce a 78.92 ± 4.99 % (n=3, P<0.001) 
inhibition. The IC50 values obtained in this study, however, differ from those reported 
previously with 5-BDBD having IC50 of 1.6 µM (Balazs et al., 2013a) and PSB-12062 
having IC50 of 1.38 µM (Hernandez-Olmos et al., 2012). Having quantified the IC50 
of the P2X4 antagonists, it is possible to claim that PSB-12062 is a much more 
potent antagonist than 5-BDBD. Despite its high potency, PSB-12062 was unable to 
completely wipe out ATP-evoked Ca2+ response in hP2X4 over expressing cells.  
 
The effect of other P2XR antagonists, P2X7 (A438079) and P2X1 (Ro0437626), 
were also tested. At all concentrations, A438079 was unable to cause any 
significant inhibition to ATP-evoked Ca2+ response (100 µM) in hP2X4 over 
expressing cells (Figure 3.4E). Meanwhile, pre-treatment of cells with Ro0437626 
caused a slight inhibition to ATP-evoked Ca2+ response at concentrations above 1 
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µM. At 30 µM, Ro0437626 caused a significant inhibition to ATP-evoked Ca2+ 
response by 22.89 ± 4.41 % (n=3, P<0.001; Figure 3.4F).  
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Figure 3.4. hP2X4 mCherry over expressing 1321N1 cells as a tool to test 
selectivity of antagonists. A) ATP dose-response curve on hP2X4 mCherry 
1321N1 cells (n=3). B) Representative time-response curve at 100 µM ATP on the 
Hi+ mCherry 1321N1 cells vs. Hi+ P2X4 mCherry over expressing cells (n=3). 
Inhibition curves of antagonists on ATP-mediated Ca2+ responses: C) 5-BDBD 
(n=3), D) PSB-12062 (n=3), E) A438079 (n=3) and F) Ro0437626 (n=3). 
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3.3.2.3. Testing the selectivity of P2XR antagonists on hP2X7 over expressing 
cell line 
P2X4 and P2X7 have been described to be the most abundantly expressed subtypes 
of P2XR in immune cells. While much effort has been invested to study the role of 
P2X7 in immune cells, the same cannot be said for P2X4, mainly due to the lack of 
selective antagonists. The main pharmacological tools for P2X4 that are used 
throughout the course of this study are selective antagonists, 5-BDBD and PSB-
12062, and positive allosteric modulator IVM. To test the selectivity of these 
compounds, their effects on BzATP-evoked Ca2+ response in hP2X7 over 
expressing cell were studied.  
 
Prior to testing the effect of each of the compounds, a BzATP dose response was 
performed on the hP2X7 over expressing cell line with concentrations ranging from 1 
µM to 500 µM (EC50 = 43.4 ± 7.23 µM; n=3; Figure 3.5A), with maximal responses 
observed at approximately 100 µM. All compounds of interest were tested against 
100 µM BzATP. To ensure that the BzATP-mediated Ca2+ response is elicited by 
activation of P2X7 receptor alone, a selective P2X7 antagonist (A438079) was 
employed. Pre-treatment of cells with 5 µM A438079 resulted in a significant 
inhibition of the BzATP-evoked intracellular Ca2+ response (88.85 ± 9.08 %; n=3, 
P<0.001; Figure 3.5C and D). ATP dose response on hP2X7 over expressing cell 
line was also performed at concentrations ranging from 3 µM to 3 mM. Intracellular 
Ca2+ response was only detected at the highest agonist concentration of 3 mM 
(Figure 3.5B). 
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Figure 3.5. hP2X
7
 mCherry over expressing 1321N1 cells as a tool to test 
selectivity of compounds. A) BzATP dose-response curve on hP2X
7
 mCherry 
over expressing 1321N1 cells. B) ATP dose-response curve on hP2X7 mCherry 
over expressing 1321N1 cells. C and D) Effect of 5 µM A438079 on 100 µM BzATP-
evoked Ca
2+
 response represented as bar chart (n=3) and representative time-
response curve (n=3), respectively. Asterisks include significant changes towards 
control (*** p<0.001, Student’s t-test).  
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Due to high variability of BzATP-evoked Ca2+ response in the hP2X7 over 
expressing cell line, only selected concentrations of compounds were tested. As 
shown on Figure 3.6A and B, 3 µM IVM caused a significant potentiation in the 
magnitude of the Ca2+ response evoked by 100 µM BzATP (0.47 ± 0.041 vs. 0.67 ± 
0.040, n=3; P<0.01) but showing limited effect on the decay response, which is in 
line with previous studies by Norenberg et al. (2012).  
 
The effect of P2X4 receptor antagonists, 5-BDBD and PSB-12062 was next studied. 
As shown on Figure 3.6C and D, 10 µM 5-BDBD had no significant effect on both 
the magnitude of the Ca2+ response evoked by 100 µM BzATP (0.47 ± 0.041 vs. 
0.54 ± 0.053 n=3, P>0.05). Therefore, although the effect of 5-BDBD has not been 
tested on other P2XR and P2YR, it is safe to assume that 10 µM 5-BDBD does not 
have the capacity to inhibit responses mediated by P2X7 activation. A dose 
response of PSB-12062 (0.3 µM to 30 µM) was tested on the BzATP-evoked Ca2+ 
response in hP2X7 over expressing cells (Figure 3.6E). All concentrations, except 
10 µM did not have a significant effect on the BzATP-evoked Ca2+ response. As 
shown on Figure 3.6E and F, 10 µM PSB-12062 caused a significant inhibition of 
27.32 ± 7.88 % to the magnitude of the Ca2+ response (0.47 ± 0.041 vs. 0.33 ± 
0.025, n=3, P<0.05). This is contradictory to what was described in a study by 
Hernandez-Olmos et al. (2012), whereby PSB-12062 was reported to be 35-fold 
selective towards P2X4 versus all other human P2XR subtypes. 
 
Together, these data illustrate that while A438079 and Ro0437626 can be used to 
selectively target P2X7 and P2X1 respectively, P2X4 antagonists (5-BDBD and PSB-
12062) must be employed with caution, avoiding use at high concentrations. In 
addition to this, the use of ATP concentration below 1 mM as an agonist is 
recommended to avoid the activation of P2X7. It is therefore important that to isolate 
P2X4-mediated Ca2+ responses in monocytes/macrophage, the use of a single 
antagonist for P2X4 must not be relied upon and that a combination of these tools is 
used.  
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Figure 3.6. Effect of IVM, 5BDBD and PSB-12062 on hP2X
7
 mCherry over 
expressing 1321N1 cells. Effect of: A and B) 3 µM IVM, C and D) 10 µM 5-BDBD 
and E and F) dose response of PSB-12062, on 100 µM BzATP-evoked Ca
2+
 
response represented as bar chart (n=3) and representative time-response curve 
(n=3) for 10 µM PSB-12062, respectively. Asterisks include significant changes 
towards control (** p<0.01, * p<0.05, Student’s t-test). 
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3.3.3. Pharmacological characterization of P2X4-mediated Ca2+ response in 
THP-1 monocytes versus TDM 
Nucleotides such as ATP can be released in high concentrations following necrotic 
cell death to mediate physiological responses in cells by activating two major cell 
surface receptors: P2X and P2Y receptors. While ATP act as the main ligand for 
P2X receptors, it is known to only activate some P2Y receptors (Jacobson et al., 
2009). Unlike GPCRs, the wild-type P2XRs do not show constitutive activity in the 
absence of agonist (North, 2002). To investigate the contribution of P2X4-mediated 
Ca2+ response in THP-1 cells and TDM, the initial aim of this chapter was to 
determine a dose response curve to ATP and the maximal concentration to activate 
P2X4 in both cell lines.  
 
ATP elicited a concentration-dependent increase in intracellular Ca2+ level in both 
cell types. Figure 3.7A illustrated a rightward shift in the concentration response 
curve of ATP in TDM (EC50= 6.25 ± 1.92 µM, n=6) versus THP-1 cells (EC50= 0.174 
± 0.01 µM, n=12). Maximal Ca2+ response was observed at 10 µM in THP-1 cells 
while in TDM cells, maximal Ca2+ response was observed at higher ATP 
concentration of 100 µM. To ensure maximal activation of P2X4, a supra-maximal 
ATP concentration of 100 µM was used throughout this study. In both cell types, 
high ATP concentrations (above 300 µM) appear to cause receptor desensitization 
as illustrated from the reduction in intracellular Ca2+ level. The representative Ca2+ 
time-response trace in THP-1 cells and TDM upon stimulation with 100 µM ATP is 
represented in Figure 3.7B. Here, ATP caused a significant increase in intracellular 
Ca2+ response, which then decayed to a sustained elevated phase in THP-1 cells or 
back to the baseline level in TDM. However, two striking phenotype differences of 
the ATP response were observed from these two cell types: 1) magnitude of Ca2+ 
response – THP-1 cells being significantly higher than TDM (F ratio 3.24 ± 0.127 
THP-1 vs. 1.09 ± 0.077 TDM; n=12 and 6, respectively; P<0.001; Figure 3.7B) and, 
2) decay kinetics – Ca2+ response in TDM decay at a rate approximately four-fold 
faster than THP-1 cells (18.64 ± 2.18 s TDM vs. 84.0 ± 5.28 s THP-1 cells) (Figure 
3.7C). These differences may be a result of several factors which include varying 
cell numbers, different receptors expressed on the cell membranes, or the varying 
calcium buffering capacity of the two cell types.  
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To identify if varying cell numbers may be responsible for the difference in ATP-
evoked intracellular Ca2+ responses in THP-1 monocytes and TDM cells, cells were 
stained with nuclear dye Hoechst-33342. The fluorescence read-out illustrated no 
significant differences in number of cells being assayed, indicating that the 
phenotype differences is likely due to other factors, such as lower expression of 
other ATP receptors in TDM such as P2YR (Figure 3.7D). However, this was not 
further explored during the study.   
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Figure 3.7. ATP-elicited Ca2+ response in both THP-1 cells and TDM. A) Dose-
response curve of ATP (0.01 – 1000 µM) in THP-1 monocytes (n=12) and TDM 
cells (n=6). Ca2+ response is represented as F ratio. B) Representative time-
response curve of THP-1 cells and TDM upon the application of 100 µM ATP 
recorded over 250 s. C) Bar chart representing decay kinetics of THP-1 cells (n=12) 
and TDM (n=6). D) Cell quantification assay using nuclear stain H-33342. Asterisks 
include significant changes towards control (***p<0.001, Student’s t-test).  
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3.3.3.1. Dependency of ATP-evoked Ca2+ response on extracellular Ca2+  
Within cells, both P2XR and P2YR are involved in extracellular ATP-dependent 
signalling. P2XR are Ca2+ permeable ligand-gated ion channels which, upon 
activation, results in an increase in intracellular Ca2+ level that is dependent on 
extracellular Ca2+ (Ryu et al., 2010). Unlike P2XR, P2YR are GPCR-coupled which 
involve a more complex downstream signalling pathway (Bhatt and Topol, 2003). To 
investigate the contribution of ionotropic receptors to ATP-evoked Ca2+ response in 
THP-1 cells and TDM cells, ATP concentration response curves were performed in 
the presence and absence of extracellular Ca2+.  
 
The effect of extracellular Ca2+ removal on ATP-evoked Ca2+ response in THP-1 
cells can be seen in Figure 3.8A and 3.8B. In the presence of 1.5 mM extracellular 
Ca2+, 100 µM ATP evoked an expected intracellular Ca2+ response generating a 
response of 3.18 ± 0.15 F ratio (n=3). In contrast, in the absence of extracellular 
Ca2+, ATP response was significantly reduced to 0.25 ± 0.01 F ratio (n=3), indicating 
a 92.0 ± 0.46% reduction (n=3, P<0.001). In TDM cells, in the presence of 1.5 mM 
extracellular Ca2+, 100 µM ATP evoked an expected intracellular Ca2+ response of 
1.47 ± 0.03 F ratio (n=3) while in the absence of extracellular Ca2+, F ratio value for 
ATP was significantly reduced to 0.43 ± 0.046 F ratio (n=3), indicating a 71.2 ± 4.0 
% (n=3, P<0.01) reduction (Figure 3.8C and 3.8D). As the majority of ATP-evoked 
Ca2+ response in both cell types was significantly inhibited by the absence of 
extracellular Ca2+, this may indicate that P2X receptors are key players that drive 
the ATP-evoked Ca2+ response in both THP-1 and TDM cells.  
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Figure 3.8. Extracellular Ca2+-dependent ATP-mediated response in THP-1 
cells and TDM. Dose response curve of ATP (0.01 – 1000 µM) in the presence and 
absence of extracellular Ca2+ and its representative time traces at 100 µM ATP in: A 
and B) THP-1 cells (n=3) or C and D) TDM (n=3).  
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3.3.3.2. Blocking metabotropic receptor-mediated Ca2+ responses using 
pharmacological tools  
As mentioned previously, ATP evoked a global Ca2+ response mediated by various 
receptors, which includes both P2XR and P2YR. In the previous section (3.3.3.1), it 
was not possible to investigate the contribution of P2XR activation by simply 
eliminating extracellular Ca2+ due to possible involvement of SOC channels. 
Therefore, to pharmacologically isolate P2X4 contribution to ATP-mediated Ca2+ 
response in THP-1 cells and TDM, pharmacological tools specifically targeting Ca2+ 
response mediated by metabotropic receptors were utilized. Here, two different 
compounds, PLC inhibitor U-73122 and non-competitive SERCA inhibitor 
Thapsigargin (Tg), were employed to reveal Ca2+ responses dependent of ionotropic 
receptors. Following this, additional pharmacological tools to confirm the 
contribution of P2X4 on Ca2+ response were utilized.  
 
3.3.3.2.1. Effect of PLC inhibition on ATP-mediated Ca2+ response  
The activation of Gaq-coupled P2YRs by ATP and its metabolite lead to downstream 
signalling pathway involving phospholipase C (PLC), which in turn results in the rise 
of intracellular Ca2+ signalling. To block this downstream signalling, PLC inhibitor, U-
73122 was employed in this study. Pre-treatment of cells with a dose-response of 
U-73122 produced a dose-dependent inhibition of Ca2+ response in both THP-1 
cells and TDM cells, with maximal inhibition observed at 10 µM (Figure 3.9A and 
3.9B, respectively). However, a residual Ca2+ response that appear to be insensitive 
to U-73122 was seen in both cell types. This was quantified to be 20 ± 1.2% (n=6; 
p<0.01) and 20 ± 0.8% (n=6; p<0.01) in THP-1 and TDM cells, respectively. To 
confirm that this residual U-73122-resistant Ca2+ response is mediated by ionotropic 
receptors, the experiments were performed in the absence of extracellular Ca2+. In 
the absence of extracellular Ca2+, U-73122-resistant Ca2+ response was completely 
abolished in THP-1 cells while 65.3 ± 1.8% was inhibited in TDM cells (Figure 3.9C 
and Figure 3.9D, respectively). This indicates that U-73122-resistant Ca2+ response 
is dependent on extracellular Ca2+ and is likely to be mediated by P2XR. However, 
as previously mentioned in the methodology section, leaving the cells in Ca2+-free 
SBS buffer is likely to deplete the intracellular stores of Ca2+, hence over-estimating 
the contribution of Ca2+ influx in ATP-evoked Ca2+ response.  
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Figure 3.9. U-73122-resistant Ca2+ response is mediated by Ca2+ influx. Dose-
response inhibition curve of U-73122 in: A) THP-1 cells (n=6) and B) TDM (n=6). 
Data is normalized to calcium response (F ratio) at 100 µM alone. C) Effect of U-
73122, represented in F ratio, in the presence (black bars) and absence (grey bars) 
of extracellular calcium in THP-1 cells (n=6). D) Effect of U-73122, represented in F 
ratio, in the presence (black bars) and absence (grey bars) of extracellular calcium 
in TDM (n=3). Asterisks include significant changes towards control (*** p<0.001, 
Student’s t-test). 
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3.3.3.2.2. Effect of IVM on U-73122-resistant Ca2+ response  
To identify the contribution of P2X4 to the U-73122-resistant Ca2+ response, a P2X4 
positive allosteric modulator, IVM, was utilized. IVM has been shown to be a 
selective P2X4 allosteric modulator used routinely as a pharmacological tool to 
identify the contribution of P2X4 in ATP-mediated processes (Asatryan et al., 2010, 
Khakh et al., 1999). IVM has also been described to potentiate P2X4 responses by 
reducing endocytosis resulting in increased pool of functional P2X4 in the plasma 
membrane (Toulme et al., 2006).  
 
Pre-treatment of cells with IVM caused a dose-dependent potentiation of magnitude 
of ATP-evoked intracellular Ca2+ response in both THP-1 cells and TDM cells 
(Figure 3.10A and 3.10B, respectively), with maximal potentiation of U-73122-
resistant Ca2+ response seen following pre-treatment with 3µM IVM. Pre-treatment 
of cells with 3µM IVM potentiated Ca2+ response in THP-1 cells by 2.2-fold (0.25 F 
ratio to 0.53 F ratio, n=6, p<0.001) and in TDM cells by 3.3-fold (0.20 F ratio to 
0.654 F ratio, n=6, p<0.001). To accompany the potentiation of the magnitude of 
Ca2+ response, IVM also appeared to cause a delay in the decay kinetics of the Ca2+ 
response as observed through the time-response traces for THP-1 cells (Figure 
3.10C) and TDM cells (Figure 3.10D). These are typical characteristics of IVM effect 
on P2X4-mediated Ca2+ responses (Norenberg et al., 2012). Lastly, IVM also 
increased the net calcium movement (as measured by area under the curve) in both 
THP-1 cells (40.6 ± 6.85 AUC without IVM versus 69.0 ± 5.87 AUC with IVM; n=6; 
P<0.01) and TDM cells (8.80 ± 1.80 AUC without IVM vs. 86.3 ± 11.08 with IVM; 
n=6; P<0.001) (Figure 3.10E and 3.10F, respectively). 
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Figure 3.10. Effect of P2X4 allosteric modulator, ivermectin, on U-73122 
resistant component of THP-1 cells and TDM. Plot of dose-response effect of 
IVM, represented as fold change normalized to 100 µM ATP in the presence of 10 
µM U-73122 on: A) THP-1 cells (n=6) and B) TDM (n=3). Representative time-
response curve at 100 µM ATP in the presence or absence of 3 µM IVM in: C) THP-
1 cells (n=6) and D) TDM (n=3). Net calcium movement is quantified as area under 
the curve in: E) THP-1 cells (n=6) and F) TDM (n=6). Asterisks include significant 
changes towards control (*** p<0.001, ** p<0.01, * p<0.05, Student’s t-test). 
  
	 134 
3.3.3.2.3. Effect of P2XR antagonists on U-73122-resistant ATP-evoked Ca2+ 
response 
To further identify the contribution of P2XR on the U-73122-resistant Ca2+ response 
in the two cell lines, various P2XR (P2X1, P2X4 and P2X7) antagonists were tested. 
Unfortunately, to date, no selective P2X5 and P2X6 antagonists are available 
commercially to be tested in this study. In THP-1 cells, none of the P2XR 
antagonists appear to have any significant effect on the U-73122-resistant Ca2+ 
response. However, in TDM cells, P2X1 antagonist (30 µM Ro0437626) significantly 
potentiated the U-73122-resistant Ca2+ response by 2.84 ± 0.56-fold while P2X7 
antagonist A438079 had no significant effect (Figure 3.11A and 3.11B, 
respectively). Both P2X4 antagonists, 5-BDBD and PSB-12062, caused a significant 
inhibition at 10 µM in TDM cells, but not in THP-1 cells (Figure 3.11C and 3.11D, 
respectively). 5-BDBD caused a 44.4 ± 9.8% (n=6, p<0.01) while PSB-12062 
caused a 31.0 ± 5.9% (n=3, p<0.01) inhibition to the magnitude of the Ca2+ 
response.  
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Figure 3.11. Effect of P2X receptor antagonists on U-73122-resistant 
component of THP-1 cells and TDM. The effect of: A) 30 µM and 100 µM P2X1 
receptor antagonist (Ro0437626) (n=3), B) 1 µM and 10 µM P2X7 receptor 
antagonist (A438079) (n=3), C) 5 µM and 10 µM P2X4 receptor antagonist (5-
BDBD) (n=6) and D) 1 µM and 10 µM P2X4 receptor antagonist (PSB-12062) (n=3), 
were studied on THP-1 cells and TDM. Asterisks include significant changes 
towards control (** p<0.01, * p<0.05, Student’s t-test). 
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3.3.3.3. Blocking metabotropic receptor-mediated Ca2+ responses using 
Thapsigargin  
Another pharmacological tool used to eliminate metabotropic responses to ATP is 
Thapsigargin (Tg). Tg is a SERCA inhibitor, which acts by depleting intracellular 
Ca2+ stores. The depletion of intracellular Ca2+ store means that upon activation of 
metabotropic P2YR, no mobilization of Ca2+ from the stores can be achieved 
resulting in no Ca2+ responses. Depletion of intracellular Ca2+ stores is evident from 
higher cytosolic Ca2+ level (F ratio 1.35 ± 0.0082 without Tg vs. 2.24 ± 0.065 with 
Tg; n=6; P<0.001, TDM cells, Figure 3.12F).  
 
Pre-treatment of THP-1 cells with 5 µM Tg resulted in a complete inhibition of ATP-
evoked Ca2+ response (Figure 3.12A and 3.12B). However, pre-treatment of TDM 
cells with 5 µM Tg resulted in 88.7 ± 3.29 % inhibition (n=6; P<0.001) of Ca2+ 
response, as shown on Figure 3.12C. Despite a significant inhibition, 11.3 ± 3.29 % 
of the Ca2+ response appeared to be insensitive to Tg. This Tg-insensitive Ca2+ 
response in TDM cells was accompanied by a second slower response above the 
baseline (Figure 3.12D). To test if this Tg-insensitive response is dependent on Ca2+ 
influx, the experiment was performed in the absence of extracellular Ca2+. Removal 
of extracellular Ca2+ resulted in Tg-insensitive Ca2+ response to be completely 
abolished (Figure 3.12E) implying that it is sensitive to extracellular Ca2+ and is 
likely to be mediated by ionotropic receptors such as P2XR. As pre-treatment with 
Tg completely abolished the ATP-evoked Ca2+ response in THP-1 cells, the rest of 
the chapter will focus only in the use of TDM cells to characterize P2X4-mediated 
Ca2+ entry.  
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Figure 3.12. Dependency of ATP-evoked Ca2+ response on ER Ca2+ store. 
Effect of 100 µM ATP in the presence and absence of 5 µM Tg in: A and B) THP-1 
cells (n=3) and C and D) TDM (n=6). E) Time-response curve of the effect of Tg on 
100 µM ATP in the presence and absence of extracellular Ca2+ (n=6). F) Effect of 5 
µM Tg on basal calcium level in TDM (n=6). Asterisks include significant changes 
towards control (*** p<0.001, Student’s t-test). 
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3.3.3.3.1. Effect of IVM on Tg-resistant Ca2+ response 
To identify if P2X4 contribute to the Tg-insensitive Ca2+ response, the effect of 3 µM 
IVM was tested in TDM cells. As can be seen, pre-treatment of TDM cells with IVM 
potentiated Tg-resistant ATP-evoked intracellular Ca2+ response by 2.1 fold (F ratio 
0.42 ± 0.025 without IVM to 0.90 ± 0.042 with IVM; n=6; P<0.001) (Figure 3.13A), 
delayed decay kinetics by 3.67 ± 0.37 fold (14.4 ± 0.78 s without IVM to 49.9 ± 3.8s 
with IVM; n=6; p<0.005) (Figure 3.13B and C) and significantly increased net 
calcium movement in TDM cells as quantified by area under the curve (AUC 19.48 ± 
2.45 without IVM vs. 80.01 ± 5.44 with IVM; n=6; p<0.001) (Figure 3.13D). The data 
so far illustrated a possible contribution of P2X4 towards Tg-resistant ATP-evoked 
intracellular Ca2+ response in TDM cells.  
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Figure 3.13. Investigating Thapsigargin (Tg) as an alternative pharmacological 
tool to isolate P2X4-mediated Ca2+ influx. A and B) Effect of 3 µM IVM in Tg-
resistant component represented as bar chart and time-response curve, 
respectively (n=6). C) Effect of 3 µM IVM on decay kinetics (t) of TDM (n=6). D) 
Effect of 3 µM IVM on net calcium movement as quantified by area under the curve 
of TDM (n=6). Asterisks include significant changes towards control (*** p<0.001, 
Student’s t-test). 
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3.3.3.3.2. Effect of P2X4 antagonists on Tg-resistant Ca2+ response  
To further confirm that P2X4 contribute to the Tg-resistant Ca2+ response in TDM 
cells, selective P2X4 antagonists, 5-BDBD and PSB-12062, were used. In the 
presence of Tg, both 5-BDBD and PSB-12062 (10 µM) significantly inhibited ATP-
elicited Ca2+ response by 52.9 ± 1.99 % (n=3; p<0.01; Figure 3.14A) and 78.5 ± 
3.23 % (n=3; p<0.001; Figure 3.14D), respectively. In addition to inhibiting the 
magnitude of the Ca2+ response, both antagonists also appear to abolish the second 
slower response observed in the presence of Tg (Figure 3.14B and 3.14E). 
Although it is still unclear what the second slower response underlies, it appeared to 
be dependent on P2X4 activation. Finally, when quantifying area under the curve, 5-
BDBD and PSB-12062 appeared to significantly reduce net calcium movement in 
TDM cells. 5-BDBD caused AUC to be reduced from 17.45 ± 2.24 to 4.43 ± 7.69 
(Figure 3.14C) while PSB-12062 caused AUC to be reduced from 17.45 ± 2.24 to 
7.21 ± 10.3 (Figure 3.14F). Together with the effect of IVM on Tg-resistant Ca2+ 
response, the data suggests contributions of P2X4 towards the magnitude and the 
decay phase of ATP-evoked Ca2+ response TDM cells.  
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Figure 3.14. Effect of P2X4 receptor antagonists on Tg-resistant ATP-evoked 
Ca2+ response in TDM cells. A-C) Effect of 10 µM 5-BDBD on magnitude of 
calcium response and net calcium movement on Tg-resistant Ca2+ response of TDM 
(n=3). D-F) Effect of 10 µM PSB-12062 on magnitude of Ca2+ response and net 
calcium movement on Tg-resistant Ca2+ response of TDM (n=3). Asterisks include 
significant changes towards control (*** p<0.001, ** p<0.01, * p<0.05, Student’s t-
test). 
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3.3.3.3.3. Effect of P2XR antagonists on Tg-resistant Ca2+ response 
As can be seen on the data discussed above on section 3.3.3.3.2, the use of 
selective P2X4 antagonists was insufficient to abolish the Tg-resistant Ca2+ 
response in TDM cells. This implies that although P2X4 may contribute to this Ca2+ 
influx, other ionotropic receptors may play a role too. Two P2XR antagonists were 
used to test for this: A438079 (P2X7 antagonist; 5 µM) and Ro0437626 (P2X1 
antagonist; 30 µM). A438079 is reported to be a selective P2X7 antagonist with IC50 
value of 0.13 µM (Donnelly-Roberts and Jarvis, 2007, Carroll et al., 2009) while 
Ro0437626 is reported to be a selective P2X1 antagonist with IC50 value of 3 µM 
(Jaime-Figueroa et al., 2005). For antagonist experiments, concentrations of at least 
10 times the IC50 value was chosen to ensure maximal inhibition.  
 
In the presence of 5 µM Tg, both A438079 and Ro0437626 had no effect on the 
magnitude of ATP-evoked Ca2+ response (Figure 3.15A and 3.15D, respectively). 
However, as can be seen (Figure 3.15B), pre-treatment of TDM cells with Tg and 
A438079 appeared to cause a significant increase in the second slower Ca2+ 
response compared to Tg pre-treatment alone. When area under the curve was 
quantified, A438079 appeared to cause a significant increase in net calcium 
movement (AUC 17.45 ± 2.24 without A438079 versus 35.63 ± 2.84 with A438079 
AUC; n=3; P<0.001) (Figure 3.15C). On the other hand, Ro0437626 had no 
significant effect on the second slower Ca2+ response (Figure 3.15E) as well as on 
the net calcium movement (Figure 3.15F). Altogether, these data suggest that Tg-
resistant Ca2+ response is dependent on Ca2+ influx and while P2X4 contributes to 
the Ca2+ response, P2X1 and P2X7 do not appear to have any contribution.  
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Figure 3.15. Effect of P2X1 and P2X7 receptor antagonist on Tg-resistant Ca2+ 
response. A-C) Effect of 5 µM P2X7 receptor antagonist (A438079) on magnitude 
of Ca2+ response and net calcium movement on Tg-resistant Ca2+ response of TDM 
(n=3). D-F) Effect of 30 µM P2X1 receptor antagonist (Ro0437626) on magnitude of 
Ca2+ response and net calcium movement on Tg-resistant Ca2+ response of TDM 
(n=3). Asterisks include significant changes towards control (*** p<0.001, Student’s 
t-test). 
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3.3.4. Generation and evaluation of P2X4 KD THP-1 monocytes  
To provide further evidence for the contribution of P2X4 in ATP-evoked Ca2+ 
responses in TDM cells, it was necessary to employ a molecular-based approach to 
silence the P2X4 gene. The approach taken to perform this study involved the use of 
a lentiviral vector to deliver an shRNA sequence that is targeted for P2X4 gene into 
THP-1 cells. This enabled the generation of a stable and long-term gene knockdown 
THP-1 cell line which can then be differentiated into TDM cells. As a negative 
control, non-target-shRNA lentiviral particle (scrambled shRNA) was used.  
 
3.3.4.1. qRT-PCR and FACS analysis  
Following the generation of stable P2X4 shRNA cell line, two methods were utilized 
to confirm the rate of knockdown of P2X4: 1) quantification of P2X4 mRNA 
expression using qRT-PCR approach and 2) flow cytometry staining to quantify the 
amount of extracellular and total P2X4 protein expression.  
 
As shown (Figure 3.16A), a 48.8 ± 9.64 % (n=4; P<0.01) reduction in P2X4 mRNA 
expression was observed in the P2X4 shRNA TDM cells in comparison to scrambled 
shRNA TDM cells using qRT-PCR. Having identified that mRNA expression of P2X4 
was successfully knocked down, extracellular and total protein expression of P2X4 
was quantified using flow cytometry for further confirmation. Cells were stained with 
rabbit polyclonal anti-human P2X4 that recognizes either the extracellular or C-
terminal epitope (cell surface or internal/total), followed by secondary staining with 
goat anti-rabbit AF488 antibody. As shown (Figure 3.16B), there was a significant 
reduction in the amount of P2X4(ext)+ cells in the P2X4 shRNA system compared to 
the scrambled shRNA control (57.7 ± 4.37 % reduction, n=4, P<0.01). Despite this 
reduction, it was an interesting observation that constitutive expression of 
P2X4(ext)+ cells in the control scrambled shRNA system was relatively low (18.61 ± 
4.01%, n=3). The low constitutive expression of cell surface P2X4 in TDM cells may 
be a result of the predominant intracellular lysosomal localization of the receptor 
(Qureshi et al., 2007). Interestingly, despite a significant reduction in the expression 
of cell surface P2X4 in the P2X4 shRNA TDM cells, no significant differences in the 
amount of total P2X4 expression was observed (Figure 3.16C).  	  
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Figure 3.16. Generation of P2X4 knockdown TDM cells. Success of knockdown 
approach was quantified using two methods: A) quantitative RT-PCR (n=4), B) 
FACS analysis to quantify cells expressing surface P2X4 receptor (n=4) and C) 
FACS analysis to quantify cells expressing total (cell surface and internal) P2X4 
receptor (n=4). Asterisks include significant changes towards control (** p<0.01, * 
p<0.05, Student’s t-test).	  
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3.3.4.2. Effect of P2X4 knockdown on ATP-evoked Ca2+ responses in TDM cells  
Having confirmed the success of P2X4 knockdown approach in the TDM cells, 
intracellular Ca2+ measurements were performed in both scrambled shRNA TDM 
versus P2X4 shRNA TDM cells. Here, several pharmacological tools that have been 
assessed earlier in the chapter were used to identify changes in Ca2+ responses 
following knockdown approach and the potential contribution P2X4 in TDM cells.  
 
Despite FACS analysis data illustrating reduction of cell surface expression of P2X4 
in the P2X4 shRNA system (Figure 3.16B), no significant changes in 100 µM ATP-
evoked intracellular Ca2+ responses were observed in P2X4-KD TDM cells when 
compared to scrambled shRNA TDM cells (Figure 3.17A). It was difficult to explain 
this lack of effect of P2X4 knock down on the magnitude of 100 µM ATP-evoked 
Ca2+ response, however, it may be due to compensatory mechanism within the cell 
upon silencing of P2X4. When P2X4 shRNA TDM cells were pre-treated with 
pharmacological tools selective for P2X4 antagonist, significant differences were 
observed in the ATP-evoked Ca2+ response compared to scrambled shRNA TDM 
cells. When cells were pre-treated with IVM, P2X4 shRNA TDM cells were found to 
be significantly less sensitive towards the allosteric positive modulator, which was 
visible from the time-response traces (Figure 3.17C and D for scrambled shRNA 
versus P2X4 shRNA TDM cells, respectively). As shown (Figure 3.17B), IVM 
potentiated the AUC of scrambled shRNA by 2.06 ± 0.23-fold (43.09 ± 3.89 without 
IVM vs. 135.55 ± 2.29 with IVM; n=4; P<0.01) but was only able to potentiate AUC 
of P2X4 shRNA TDM cells by 1.53 ± 0.055 fold (45.8 ± 4.23 without IVM vs. 93.3 ± 
7.18 with IVM; n=4, P<0.01). In addition to this, when compared to scrambled 
shRNA cells, ATP-evoked Ca2+ response in P2X4 shRNA TDM cells appeared to be 
insensitive to pre-treatment of 10 µM PSB-12062 (Figure 3.17E and F for scrambled 
shRNA vs. P2X4 shRNA cells, respectively). Finally, in the presence of IVM, ATP-
evoked Ca2+ response in the P2X4 shRNA cells appeared to be insensitive towards 
PSB-12062 (AUC 117.23 ± 4.22 without PSB-12062 vs. 91.02 ± 20.38 with PSB-
12062; n=4; P>0.05; Figure 3.17F), when compared to scrambled shRNA (AUC 
166.73 ± 18.66 without PSB-12062 vs. 72.17 ± 26.49 with PSB-12062; n=4; P<0.05; 
Figure 3.17E). These data suggest that P2X4 shRNA TDM cells are less sensitive to 
IVM and PSB-12062, indicating a reduction in functional P2X4 within the cell, as 
assessed through intracellular Ca2+ measurements.   
	 	
 147 
	
	
Figure 3.17. Knocking down of P2X4 receptor reduced the effect of IVM on 
ATP-mediated calcium response in TDM. A) ATP-mediated calcium response at 
100 µM on scrambled shRNA and P2X4 shRNA TDM cells (n=4). B) Bar chart 
illustrating the effect of IVM on 100 µM ATP response in scrambled (black bars) 
versus P2X4 shRNA (grey bars) TDM (n=6). Representative time-response curves 
of the effect of IVM on ATP response in: C) scrambled shRNA TDM (n=4) versus D) 
P2X4 shRNA TDM (n=4). Effect of 10 µM PSB-12062 on ATP response in the 
presence and absence of IVM in: E) scrambled shRNA TDM (n=4) vs. F) P2X4 
shRNA TDM (n=4). Asterisks include significant changes towards control (*** 
p<0.001, ** p<0.01, * p<0.05, Student’s t-test).  
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3.3.4.3. Effect of P2X4 knockdown on Tg-resistant Ca2+ response  
Earlier in the chapter, some evidence was provided suggesting the use of Tg to 
remove metabotropic responses in TDM cells (Section 3.3.3.3). Here, the effect of 
Tg on ATP-evoked Ca2+ responses of the P2X4 shRNA TDM cells was investigated. 
As shown on Figure 3.18A, silencing of P2X4 resulted in a significant reduction in 
magnitude of Tg-resistant Ca2+ response, when compared to scrambled shRNA 
control cells (0.14 ± 0.02 scrambled shRNA vs. 0.025 ± 0.014 P2X4 shRNA; both 
n=3; P<0.001). This can also be observed in the representative time-response 
traces for scrambled shRNA and P2X4 shRNA TDM cells (Figure 3.18C and D, 
respectively). In addition to this, the ability of IVM to potentiate Tg-resistant ATP-
evoked Ca2+ response was tested in the P2X4 shRNA cells. As shown on Figure 
3.14B, Tg-resistant ATP-evoked Ca2+ response was significantly less sensitive 
towards IVM in the P2X4 shRNA TDM when compared to scrambled shRNA control 
TDM (0.55 ± 0.053 scrambled vs. 0.095 ± 0.022 P2X4 shRNA; n=3; P<0.001). With 
these observations, it was possible to confirm the contribution of P2X4 towards the 
Tg-resistant response of ATP-evoked Ca2+ response in TDM cells. 
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Figure 3.18. Knocking down of P2X4 receptor resulted in reduction of Tg-
resistant ATP-evoked Ca2+ response in TDM. A) Effect of Tg on 100 µM ATP 
response in scrambled versus P2X4 shRNA TDM (n=3). B) Effect of IVM on Tg-
resistant response in scrambled versus P2X4 shRNA TDM (n=3). Representative 
time response curve on the effect of Tg on 100 µM ATP response in: C) Scrambled 
(n=3) and D) P2X4 shRNA TDM (n=3). Asterisks include significant changes 
towards control (*** p<0.001, Student’s t-test). 
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3.3.5. Investigating contribution of P2X4 towards ATP-evoked Ca2+ response 
by targeting mechanism of receptor trafficking  
The results described within this chapter, so far, elaborated that P2X4 can contribute 
to ATP-evoked Ca2+ responses. Since P2X4 have been described to be 
predominantly localized within lysosomal compartments (Qureshi et al., 2007) and 
are constantly recycled from the cell surface to intracellular compartments, targeting 
mechanism of receptor trafficking will allow the further confirmation of P2X4 
contribution towards ATP-evoked Ca2+ responses in TDM cells.   
 
3.3.5.1. Effect of dynasore on Tg-resistant ATP-evoked Ca2+ response   
Previous studies have revealed that plasma membrane expression of P2X4 receptor 
is regulated by dynamin-dependent endocytosis (Stokes et al., 2013), therefore it is 
important to identify if the Tg-resistant Ca2+ response in TDM cells can be blocked 
by a dynamin inhibitor, dynasore. Dynasore is a GTPase inhibitor, which target 
dynamin-1, dynamin-2 and Drp2 resulting in the blocking of dynamin-dependent 
endocytosis (Boumechache et al., 2009). As shown (Figure 3.19A), in the presence 
of Tg, pre-treatment of TDM cells with 80 µM dynasore caused a significant 
reduction in the magnitude of ATP-evoked Ca2+ response in TDM cells (0.42 ± 0.17 
vs. 0.17 ± 0.25; n=3; P<0.001). However, dynasore appeared to cause a significant 
delay in the decay kinetics of the ATP-evoked Ca2+ response (16.2 ± 1.20 s vs. 81.5 
± 7.03 s; n=3; P<0.001; Figure 3.19B) as well as a significant increase in the net 
calcium movement within the cell as quantified using area under the curve (AUC 
19.9 ± 2.02 without dynasore vs. 33.36 ± 5.56 with dynasore; n=3; P<0.05; Figure 
3.19C).   
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Figure 3.19. Dynasore significantly reduced magnitude of Tg-resistant ATP-
evoked Ca2+ response and delayed decay kinetics. A-C) Effect of 80 µM 
dynasore on magnitude of Tg-resistant ATP-evoked Ca2+ response and net calcium 
movement in TDM (n=3). Asterisks include significant changes towards control (*** 
p<0.001, * p<0.05, Student’s t-test).  
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3.3.5.2. Effect of vacuolin-1 on Tg-resistant ATP-evoked Ca2+ response   
Lysosomal exocytosis induced by factors such as Ca2+ ionophores resulted in the 
trafficking of P2X4 to the plasma membrane of cells (Qureshi et al., 2007). To 
investigate if P2X4 contribution to Tg-resistant Ca2+ response in TDM cells is 
dependent on lysosomal exocytosis, vacuolin-1 was used. Vacuolin-1 is a lipid-
soluble polycyclic triazine that can selectively increase the size of intracellular 
endosomes and lysosomes as well as causing a block to Ca2+-dependent 
exocytosis of lysosomes (Huynh & Andrews, 2005).  
 
As shown (Figure 3.20A and B), 1 µM of vacuolin-1 had no significant effect on the 
magnitude of ATP-evoked Ca2+ response in TDM cells. However, net calcium 
movement in TDM cells was significantly reduced when cells were pre-treated with 
vacuolin-1 (Figure 3.20C) (AUC 57.45 ± 2.10 vs. 47.75 ± 3.04, n=3, P<0.05). The 
effect of vacuolin-1 on Tg-insenstive Ca2+ response in TDM cells was also 
investigated and data is shown in Figure 3.20D-F. As shown (Figure 3.20D and E), 
vacuolin-1 had no significant effect on the magnitude of Tg-insensitive Ca2+ 
response. In addition to this, vacuolin-1 also caused no significant effect on net 
calcium movement of Tg-resistant Ca2+ response in TDM cells (Figure 3.20F). 
These findings illustrated that inhibition of lysosomal exocytosis in TDM cells had 
little or no significant effect on magnitude of Ca2+ response. Although vacuolin-1 
appeared to significantly reduce net calcium movement in ATP-evoked Ca2+ 
response, it was unable to cause any inhibition in the presence of Tg, indicating that  
these Ca2+ responses are likely to be independent on the receptor trafficking from 
lysosomes to plasma membrane.  
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Figure 3.20. Effect of vacuolin-1 on ATP response and Tg-resistant Ca2+ 
response. Effect of 1 µM vacuolin-1 on: A-C) ATP-elicited Ca2+ response in TDM 
(n=3) or D-F) Tg-resistant component in TDM (n=3). Asterisks include significant 
changes towards control (* p<0.05, Student’s t-test). 
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3.4. Summary 
This chapter utilized THP-1 cells and TDM cells as in vitro models to 
pharmacologically characterize contribution of P2X4 towards ATP-evoked Ca2+ 
responses. As working with human primary cells can proof challenging due to low 
cell number yield, this chapter also serves to identify which of the two cells – 
monocytes or macrophages – is a better model to study P2X4. Through qRT-PCR 
and confocal microscopy, P2X4 was shown to be expressed at both the 
transcriptional and translational level in both THP-1 cells and TDM cells. In addition 
to this, at the mRNA level, P2X4 expression was shown to be up-regulated in TDM 
compared to THP-1 cells.  
 
To study functional P2X4 in THP-1 and TDM cells, intracellular Ca2+ measurement 
was employed. Agonist (ATP) concentration of 100 µM was used throughout the 
study to maximally activate P2X4 receptor. To reveal the contribution of P2X4 in 
these cells, two pharmacological tools were employed to block metabotropic-
mediated Ca2+ responses in the two cell lines: U-73122 and Tg. In the presence of 
U-73122 or Tg, ATP-evoked Ca2+ responses in THP-1 cells lack sensitivity towards 
P2XR antagonists, suggestive of their limited contribution. On the other hand, in the 
presence of U-73122 or Tg, ATP-evoked Ca2+ responses in TDM cells were 
sensitive towards IVM, 5-BDBD and PSB-12062. The P2X4 shRNA knockdown 
approach also confirmed the contribution of P2X4 towards ATP-evoked Ca2+ 
responses in TDM cells, whereby P2X4 shRNA cells were found to have reduced 
sensitivity towards IVM and PSB-12062. The knockdown approach also allowed the 
verification of IVM and PSB-12062 as a good pharmacological tool to study P2X4. 
However, it was important to note that although PSB-12062 has been reported as a 
selective non-competitive antagonist for P2X4, it must be used with caution as 
selectivity studies on hP2X7 over expressing cell line illustrated that at 10 µM, it was 
not selective for P2X4. Taken together, these findings suggested that TDM cells act 
as a better model to study functional P2X4 when compared to THP-1 cells and when 
used in conjunction, IVM, PSB-12062 and 5-BDBD are reliable pharmacological 
tools for the study of P2X4. In the next chapter, contribution of P2X4 towards ATP-
evoked Ca2+ responses in primary macrophages will be investigated, although the 
use of U-73122 or Tg will be minimized to mimic physiological condition as much as 
possible.  
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Chapter 4: Investigating contribution 
of P2X4-mediated Ca2+ response in 
primary human monocyte-derived 
macrophages differentiated using GM-
CSF versus M-CSF 
 
4.1. Introduction 
The generation of in vitro monocyte-derived macrophages (MDMs) can be achieved 
through the use of colony-stimulating factors (CSFs). CSFs are secreted 
glycoproteins, which can recognize and bind to receptor proteins found on the 
surface of haemopoietic stem cells that induces cells to proliferate and differentiate 
into a specific type of blood cell. There are currently three types of CSFs: CSF1 or 
also known as macrophage colony-stimulating factor (M-CSF), CSF2 or granulocyte 
macrophage colony-stimulating factor (GM-CSF) and finally, CSF3 or granulocyte 
colony-stimulating factors (G-CSF). The CSFs classically used for the generation of 
in vitro monocyte-derived macrophages are M-CSF and GM-CSF. While M-CSF is 
ubiquitously produced by various tissues and plays a key role in controlling 
macrophage numbers (Stanley et al., 1997, Wiktor-Jedrzejczak et al., 1990), GM-
CSF is found at low basal circulating levels and is often only elevated in response to 
inflammatory reactions (Lacey et al., 2012). Each of the two CSFs is able to activate 
different receptors leading to different downstream signalling pathways. Their 
receptors have different distribution on myeloid cell populations with one common 
example being macrophages (Hamilton, 2008). Despite acting on different 
receptors, both CSFs are capable of promoting cell survival and proliferation, 
differentiation as well as activation in macrophages (Chitu and Stanley, 2006, 
Fleetwood et al., 2005).  
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Monocytes have been reported to respond differently to M-CSF and GM-CSF but 
there is limited understanding to the nature and mechanism underlying this 
difference.  M-CSF-treated human blood monocytes are widely used to generate 
MDMs as a model for tissue macrophages. Differentiated macrophages resulting 
from the treatment with M-CSF are often referred to as M2-macrophages with ‘anti-
inflammatory’ cytokine profile (Verreck et al., 2004). They were first described by 
Akagawa et al. (1988) as cells resembling peritoneal macrophages. Meanwhile, 
differentiated macrophages resulting from the treatment with GM-CSF are often 
referred to as M1 macrophages with ‘pro-inflammatory’ cytokine profile and 
resembling tissue macrophages in lung alveoli (Akagawa et al., 1988). GM-CSF-
treated human blood monocytes are also often used to generate cells with dendritic 
cell antigen-presenting properties. However, bioinformatics analysis of the GM-CSF-
treated monocytes transcriptome revealed that they are in fact closer to 
macrophages than to DCs (Lacey et al., 2012). To further polarize these MDMs 
towards M1- or M2- macrophages, the supplementation of cytokines are often used. 
This includes the use of IFN-g and LPS in combination with GM-CSF to generate 
M1- polarized macrophages and IL-4 and IL-13 in combination with M-CSF to 
generate M2- polarized macrophages (Mantovani et al., 2002, Mosser and 
Edwards, 2008). Throughout this thesis, M-CSF-differentiated MDMs will be referred 
to as M-MDM while GM-CSF-differentiated MDMs will be referred to as GM-MDM.  
 
4.2. Aims 
GM-MDM and M-MDM were employed in a side-by-side comparison study as in 
vitro primary monocyte-derived macrophage (MDM) models to investigate the 
contribution of functional P2X4 receptor towards ATP-evoked Ca2+ responses. To 
address this aim, several pharmacological tools that were investigated in chapter 3 
were employed to help characterize P2X4 through quantification of intracellular Ca2+ 
measurements. In addition to this, this chapter also aimed to characterize the 
contribution of other functional purinergic receptors (P2X and P2Y receptors) within 
the two macrophage models. 
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4.3. Results  
 
4.3.1. Morphological differences between GM-MDM vs. M-MDM cells 
It has been well defined in the literature that MDMs possess different morphological 
features depending on their cytokine microenvironments (Waldo et al., 2008). 
Human monocytes differentiated in the presence of GM-CSF have been described 
to possess a classic rounded shape of the original monocyte precursor resembling 
the ‘fried egg’ phenotype (Babu and Brown, 2013, Baj-Krzyworzeka et al., 2016, 
Eligini et al., 2013, Waldo et al., 2008). On the other hand, human monocytes that 
are differentiated in the presence of M-CSF resulted in macrophages with numerous 
vacuoles and elongated shape (Eligini et al., 2013). In order to better characterize 
the two types of macrophage lineages used throughout the study, a comparative 
study of the morphological differences between the two cells were performed. This 
was performed using a combination of observations under high-magnification 
microscopy and flow cytometry scatter analysis. Staining of cells with CD14 surface 
markers was also performed on the two types of macrophages.  
 
As shown in Figure 4.1A and 4.1B, following 6d treatment with colony stimulating 
factors (GM-CSF or M-CSF, respectively), morphological characteristics of both 
GM-MDM and M-MDM cells resemble structure described in the literature. GM-
MDM cells possess a classical granular and rounded ‘fried-egg’ morphology while 
M-MDM cells possess an elongated structure that appear to be less granular. To 
further confirm this, the size and granularity of each of the two macrophage lineages 
were analysed using forward (FSC) and side scatter (SSC) plot through the use of 
flow cytometer. FSC analysis is proportional to cell surface area or size while SSC 
analysis is proportional to cell granularity or internal complexity. Two sets of gating 
were established, P2 that cover cells of smaller surface area and lower granularity 
and P3 that cover cells of larger surface area and higher granularity. As can be 
seen in Figure 4.1C and 4.1D, an excess of approximately 15% of the M-MDM cells 
were found within P2 gate compared to GM-MDM cells. Meanwhile, a higher 
proportion of GM-MDM cells were found within P3 gate when compared with M-
MDM cells. This is in line with the general observation that GM-MDM cells possess 
a more rounded and granular structure in comparison to M-MDM cells, which tend 
to be less granular and more elongated in shape. 
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To further characterize each of the two macrophage lineages in culture, expression 
of CD14 on the cell surface were studied using flow cytometry. CD14 is a classical 
cell surface marker that is found in monocytes, macrophages, neutrophils as well as 
some dendritic cells (Ziegler-Heitbrock and Ulevitch, 1993). Following 6d treatment 
with colony stimulating factors, 70.5 ± 4.6 % of GM-MDM cells and 99.6 ± 2.8 % of 
M-MDM cells were found to be CD14+ (Figure 4.1E and F, respectively). This is in 
line with immunocytochemistry studies performed by Waldo et al. (2008), which 
confirmed enhanced expression of cell surface marker CD14 in M-MDM when 
compared to GM-MDM cells. Studies by Kruger et al. (1996) also revealed that GM-
CSF treatment down-regulates CD14 expression in in vitro cultured monocytes in a 
dose-dependent manner.  
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Figure 4.1. Morphological characteristics of monocyte-derived macrophages 
following 6d treatment with colony stimulating factor. Morphological differences 
as seen under inverted microscope of: A) GM-MDM and B) M-MDM following 6d 
treatment with colony stimulating factor (representative of N=6 donors). Scale bar 
on each images is representative of 20 µm. Flow cytometry forward (FSC) and side 
(SSC) scatter analysis for: C) GM-MDM and D) M-MDM cells. Flow cytometry 
analysis of CD14 surface marker on: E) GM-MDM and F) M-MDM cells. Red: cells 
stained with isotype control IgGk PE, Green: cells stained with CD14 PE. All flow 
cytometry analysis is representative of N=3 donors.  
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4.3.2. Investigating the mRNA and protein expression of P2XR and P2YR in 
GM-MDM and M-MDM  
 
4.3.2.1. Quantification of mRNA transcript using qRT-PCR 
Monocyte-derived macrophages generated by colony stimulating factor stimulation 
has become a well-established model for studying human macrophages (Daigneault 
et al., 2010, Erbel et al., 2013, Gantner et al., 1997). However, expression of 
purinergic receptors (P2X and P2Y receptors) in these cells has not been 
documented. Here, through the use of qRT-PCR, mRNA expression of P2XR and 
P2YR in both macrophage models was investigated. Initially, the presence or 
absence of P2XR and P2YR genes were assessed in GM-MDM and M-MDM cells, 
following 6d treatment with the respective colony stimulating factors, based on their 
Ct values (Figure 4.2A). Genes amplified at Ct values higher than 35.0 were 
considered absent. Across five independent donors, mRNA transcript of P2X1, 
P2X4, P2X5 and P2X7 were all expressed in both GM-MDM and M-MDM cells while 
mRNA transcript of P2X2, P2X3 and P2X6 were found to be absent in both cell 
systems. As for the mRNA transcript of P2YR, all but P2Y12 and P2Y14, were 
expressed in both GM-MDM and M-MDM. In addition to this, non-quantitative RT-
PCR was also performed to investigate if MDM cells express the functional or non-
functional isoform of P2X5. As previously mentioned in chapter 3, SNP at the 3’ 
splice end of exon 10 of human P2X5 gene can result in an exon 10-deleted isoform 
of P2X5 yielding a non-functional receptor. Figure 4.2B and C illustrated that both 
GM-MDM and M-MDM express the non-functional (exon 10-less) P2X5 as observed 
with a band size of 395 bp, respectively.  
 
Having identified which receptors are present at the transcriptional level in the GM-
MDM and M-MDM cells, differences in the fold change of mRNA expression level of 
each receptor were quantified (Figure 4.3 and 4.4), respectively. Figure 4.3 
illustrated no significant differences in mRNA expression of P2X1, P2X4, P2X5 and 
P2X7 in M-MDM vs. GM-MDM cells. Unlike P2XR genes, Figure 4.4 illustrated 
significant differences in several of the P2YR genes. As can be seen, mRNA 
expression of P2Y1 is significantly down regulated in M-MDM cells by 2.05 ± 0.078 
fold (N=5; P<0.01) when compared to GM-MDM cells (normalized value of 1.0 
indicated no change). On the other hand, mRNA expression of P2Y6 and P2Y11 was 
found to be significantly up-regulated in M-MDM cells by 18.64 ± 4.54 fold (N=5; 
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P<0.05) and 5.58 ± 1.60 fold (N=5; P<0.05), respectively, when compared to GM-
MDM cells. No significant differences in mRNA expression were observed for P2Y2, 
P2Y4 and P2Y13 genes in both macrophage systems.  
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Figure 4.2. mRNA expression of P2XR and P2YR genes in GM-MDM and M-
MDM cells. A) Average Ct values for P2XR and P2YR genes. Ct values were 
obtained from qRT-PCR for both GM-MDM (N=5 donors) and M-MDM (N=5 donors) 
cells. Ct values that appear >35 were considered absent. N/A denotes genes that 
were found undetected during 40 cycles of amplification. Reaction containing no 
reverse transcriptase (No RT’) enzyme serve as negative control in these 
experiments and Ct values for these samples were ensured to be >39.0 (N=5 
donors). B and C) Non-quantitative RT-PCR analysis of P2X5 mRNA expression to 
distinguish non-functional and functional isoform of the receptor in GM-MDM and M-
MDM, respectively. Bands corresponding to functional hP2X5 is found at 461 bp 
while bands corresponding to non-functional hP2X5 is found at 395 bp. b-Actin was 
used as a positive control. Images are representative of N=3 donors.  
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Figure 4.3. Quantitative real-time PCR to identify fold change of mRNA 
expression of P2X receptor genes in M-MDM cells vs. GM-MDM cells. For each 
donor, Ct values were normalized to housekeeping gene RPLP0 and to GM-MDM 
cells to obtain DDCt (N=5 donors). No change in fold change of mRNA expression is 
represented by a value of 1.0. Values greater than 1.0 illustrated an up-regulation 
while values lower than 1.0 illustrated a down-regulation in mRNA expression.  
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Figure 4.4. Quantitative real-time PCR to identify fold change of mRNA 
expression of P2Y receptor genes in M-MDM cells vs. GM-MDM cells. For each 
donor, Ct values were normalized to housekeeping gene RPLP0 and to GM-MDM 
cells to obtain DDCt (N=5 donors). No change in fold change of mRNA expression is 
represented by a value of 1.0. Values greater than 1.0 illustrated an up-regulation 
while values lower than 1.0 illustrated a down-regulation in mRNA expression. 
Asterisks include significant changes towards control (** p<0.01, * p<0.05, Student’s 
t-test). 
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4.3.2.2. Assessing protein expression of P2XR and P2YR using confocal 
microscopy 
Expression of P2X and P2Y receptors in the GM-MDM and M-MDM was also 
studied at the protein level using confocal microscopy (Figure 4.5 and 4.6, 
respectively). All P2X and P2Y receptor antibodies detected intracellular epitope, 
which required the cells to be fixed and permeabilized prior to staining.   
 
Figure 4.5A and B illustrated similar expression of P2X receptors in GM-MDM and 
M-MDM, respectively. Corresponding with the mRNA expression of P2X receptors, 
protein expression was detected for P2X1, P2X4, P2X5 and P2X7 in both cell types, 
with each receptors showing punctate distribution. Similarly, Figure 4.6A and 4.6B 
illustrated protein expression of P2Y receptors in GM-MDM and M-MDM, 
respectively. In both cell types, the expression of P2Y1, P2Y2, P2Y6 and P2Y13 was 
all detected at the protein level and illustrated a punctate distribution. No positive 
staining was observed for P2Y12, which corroborates with the absence of P2Y12 
mRNA expression in these cells (Figure 4.2A). Altogether, the data illustrated that 
GM-MDM and M-MDM cells express similar profile of P2X and P2Y receptors at 
both the mRNA and protein level.  
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Figure 4.5. Expression of P2X receptors in human MDM cells. Expression of P2X1, P2X4, P2X5 and P2X7 conjugated to Alexa Fluor 488 
(AF488) fluorochrome on A) GM-MDM cells and B) M-MDM cell. AF488 alone represented a secondary antibody negative control and scale bar 
on each image is representative of 10 µm. Images are representative of N=3 donors.   
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Figure 4.6. Expression of P2Y receptors in human MDM cells. Expression of P2Y1, P2Y2, P2Y6, P2Y12 and P2Y13 conjugated to Alexa Fluor 
488 (AF488) fluorochrome on A) GM-MDM cells and B) M-MDM cell. AF488 alone represented a secondary antibody negative control and 
scale bar on each image is representative of 10 µm. Images are representative of N=3 donors.
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4.3.3. ATP-evoked intracellular Ca2+ response in primary human MDMs  
In the previous chapter, the contribution of P2X4-mediated Ca2+ response in 
macrophage cell line model, TDM, was investigated using various pharmacological 
tools. Here, the contribution of P2X4-mediated Ca2+ response in human primary 
macrophages – GM-MDM and M-MDM – was investigated thoroughly. The initial 
aim of this chapter was to determine a dose response curve of ATP and the 
maximal concentration to activate P2X4 in both macrophage systems. 
 
ATP elicited a concentration-dependent increase in intracellular Ca2+ level in both 
GM-MDM and M-MDM cells. Figure 4.7A and 4.7B illustrated concentration-
response curve in presence and absence of extracellular Ca2+ for GM-MDM and M-
MDM, respectively. In both macrophage systems, maximal Ca2+ responses were 
observed at a similar ATP concentration, which is at 100 µM, similar to that 
observed in macrophage cell line. For this reason, ATP concentration of 100 µM 
was used for the rest of the study involving human primary MDM. In the presence of 
extracellular Ca2+, similar EC50 values were observed in both macrophage systems, 
with GM-MDM having EC50 of 11.4 ± 2.9 µM (N=3 donors; Figure 4.7A) and M-MDM 
having EC50 of 13.3 ± 1.4 µM (N=3 donors; Figure 4.7B). However, in the absence 
of extracellular Ca2+, GM-MDM illustrated an EC50 value of 9.77 ± 2.4 µM (N=3 
donors; Figure 4.7A) while M-MDM illustrated an EC50 value of 7.8 ± 2.9 µM (N=3 
donors; Figure 4.7B). The representative Ca2+ time-response trace in GM-MDM and 
M-MDM cells upon stimulation with 1, 10 and 100 µM ATP is represented in Figure 
4.7C and 4.7D, respectively. As shown in Figure 4.7C, 100 µM ATP caused a 
significant increase in intracellular Ca2+ response, which was followed by a decay 
back to baseline level in GM-MDM cells. However, as shown in Figure 4.7D, ATP 
elicited a different Ca2+ response profile in M-MDM cells. Following challenge with 
lower ATP concentration (1 and 10 µM), ATP elicited a significant increase in 
intracellular Ca2+ response, which decayed back to baseline level. Despite having a 
similar profile to GM-MDM cells at lower agonist concentrations, higher ATP 
concentration (100 µM) application in M-MDM cells caused a significant increase in 
intracellular Ca2+ response followed by a second slower response before decaying 
back to a sustained elevated phase. The difference in Ca2+ profile evoked by 100 
µM ATP in GM-MDM and M-MDM cells was confirmed through quantification of 
area under the curve (AUC 41.93 ± 6.41 GM-MDM vs. 147.36 ± 9.94 M-MDM; N=3 
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donors; P<0.01; Figure 4.7E). Factors underlying this difference will be discussed 
further in section 4.3.4.   
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Figure 4.7. ATP elicited a dose-dependent intracellular Ca2+ response in both 
GM-MDM and M-MDM cells. Dose-response curve of ATP (0.01 – 1000 µM) in the 
presence and absence of extracellular Ca2+ in: A) GM-MDM cells (N=3 donors) and 
B) M-MDM cells (N=3 donors). C) Representative time-response curve of GM-MDM 
cells in response to 1 – 100 µM ATP recorded over 250 s. D) Representative time-
response curve of M-MDM cells in response to 1 – 100 µM ATP recorded over 250 
s. E) Area under the curve quantified following 100 µM ATP challenge in GM-MDM 
and M-MDM cells. Asterisks include significant changes towards control (** p<0.01, 
Student’s t-test).  
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4.3.4. Contribution of metabotropic receptor to ATP-evoked Ca2+ responses in 
GM-MDM vs. M-MDM cells  
 
As discussed in section 4.3.3, 100 µM ATP elicited a Ca2+ response profile that was 
significantly different in macrophage systems GM-MDM and M-MDM. As discussed 
previously in section 4.3.2.1, there are key differences in mRNA expression of 
various P2YR genes in GM-MDM and M-MDM, which may be one of the key factors 
underlying the difference in ATP-evoked Ca2+ response found in both macrophage 
systems. Hence, to better understand the nature and phenotype of the two cells, it 
was important to investigate the contribution of metabotropic P2Y receptors through 
the use of pharmacological tools such as U73122 and selective P2YR antagonists.  
 
4.3.4.1. Effect of PLC inhibitor, U73122, on ATP-mediated Ca2+ response in 
GM-MDM versus M-MDM 
To identify the contribution of Gq-coupled P2YR on ATP-evoked Ca2+ responses in 
human GM-MDM and M-MDM, U73122 was utilized. Pre-treatment of cells with 10 
µM U-73122 significantly inhibited the magnitude of ATP-evoked Ca2+ response in 
both macrophage systems (GM-MDM: 90.0 ± 0.96 %; N=3; P<0.001; Figure 4.8A 
and B, and M-MDM: 65.0 ± 3.08 %; N=3; P<0.001; Figure 4.8C and D). These data 
illustrated that the magnitude of ATP-evoked Ca2+ response in both macrophage 
systems is highly dependent upon the activation of metabotropic P2YR coupled to 
Gaq subunit. For this reason, the effect of several P2YR antagonists were tested to 
assess their contribution towards ATP-evoked Ca2+ response. However, due to the 
lack of commercially available selective antagonists for P2Y4 and P2Y14, these 
receptors were not investigated.  
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Figure 4.8. Effect of PLC inhibitor, 10 µM U73122, on ATP-mediated calcium 
response in GM-MDM. Data is represented as: A and C) percentage increase in 
Ca2+ response and B and D) representative time-response curve at 100 µM ATP in 
the presence or absence of 10 µM U73122 in GM-MDM (N=3 donors) and M-MDM 
cells (N=3 donors), respectively. Asterisks include significant changes towards 
control (** p<0.01, * p<0.05, Student’s t-test). 
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4.3.4.2. Using P2Y receptor selective antagonist  
To identify which metabotropic P2Y receptors may be responsible for the magnitude 
of the Ca2+ response in GM-MDM and M-MDM cells, various selective antagonist of 
P2Y receptors were employed. Two groups of P2Y receptors will be investigated: 
ADP-activated P2Y receptors (P2Y2, P2Y6 and P2Y11) and ATP-activated P2Y 
receptors (P2Y1, P2Y12 and P2Y13). The agonist that was employed throughout this 
study is 100 µM ATP.  
 
4.3.4.2.1. Targeting ADP-activated P2Y receptors  
Although ATP was used as the main agonist in these studies, it was important to 
investigate the contribution of ADP-activated P2YR since extracellular ATP can be 
hydrolysed into ADP and AMP. Local increase in nucleotides is controlled by 
ectonucleotidases such as CD39/E-NTPDase family and CD73/ecto-5’-
nucleotidase. CD39 hydrolyzes extracellular nucleotides (ATP) to their respective 
nucleosides (AMP) with the transient production of free ADP, which can 
subsequently activate P2Y receptors (Robson et al., 2006).  
 
P2Y receptors that can be activated by ADP include P2Y1, P2Y12 and P2Y13. 
Although not the main agonist, ADP has been speculated to be able to activate 
P2Y6 (Communi et al., 1996). While P2Y1 and P2Y6 are coupled to Gaq subunit 
leading to activation of PLCb, P2Y12 and P2Y13 are coupled to Gai subunit leading to 
adenylyl cyclase (AC) inhibition (Jacobson et al., 2009). Although activation of Gai-
coupled P2Y receptors, such as P2Y13, in theory do not lead to a raise in 
intracellular Ca2+ response, there is a possibility that it can form heterodimers with 
other P2YR such as P2Y1 to activate PLC resulting in increase in intracellular Ca2+ 
level (Perez-Sen et al., 2015) or even possibly interacting with P2X receptors 
leading to intracellular Ca2+ increase. However, no evidence has ever been made 
on this account. Here, only the contribution of P2Y1, P2Y6 and P2Y13 were 
investigated as P2Y12 mRNA and protein expression was undetected in both 
macrophage systems (Table 4.2).  
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4.3.4.2.1.1. P2Y1 Receptor  
A selective and competitive antagonist for P2Y1, MRS2500, was utilized in this 
study. MRS2500 is reported to be a highly potent antagonist with Ki of 0.78 nM (Kim 
et al., 2003). Pre-treatment of GM-MDM and M-MDM cells with 1 µM MRS2500 had 
a small but insignificant effect on the magnitude of the Ca2+ response in both 
macrophage systems (Figure 4.9). Moreover, the antagonist had no effect on the 
decay kinetics and net calcium movement of the Ca2+ response. This indicates 
minimal contribution of P2Y1 towards ATP-evoked Ca2+ response in both GM-MDM 
and M-MDM cells. 
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Figure 4.9. Effect of P2Y1 receptor antagonist, 1 µM MRS2500, on ATP-evoked Ca2+ response in GM-MDMs versus M-MDMs. Data is 
represented as percentage increase in Ca2+ response, representative time-response curve and bar chart representing net calcium movement 
(AUC) at 100 µM ATP in the presence or absence of 1 µM P2Y1 antagonist, MRS2500, for: A) GM-MDM cells (N=3 donors) or B) M-MDM cells 
(N=3 donors). Asterisks include significant changes towards control (** p<0.01, * p<0.05, Student’s t-test). 
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4.3.4.2.1.2. P2Y6 Receptor  
A selective and non-competitive antagonist for P2Y6, MRS2578, was utilized to 
assess the contribution of P2Y6 towards ATP-evoked Ca2+ response in human 
macrophages. MRS2578 has a reported IC50 value of 37 ± 16 nM when tested for 
inhibition of UDP response in over expressing astrocytoma cell line (Mamedova et 
al., 2004). Although it is well established that the main agonist for P2Y6 is UDP, it is 
thought that ADP can also act as a weak agonist (Communi et al., 1996). Pre-
treatment of GM-MDM cells with 10 µM of MRS2578 had no significant effect on the 
magnitude of ATP-evoked Ca2+ response but appeared to cause a slight increase 
towards the decay phase of the response (Figure 4.10A). Despite subtly increasing 
the decay phase of the Ca2+ response, no significant change was observed in the 
net Ca2+ movement as quantified by area under the curve. Similarly, pre-treatment 
of M-MDM cells with MRS2578 antagonist had no significant effect towards 
magnitude of the ATP-evoked Ca2+ response as well as area under the curve 
(Figure 4.10B).   
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Figure 4.10. Effect of P2Y6 antagonist, 10 µM MRS2578, on ATP-evoked Ca2+ response of human GM-MDMs versus M-MDMs. Data is 
represented as percentage increase in Ca2+ response, representative time-response curve and bar chart representing net calcium movement 
(AUC) at 100 µM ATP in the presence or absence of 10 µM P2Y6 antagonist, MRS2578, for: A) GM-MDM cells (N=3 donors) or B) M-MDM 
cells (N=3 donors).  
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4.3.4.2.1.3. P2Y13 Receptor  
The contribution of P2Y13 on ATP-evoked Ca2+ response in primary macrophages 
was studied using a competitive P2Y13 antagonist, MRS2211. MRS2211 is reported 
to be a selective antagonist for P2Y13 with pIC50 of 5.97 with over 20-fold selectivity 
against other P2YR such as P2Y1 (Kim et al., 2005). Pre-treatment of GM-MDM with 
10 µM of MRS2211 significantly inhibited magnitude of Ca2+ response in GM-MDM 
cells (48.6 ± 4.56 % inhibition; N=3 donors; P<0.001; Figure 4.11A) as well as area 
under the curve (AUC 44.52 ± 7.23 without MRS2211 vs. 25.52 ± 4.37 with 
MRS2211; N=3 donors; P<0.01; Figure 4.11A). It can also be seen that although 
MRS2211 significantly inhibited peak of the Ca2+ response, it appeared to have little 
effect on the decay phase of the response. On the contrary, in M-MDM cells, 
MRS2211 did not have any significant effect towards the magnitude of Ca2+ 
response as well as the area under the curve (Figure 4.11B).  
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Figure 4.11. Effect of P2Y13 antagonist, 10 µM MRS2211, on ATP-evoked Ca2+ response in GM-MDMs vs. M-MDMs. Data is represented 
as percentage increase in Ca2+ response, representative time-response curve and bar chart representing net calcium movement (AUC) at 100 
µM ATP in the presence or absence of 10 µM P2Y13 antagonist, MRS2211, for: A) GM-MDM cells (N=3 donors) or B) M-MDM cells (N=3 
donors). Asterisks include significant changes towards control (*** p<0.001, ** p<0.01, Student’s t-test).  
 180 
4.3.4.2.2. Targeting ATP-activated P2Y receptors  
The main P2Y receptors activated by ATP are P2Y2 (coupled to Gaq subunit) and 
P2Y11 (coupled to Gaq subunit or Gas subunit). Activation of P2Y2 leads to PLCb 
activation while activation of P2Y11 leads to PLCb and AC activation (Erb and 
Weisman, 2012, Jacobson et al., 2009). The activation of PLCb results in 
mobilization of intracellular Ca2+.  
 
4.3.4.2.2.1. P2Y2 Receptor 
A selective and competitive antagonist of P2Y2, ARC-118925XX, was utilized in this 
study to identify contribution of P2Y2 in ATP-evoked Ca2+ response of GM-MDM and 
M-MDM. It has a reported IC50 of 1 µM in bronchial epithelial cells and has been 
shown to be inactive against 37 other receptors when used at concentration of 10 
µM (Kemp et al., 2004). Pre-treatment of macrophages with 10 µM ARC-118925XX 
had no significant inhibitory effect on the magnitude of ATP-evoked Ca2+ response 
in both GM-MDM and M-MDM cells (Figure 4.12A and 4.12B, respectively). Instead, 
ARC-118925XX significantly increase the magnitude of Ca2+ response (23.74 ± 7.54 
% potentiation; N=3 donors; P<0.05; Figure 4.12B) in M-MDM cells but not GM-
MDM cells.  
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Figure 4.12. Effect of P2Y2 antagonist, 10 µM ARC-118925xx, on ATP-evoked Ca2+ response in GM-MDMs versus M-MDMs. Data is 
represented as percentage increase in Ca2+ response, representative time-response curve and bar chart representing net calcium movement 
(AUC) at 100 µM ATP in the presence or absence of 10 µM P2Y2 antagonist, ARC-118925xx for: A) GM-MDM cells (N=3 donors) or B) M-MDM 
cells (N=3 donors). Asterisks include significant changes towards control (* p<0.05, Student’s t-test). 
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4.3.4.2.2.2. P2Y11 Receptor 
Lastly, a P2Y11 receptor antagonist, NF340, was utilized to identify its role in ATP-
evoked Ca2+ response of human primary macrophages. NF340 is reported have a 
pIC50 value of 6.43 through Ca2+ measurements and to be highly selective for P2Y11 
receptor with 520-fold selectivity over P2Y1, P2Y2, P2Y4, P2Y6 and P2Y12 (Meis et 
al., 2010). Pre-treatment of GM-MDM cells with 10 µM NF340 significantly reduced 
the magnitude of the ATP-evoked Ca2+ response by 20.52 ± 3.20 % (N=3 donors; 
P<0.05; Figure 4.12A). Moreover, blocking P2Y11 had no effect on the decay 
kinetics of the ATP-evoked Ca2+ response in GM-MDM cells as reflected by no 
significant change in area under the curve (AUC 56.06 ± 4.20 without NF340 versus 
57.46 ± 5.86 with NF340; N=3 donors; P>0.05; Figure 4.13B). Interestingly, pre-
treatment of M-MDM cells with 10 µM NF340 significantly reduced not only the 
magnitude of the ATP-evoked Ca2+ response (35.54 ± 2.60 % inhibition; N=3 
donors; P<0.001; Figure 4.12B), but also abolished the second slower decay phase 
that was induced by 100 µM ATP (AUC 78.69 ± 20.26 without NF340 vs. 32.52 ± 
12.73 with NF340; N=3 donors; P<0.05; Figure 4.12B). Based on this observation, 
P2Y11 is a major contributor for the decay phase observed in M-MDM cells following 
stimulation with high ATP concentration (100 µM). This observation is in accordance 
with findings shown in Figure 4.4 illustrating that P2Y11 mRNA expression is up-
regulated (5.58 ± 1.60 fold; N=5 donors; P<0.05) in M-MDM cells, when compared 
to GM-MDM cells.  
 
The data so far illustrated that the activation of P2Y11 and P2Y13 are responsible for 
the magnitude of the ATP-evoked Ca2+ response in both GM-MDM and M-MDM 
cells. In addition to this, P2Y11 appeared to also be responsible for the decay 
response in M-MDM cells, but not GM-MDM cells. Surprisingly, P2Y1, P2Y2 and 
P2Y6 lack contribution towards the ATP-evoked Ca2+ response in these cells 
although this may be explained by the competitive nature of the antagonists being 
used in this study. 
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Figure 4.13. Effect of P2Y11 antagonist, 10 µM NF340, on ATP-evoked Ca2+ response in GM-MDMs versus M-MDMs. Data is represented 
as percentage increase in Ca2+ response, representative time-response curve and bar chart representing net calcium movement (AUC) at 100 
µM ATP in the presence or absence of 10 µM P2Y11 antagonist, NF340, for: A) GM-MDM cells (N=3 donors) or B) M-MDM cells (N=3 donors). 
Asterisks include changes towards control (*** p<0.001, ** p<0.01, * p<0.05, Student’s t-test). 
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4.3.5. Pharmacological characterization of P2X4-evoked Ca2+ response in 
human MDMs  
One of the key aims of this chapter was to identify the contribution of P2X4 receptor 
towards ATP-evoked Ca2+ responses in human primary macrophages. In the 
previous chapter, P2X4 appeared to contribute to the magnitude of ATP-evoked 
Ca2+ response in TDM cells. It was therefore important to identify if P2X4 can 
contribute in a similar manner in primary macrophages. A side-by-side comparison 
of P2X4 contribution in GM-MDM and M-MDM cells was studied using 
pharmacological tools. These pharmacological tools include previously used P2X4 
positive allosteric modulator (IVM), selective P2X4 antagonists (5-BDBD and PSB-
12062) and other P2X antagonists (P2X1 antagonist, Ro0437626, and P2X7 
antagonist, A438079). Although there were no significant differences in the level of 
P2X4 mRNA expression in GM-MDM and M-MDM cells (Figure 4.3), flow cytometry 
analysis was also performed to allow the quantitation of P2X4 protein on the surface 
of the cells as well as P2X4 protein localized within intracellular compartments.    
 
4.3.5.1. Effect of Ivermectin (IVM) on ATP-evoked Ca2+ response in human GM-
MDM versus M-MDM  
IVM has been reported to act on both hP2X4 and hP2X7 receptor (Norenberg et al., 
2012). Despite the lack of selectivity, it is still one of the most commonly used 
pharmacological tools to characterize activation of P2X4. Here, 3 µM IVM was used 
to isolate contribution of P2X4-mediated Ca2+ responses in human GM-MDM and M-
MDM cells. Pre-treatment of GM-MDM cells with IVM resulted in significant 
potentiation in magnitude of Ca2+ response (18.2 ± 4.58 %, N=12 donors, P<0.01; 
Figure 4.14A) and significantly delayed decay kinetics. This can be observed from 
the time-response trace as well as bar chart representing a significant increase in 
net calcium movement as measured by area under the curve (AUC 45.3 ± 8.1 
without IVM versus 90.1 ± 11.0 with IVM; N=12 donors; P<0.01; Figure 4.14A). 
These observations are consistent to the effect of IVM that was observed in TDM 
cells (Chapter 3), and to the literature, whereby IVM not only potentiated P2X4-
mediated current but also delayed decay kinetics (Norenberg et al., 2012). 
 
Unlike the effect it has on GM-MDM cells, IVM affected M-MDM cells differently. As 
shown on Figure 4.14B, IVM caused a significant potentiation in the magnitude of 
ATP-evoked Ca2+ response in M-MDM cells (127.14 ± 4.97 %; N=7; P<0.001). 
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However, IVM did not appear to have any effect on the decay kinetic of the Ca2+ 
response in M-MDM cells, therefore no significant effect on net calcium movement 
as quantified by area under the curve (AUC 91.89 ± 35.07 without IVM versus 162.5 
± 48.1 with IVM; N=7 donors; P>0.05; Figure 4.14B). The different effect IVM has on 
the GM-MDM and M-MDM cells may be due to several factors such as different 
amount of functional P2X4 receptor in the two macrophage systems studied as well 
as different mechanism of P2X4 recruitment from intracellular stores. Although the 
latter will not be investigated within this study, the amount of surface and 
intracellular P2X4 was quantified using flow cytometry (section 4.3.5.5).  
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Figure 4.14. Effect of P2X4 positive allosteric modulator, 3 µM Ivermectin, on ATP-evoked Ca2+ response in GM-MDMs versus M-
MDMs. Data is represented as percentage increase in Ca2+ response, net calcium movement and representative time-response curve at 100 
µM in the presence or absence of 3 µM IVM in: A) GM-MDM cells (N=12 donors) and B) M-MDM cells (N=7 donors). Asterisks include 
significant changes towards control (*** p<0.001, ** p<0.01, Student’s t-test). 
 187 
4.3.5.2. Effect of selective P2X4 antagonists on ATP-evoked Ca2+ response in 
GM-MDM versus M-MDM cells  
Two selective antagonists for P2X4 receptor, PSB-12062 and 5-BDBD, were utilized 
in this chapter to characterize the contribution of P2X4 in ATP-evoked Ca2+ 
responses in human primary macrophages. Both antagonists were used at 10 µM 
concentration to ensure maximal inhibition of P2X4, as determined through an IC50 
curve described previously (Figure 3.18C and D). 
 
4.3.5.2.1. PSB-12062  
Treatment of GM-MDM cells with 10 µM PSB-12062 had a significant effect on both 
magnitude of ATP-evoked Ca2+ response as well as net calcium movement (Figure 
4.14A). Blocking P2X4 receptor resulted in a small but significant reduction in 
magnitude of ATP-evoked Ca2+ response (7.7 ± 2.7 %; N=12 donors; P<0.05) and a 
significant reduction in net calcium movement as quantified by area under the curve 
(AUC 44.8 ± 7.9 without PSB-12062 versus 27.5 ± 6.3 with PSB-12062; N=12 
donors; P<0.01). As shown on the time-response curve (Figure 4.14A), blocking 
P2X4 shifted the decay phase of the ATP-evoked Ca2+ response towards the left. 
Similarly, pre-treatment of M-MDM cells with 10 µM PSB-12062 resulted in a small 
but significant reduction in magnitude of ATP-evoked Ca2+ response (10.52 ± 3.16 
%; N=7 donors; P<0.05; Figure 4.15B). As shown on the time-response curve 
(Figure 4.14B), blocking P2X4 shifted the decay phase of the Ca2+ response towards 
the left, just as observed in GM-MDM cells. However, due to large donor-to-donor 
variability in M-MDM cells, this shift did not equate to significant reduction in net 
calcium movement (AUC 162.98 ± 31.68 without PSB-12062 versus 134.50 ± 24.22 
with PSB-12062; N=7 donors; P>0.05).  
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Figure 4.15. Effect of P2X4 receptor antagonist, 10 µM PSB-12062 on ATP-evoked Ca2+ response in GM-MDMs versus M-MDMs. Data is 
represented as percentage increase in Ca2+ response, net calcium movement and representative time-response curve at 100 µM in the 
presence or absence of 10 µM PSB-12062 in: A) GM-MDM cells (N=12 donors) and B) M-MDM cells (N=7 donors).	Asterisks include significant 
changes towards control (** p<0.01, * p<0.05, Student’s t-test).	
 189 
4.3.5.2.2. 5-BDBD 	
Treatment of GM-MDM cells with 10 µM 5-BDBD had a significant effect on 
magnitude of ATP-evoked Ca2+ response (17.47 ± 6.74 %; N=4 donors; P<0.05; 
Figure 4.16A) but no effect on the decay kinetics and net calcium movement (AUC 
37.07 ± 7.61 without 5-BDBD versus 37.50 ± 14.26 with 5-BDBD; N=4 donors; 
P>0.05; Figure 4.16A). Similar to the effect 5-BDBD had on GM-MDM, blocking 
P2X4 in M-MDM cells using 5-BDBD significantly reduced magnitude of Ca2+ 
response (31.75 ± 9.11 %; N=4 donors; P<0.05; Figure 4.16B) but had no 
significant effect on the decay kinetics as well as net calcium movement (AUC 70.70 
± 28.03 without 5-BDBD versus 46.81 ± 3.395 with 5-BDBD). 
 
The difference in effect observed with these two selective P2X4 receptor 
antagonists, PSB-12062 and 5-BDBD, may be due to the difference in their nature 
of mechanism. While PSB-12062 has been described to act as an allosteric 
antagonist of P2X4, 5-BDBD has been reported to act as a competitive antagonist of 
P2X4. When effect of IVM or PSB-12062 was observed, it was apparent that 
although P2X4 activation appeared to play a minor role in the magnitude of ATP-
evoked Ca2+ response, it had a bigger contribution towards the decay phase of the 
ATP-evoked Ca2+ response instead. However, the effect of 5-BDBD on ATP-evoked 
Ca2+ response did not mimic the effect observed by pre-treatment of PSB-12062. 
This may be due to the fact that as a competitive antagonist, the agonist 
concentration (100 µM ATP) utilized in these experiments was too high, shielding 
the inhibitory effect of 5-BDBD.  
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Figure 4.16. Effect of P2X4 receptor antagonist, 10 µM 5-BDBD, on ATP-evoked Ca
2+ response in GM-MDMs versus M-MDMs. Data is 
represented as percentage increase in Ca2+ response, net calcium movement and representative time-response curve at 100 µM ATP in the 
presence or absence of 10 µM 5-BDBD in: A) GM-MDM cells (N=4 donors) and B) M-MDM cells (N=4 donors). Asterisks include significant 
changes towards control (* p<0.05, Student’s t-test). 
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4.3.5.3. Effect of selective P2X4 antagonists on IVM-potentiated ATP-evoked 
Ca2+ response in GM-MDM versus M-MDM cells  
To further confirm the contribution of P2X4 towards ATP-evoked Ca2+ response in 
human primary macrophages, the effect of PSB-12062 and 5-BDBD were tested in 
the presence of IVM.  
 
4.3.5.3.1. PSB-12062  
Blocking P2X4 with PSB-12062 caused no significant effect towards the magnitude 
of the IVM-potentiated ATP-evoked Ca2+ response but significantly reduced decay 
response in GM-MDM cells. This can be observed in the time-response curve as 
well as area under the curve (AUC 98.83 ± 15.41 without PSB-12062 versus 63.42 
± 13.92 with PSB-12062; N=12 donors; Figure 4.17A). On the other hand, blocking 
P2X4 activation in M-MDM cells appeared to have a different effect. As shown in 
Figure 4.17B, PSB-12062 caused a significant reduction in the magnitude of IVM-
potentiated Ca2+ response (11.53 ± 4.47 %; N=6 donors; P<0.05) but had no 
significant effect towards the net calcium movement in M-MDM cells (AUC 162.5 ± 
48.11 without PSB-12062 versus 108.35 ± 15.11 with PSB-12062; N=6 donors; 
P>0.05). Although the time-response curve illustrated a slight shift towards the left 
of the decay response, the error bars were large and no significant changes were 
observed. However, it was noticeable that blocking P2X4 in M-MDM cells did not 
return the decay response back to the baseline, rather it remained on a sustained 
elevated phase. This difference in effect of PSB-12062 on the two macrophage 
system may be due to the fact that the amount of functional P2X4 within the two 
systems is different.  
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Figure 4.17. Effect of P2X4 receptor antagonist, 10 µM PSB-12062, on IVM-potentiated ATP-evoked Ca2+ response in GM-MDMs versus 
M-MDMs. Data is represented as percentage increase in Ca2+ response, net calcium movement and representative time-response curve upon 
stimulation with 100 µM ATP and 3 µM IVM in the presence or absence of 10 µM PSB-12062 in: A) GM-MDM cells (N=12 donors) and B) M-
MDM cells (N=6 donors).	Asterisks include significant changes towards control (* p<0.05, Student’s t-test).	
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4.3.5.3.2. 5-BDBD 
To study the effect of selective antagonist, 5-BDBD, on IVM-potentiated ATP-
evoked Ca2+ response in human primary macrophages, IVM treatment was 
performed in the presence of vehicle (1% DMSO). In Figure 4.18A and B, the 
presence of 1% DMSO vehicle (illustrated as ‘– 5-BDBD’) altered the IVM-
potentiated ATP-evoked Ca2+ response in these cells. Pre-treatment of GM-MDM 
cells with 5-BDBD caused a significant reduction in the magnitude of IVM-
potentiated ATP-evoked Ca2+ response (16.31 ± 3.47 %; N=3 donors; P<0.05; 
Figure 4.18A) and decay kinetics as represented by time-response curves and net 
calcium movement (64.08 ± 12.08 without 5-BDBD vs. 27.49 ± 7.47 with 5-BDBD; 
N=3 donors; P<0.01; Figure 4.18A). Pre-treatment of M-MDM cells with 5-BDBD 
also had a similar effect in which 5-BDBD caused a significant reduction in the 
magnitude of IVM-potentiated Ca2+ response (22.06 ± 3.60 %; N=3 donors; P<0.01; 
Figure 4.18B) and net calcium movement (AUC 75.38 ± 17.37 without 5-BDBD 
versus 33.92 ± 0.84 with 5-BDBD; N=3 donors; P>0.05; Figure 4.18B). Unlike the 
effect of PSB-12062 on IVM-potentiated ATP-evoked Ca2+ response in M-MDM 
cells, 5-BDBD caused the decay response to return to its baseline level.  
 
Taken together, the effects observed by the use of IVM, PSB-12062 or 5-BDBD 
allowed the conclusion that P2X4 receptor found in GM-MDM and M-MDM cells are 
functional and contribute mainly towards the decay phase of the ATP-evoked Ca2+ 
response.  
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Figure 4.18. Effect of P2X4 receptor antagonist, 10 µM 5-BDBD, on IVM-sensitive ATP-evoked Ca
2+ response in GM-MDMs versus M-
MDMs. Data is represented as percentage increase in Ca2+ response, net calcium movement and representative time-response curve upon 
stimulation with 100 µM ATP and 3 µM IVM in the presence or absence of 10 µM 5-BDBD in: A) GM-MDM cells (N=3 donors) and B) M-MDM 
cells (N=3 donors).	Asterisks include changes towards control (** p<0.01, * p<0.05, Student’s t-test).	 
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4.3.5.4. Assessing P2X4 protein expression in GM-MDM versus M-MDM cells 
using flow cytometry analysis 
Distribution of P2X4 has been described as predominantly localized within 
intracellular lysosomal compartments of human macrophages (Stokes and 
Surprenant, 2009). This observation has also been shown in both rodent 
macrophages and microglial cells (Boumechache et al., 2009). Study by Stokes and 
Surprenant (2009) also revealed that unstimulated macrophages showed high total 
protein expression of P2X4 but very low functional expression. It is unknown if the 
expression of P2X4 receptor protein in human primary macrophage models, GM-
MDM and M-MDM, are different. Results obtained from functional Ca2+ response in 
these cells using P2X4-specific pharmacological tools (section 4.3.5), so far, 
revealed that GM-MDM cells are more sensitive to IVM and P2X4 antagonists (PSB-
12062 and 5-BDBD) when compared to M-MDM cells. One of the main factors that 
may underlie the difference in sensitivities of the macrophage systems could be the 
different expression of surface and total P2X4 protein. Therefore, it was important to 
quantify the expression of P2X4 in both macrophage systems using flow cytometry.  
 
Flow cytometry was performed on GM-MDM and M-MDM cells following 6 days 
treatment with the corresponding colony stimulating factors. As shown in Figure 
4.19A, surface staining of P2X4 on the two macrophage systems revealed that in 
fact, both macrophage models express very low amount of the receptor on the cell 
surface membrane. Across three independent donors, GM-MDM cells averaged to 
3.34 ± 0.071 % P2X4(ext)+ positive cells while M-MDM cells averaged to 1.53 ± 0.11 
% P2X4(ext)+ positive cells. Despite very low expression of P2X4 on the surface of 
the cells, there was significantly less P2X4(ext)+ M-MDM cells compared to GM-
MDM cells (54.08 ± 4.14 % reduction; N=3 donors; P<0.01; Figure 4.19A). Total 
P2X4 protein expression was also quantified in GM-MDM and M-MDM cells. Across 
three independent donors, GM-MDM cells averaged to 73.9 ± 6.93 % total 
P2X4(total)+ cells while M-MDM cells averaged to 54.96 ± 9.21 % total P2X4(total)+ 
cells (Figure 4.19B). Comparing the data obtained from both macrophage systems, 
M-MDM cells had significantly lower proportion of cells expressing total P2X4 (23.01 
± 0.64 %; N=4 donors; P<0.01; Figure 4.19B) when compared to GM-MDM. As 
there is currently no reported knowledge about the expression of P2X4 in GM-MDM 
and M-MDM cells, these observations are important in identifying if P2X4 receptor 
activation has a bigger contribution in either one of the macrophage model.   
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Figure 4.19. Flow cytometry analysis to quantify P2X4-positive cells in GM-
MDM and M-MDM cells. Quantification of macrophages expressing: A) P2X4 
receptor on the cell surface membrane (N=3 donors) and B) total (cell surface and 
internal) P2X4 receptor (N=3 donors). Data is represented as percentage of positive 
cells gated against negative isotype control. Asterisks include significant changes 
towards control (** p<0.01, Student’s t-test). 
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4.3.5.5. Effect of selective P2XR antagonists on ATP-evoked Ca2+ response in 
GM-MDM versus M-MDM cells  
The main P2X receptors expressed in immune cells are P2X4 and P2X7. As the 
main interest in this research is to study the contribution of P2X4 receptor towards 
ATP-evoked Ca2+ response in human primary macrophages as well as identifying its 
functional role, it was important to investigate the contribution of other P2X 
receptors, in particular P2X7, towards ATP-evoked Ca2+ responses. In addition to 
P2X7, P2X1 was also investigated. Other P2X receptors were not investigated, as 
they are either not expressed in these primary macrophages (P2X2, P2X3 and P2X6, 
Table 4.2) or are known to be expressed as non-functional isoform (P2X5) (Kotnis et 
al., 2011). Here, two pharmacological tools were used to study possible 
contributions of P2X1 and P2X7 to ATP-evoked Ca2+ response in human GM-MDM 
and M-MDM cells.  
 
4.3.5.5.1. P2X1 antagonist 
Selective P2X1 antagonist, Ro0437626, was used to study the possible contribution 
of P2X1 in human primary macrophages. This antagonist has been reported to be a 
competitive antagonist with IC50 value of 3 µM and over 30-fold selectivity against 
other P2XR (Jaime-Figueroa et al., 2005). Since the agonist concentration used in 
this study was 100 µM ATP, maximal concentration of the antagonist (30 µM) was 
tested to ensure maximal activity. Pre-treatment of GM-MDM and M-MDM cells with 
Ro0437626 did not cause any inhibition towards the magnitude of ATP-evoked Ca2+ 
response. Instead, it significantly potentiated magnitude of ATP-evoked Ca2+ 
response in both cells (GM-MDM 31.29 ± 10.26 %; N=4 donors; P<0.01; Figure 
4.20A versus M-MDM 17.31 ± 7.21 %; N=4 donors; P<0.01; Figure 4.20B). In both 
macrophage systems, pre-treatment of cells with Ro0437626 had no significant 
effect towards the net calcium movement as measured through area under the 
curve (AUC GM-MDM 40.76 ± 12.67 without Ro0437626 versus 49.56 ± 10.07 with 
Ro0437626; N=4 donors; P>0.05; Figure 4.20A and AUC M-MDM 99.27 ± 37.21 
without Ro0437626 versus 107.88 ± 29.89 with Ro0437626; N=4 donors; P>0.05; 
Figure 4.20B). This observation correlated with findings in the macrophage cell line 
whereby treatment with P2X1 antagonist resulted in significant potentiation of the 
ATP-evoked Ca2+ response, instead of inhibition (Figure 3.7A). 
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Figure 4.20. Effect of P2X1 receptor antagonist, 30 µM Ro0437626, on ATP-evoked Ca2+ response in MDMs. Data is represented as 
percentage increase in Ca2+ response, net calcium movement and representative time-response curve at 100 µM in the presence or absence 
of 30 µM Ro0437626 in: A) GM-MDM cells (N=4 donors) and B) M-MDM cells (N=4 donors). Asterisks include significant changes towards 
control (** p<0.01, Student’s t-test). 
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4.3.5.5.2. P2X7 antagonist  
Selective P2X7 antagonist, A438079, was used to study the contribution of P2X7 in 
ATP-evoked Ca2+ response of human primary macrophages. A438079 is a 
competitive P2X7 antagonist with reported pIC50 of 6.9 for the inhibition of Ca2+ influx 
in human recombinant P2X7 cell line (Donnelly-Roberts and Jarvis, 2007, Nelson et 
al., 2006). To ensure maximal antagonism of the compound, 5 µM A438079 was 
used in this study. Pre-treatment of GM-MDM and M-MDM cells with A438079 had 
no significant inhibitory effect on the magnitude of ATP-evoked Ca2+ response 
(Figure 4.21A and 4.21B, respectively). In addition to this, A438079 also had no 
significant effect on the net calcium movement in both macrophage systems. P2X7 
receptor is highly expressed on immune cells which include glial cells and 
macrophages (Surprenant, 1996). Compared to other P2XR, the activation of P2X7 
requires higher concentrations of ATP (EC50 > 100 µM). The lack of effect by 
A438079 on GM-MDM and M-MDM cells (Figure 4.21A and 4.21B) indicated that 
P2X7 do not contribute to ATP-evoked Ca2+ response at 100 µM concentration and 
this may be due to the lack of activation of P2X7 at the agonist concentration used, 
in these human primary macrophages. Hence, it is likely that the agonist 
concentration used throughout the study (100 µM) is not sufficient to activate P2X7 
in human primary MDM.   
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Figure 4.21. Effect of P2X7 receptor antagonist, 5 µM A438079, on ATP-evoked Ca2+ response in GM-MDMs versus M-MDMs. Data is 
represented as percentage increase in Ca2+ response, net calcium movement and representative time-response curve at 100 µM in the 
presence or absence of 5 µM A438079 in: A) GM-MDM cells (N=6 donors) and B) M-MDM cells (N=6 donors).  
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4.4. Summary 
 
Monocyte-derived macrophages differentiated using GM-CSF or M-CSF serve as a 
well-established tool to study primary tissue-specific macrophages (van Wilgenburg 
et al., 2013). This chapter utilized both GM-MDMs and M-MDMs in a side-by-side 
comparison to study ATP-evoked Ca2+ responses with the goal of identifying P2X4 
contribution. To accompany this, the involvement of other purinergic receptors in 
ATP-evoked Ca2+ response was also studied.  
 
All P2XR (with the exception of P2X2, P2X3 and P2X6) were found to be expressed 
at the transcriptional and translational level in both GM-MDM and M-MDM cells. In 
both cell types, all P2YR (with the exception of P2Y12 and P2Y14) were also found to 
be expressed at the transcriptional level but only the expression of P2Y1, P2Y2, 
P2Y6 and P2Y13 were confirmed at the translational level. While no significant 
differences were observed in mRNA expression of P2XR in the two MDMs, P2Y1 
were found to be significantly down-regulated while P2Y6 and P2Y11 were 
significantly up-regulated in M-MDM, compared to GM-MDM.  
 
In both GM-MDM and M-MDM cells, ATP elicited a biphasic Ca2+ response 
involving an increase in intracellular Ca2+ reflected by peak magnitude and a second 
response which corresponds to decay phase. Unlike observations made in TDM 
cells (Chapter 3), pre-treatment of both GM-MDM and M-MDM with U73122 almost 
completely abolished the magnitude of the ATP-evoked Ca2+ response suggesting 
Gaq-coupled P2YR activation to be the sole contributor to the peak response. Using 
selective P2YR antagonists, it was revealed that the activation of both P2Y11 and 
P2Y13 contribute towards the peak of the response in GM-MDM and M-MDM cells, 
with P2Y11 also playing a substantial role in the decay phase of the ATP-evoked 
Ca2+ response in M-MDM cells. This observation corroborated findings from qRT-
PCR illustrating a significant up-regulation of P2Y11 mRNA expression in M-MDM 
cells, when compared to GM-MDM cells. In the interest of studying contribution of 
P2XR towards the ATP-evoked Ca2+ response in GM-MDM and M-MDM cells, the 
effect of positive allosteric modulator IVM and P2XR selective antagonists were 
assessed. While P2X1 and P2X7 did not appear to contribute towards the ATP-
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evoked Ca2+ response of both macrophages, P2X4 appeared to significantly 
contribute towards the second decay phase of the ATP-evoked Ca2+ response, 
although a more significant role of P2X4 was observed in GM-MDM vs. M-MDM. 
This was evident from the effect observed using IVM, PSB-12062 or 5-BDBD. The 
fact that P2X4 appear to contribute only towards the second decay response of the 
ATP-evoked Ca2+ response in these cells illustrate a possibility that they may work 
in close relationship with P2YR. The lack of effect of P2X4 antagonist on the peak of 
the Ca2+ response may also be explained by the low surface P2X4 expression in 
both macrophage systems. In addition to this, the difference in sensitivity of GM-
MDM and M-MDM cells towards IVM and P2X4 antagonist may be explained by the 
difference in level of surface and intracellular expression of P2X4 as quantified via 
flow cytometry. FACS analysis illustrated that across three independent donors, 
GM-MDM cells expressed a higher amount of both surface and total P2X4, in 
comparison to M-MDM cells. Altogether, this chapter has illustrated that to elucidate 
a functional role of P2X4 in human primary MDM, GM-MDM cells may act as a 
better system due to higher expression of surface and total P2X4 receptor.  
  
	
 
 
 
203 
Chapter 5: Involvement of P2X4 in 
ATP-induced cytokine and chemokine 
levels in human monocyte-derived 
macrophages  
 
5.1. Introduction 
Cytokines and chemokines are potent signalling molecules produced by many cell 
types, especially those of the immune system. These molecules regulate 
inflammation and play a vital role in regulating the immune response in health and 
disease. This includes regulation of cellular proliferation, chemotaxis, tissue repair 
as well as metabolism (Arango Duque and Descoteaux, 2014). While their function 
within the immune system has been explored greatly in the literature, little is known 
about how they are packaged and secreted from various immune cells. The 
common assumption for the mechanism of cytokine and chemokine trafficking and 
secretion is through endoplasmic reticulum (ER) and Golgi pathway before being 
transported to cell surface through a simple, unidirectional secretory vesicle (Lacy, 
2015). However, the pathway is much more complex involving a combination of 
secretory granules and vesicles for trafficking and various endocytic pathways for 
secretion. The release of cytokines and chemokines by activated macrophages are 
a major component of the innate immune response (Hume, 2006). Macrophages, 
being one of the most abundant sources of inflammatory cytokines, can secrete 
these proteins inappropriately leading to chronic conditions such as diabetes and 
obesity to vascular and neurodegenerative diseases (Chawla et al., 2011, Neurath, 
2014, Tabas and Glass, 2013). Therefore, many of the newer therapeutics aim to 
target cytokines directly, either through their modes of release or receptor 
engagement. 
 
One of the most studied endogenous insults that can activate the immune system is 
ATP. Extracellular ATP is elevated following inflammation and injury and can act on 
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purinergic receptors such as P2X4 and P2X7, which are the predominant purinergic 
P2X receptor subtypes expressed on immune cells (de Rivero Vaccari et al., 2012). 
Extensive research has been invested in studying the role of P2X7 in inflammation 
and pain (Chessell et al., 2005, McGaraughty et al., 2007), where it has been 
identified to provide physiological stimulus for activation of caspase-1 and release of 
pro-inflammatory cytokine, IL-1b (Pelegrin and Surprenant, 2006). However, due to 
the lack of selective pharmacological tools, efforts to elucidate the function of P2X4 
in human macrophages have been hampered significantly. More recently, P2X4 has 
been associated with roles such as mediating PGE2 release, initiating inflammatory 
pain (Ulmann et al., 2010) and regulating inflammasome signalling that involves 
caspase-1 activation and IL-1b processing (de Rivero Vaccari et al., 2012). Despite 
this, there has been no direct report correlating the role of P2X4 and cytokine 
secretion. Increasing understanding of P2X4 functional role in macrophages may 
offer a potential target for treatment of inflammatory conditions.  
 
5.2. Aims  
The aim of this chapter is to elucidate a functional role of P2X4 within the 
macrophage system. Although abundantly expressed in immune cells, it is unknown 
if P2X4 can regulate ATP-induced cytokine and chemokine production in human 
monocyte-derived macrophages. To address this aim, an mRNA profiler screen was 
performed to identify candidate genes that are induced following ATP stimulation in 
the presence and absence of P2X4 antagonist. This was then further studied at the 
protein level using ELISA technique.  
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5.3. Results  
5.3.1. RT2 Profiler mRNA Array  
To identify a functional role of P2X4 in human macrophages, RT2 profiler mRNA 
array was employed to screen for 84 different genes of various cytokines and 
chemokines that has been associated with inflammation of the immune system. 
Throughout the study, 100 µM ATP was used as the main stimulus for activation of 
P2X4 in human GM-MDM cells. Transcriptional screening for candidate genes were 
performed at one time point (6h) following pre-treatment of either vehicle or P2X4 
selective antagonist (10 µM PSB-12062).  
 
5.3.1.1. Identifying genes constitutively expressed in human monocyte-
derived macrophages 
By screening for 84 different genes that are expressed in human GM-MDM cells, it 
was possible to identify which genes are constitutively expressed in the absence of 
any agonist stimulation. As shown on Table 5.1, under no agonist stimulation, GM-
MDM constitutively expressed various genes, as quantified across 6 independent 
donors. Genes that were amplified at cycle threshold 35 or above were considered 
absent and these genes included BMP4, CCL19, CXCL11, CXCL12, IFNg, IL12a, 
IL17A, IL2, TNFRSF11B and XCL1 (highlighted in Table 5.1 as grey). A few genes 
were found to be highly abundant (amplified <Ct 20) and this included CCL22, 
CSF1, CXCL16, GPI and SPP1. These were important observations as to date, 
there has been no detailed report elaborating what genes are constitutively 
expressed in GM-MDM cells. In addition to this, identification of constitutively 
expressed genes may allow the phenotype of these macrophage system to be 
studied in greater detail.  
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Table 5.1. RT2 Profiler mRNA Array to identify constitutively expressed genes 
in human GM-MDM. Average Ct values were taken from 6 independent donors and 
represented ± SEM values. Genes amplified at or above Ct 35.0 were considered 
absent and are highlighted in grey. Genes that were undetected during the 
amplification run are represented as N/A.  
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5.3.1.2. Identifying genes induced by ATP stimulation  
Extracellular ATP is regarded as a danger signal which can activate the immune 
system by acting on purinergic receptors (P2X and P2Y) found in immune cells. The 
activation of purinergic receptors by extracellular ATP in macrophages can trigger 
the secretion of various cytokines and chemokines (Zhang and Mosser, 2008). 
Although macrophages have been described to be capable of secreting various 
cytokines and chemokines (Fujiwara and Kobayashi, 2005), a thorough 
transcriptional screening has not been performed to investigate what genes may be 
expressed in GM-MDMs following 100 µM ATP stimulation. Log2 fold change in 
expression of all the genes screened are shown as a heat map in Figure 5.1, with 
blue and negative value representing down-regulation while red and positive value 
representing up-regulation of mRNA expression. Genes that were unaffected 
following ATP stimulation are represented as white. Expression levels were 
normalized to the geometric mean of five housekeeping genes (ACTB, GAPDH, 
B2M, RPLP0 and HPRT1) and to unstimulated control with no change in expression 
denoted as a value of 0. As a positive control, GM-MDM cells were also treated with 
100 ng/ml of LPS for 6h.  
 
As discussed in section 5.3.1.1, ten genes (BMP4, CCL19, CXCL11, CXCL12, 
IFNg, IL12a, IL2, IL17A, TNFRSF11B and XCL1) were found at undetectable levels 
in all conditions and have therefore been excluded from the heat map. As can be 
seen, LPS stimulation caused the up-regulation of no less than 35 genes and the 
down-regulation of no less than 15 genes. In comparison to LPS treatment, 
stimulation of GM-MDM cells with 100 µM ATP resulted in a more subtle effect with 
only 6 genes that were up regulated. These genes include CXCL2, CXCL5, IL12b, 
OSM, PPBP and TGF-b2 (Table 5.2).  
 
  
	
 
 
 
208 
 
Table 5.2. Genes up-regulated following 6h stimulation with 100 µM ATP. 
Averaged across 4 independent donors, fold change is represented as Log2 values 
and DDCt values in which positive values indicate up-regulation, normalized to 
unstimulated control indicated by a value of 0 for log2 fold change or 1 for DDCT fold 
change.  
	
 
 
 
209 
 
Figure 5.1.  ATP induced the expression of various genes in human GM-MDM 
cells. Heat map summarizing expression data for 76 genes exhibiting differential 
expression across various stimulation conditions at 6h (LPS (N=1 donor), ATP (N=5 
donors), PSB-12062 (N=5 donors) and ATP + PSB-12062 (N=3 donors)). 
Expression of genes presented by intensity of colour as log2 fold change.  
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5.3.1.3. Identification of CXCL5 and TGF-b2 as potential candidate genes  
To screen for potential candidate genes using the RT2 profiler PCR array, selective 
antagonist for P2X4 (PSB 12062) was utilized. The effect on cytokines and 
chemokines expression in GM-MDM following 30 min pre-treatment with 10 µM 
PSB-12062 in the presence and absence of agonist ATP was assessed. Several 
criteria were set to filter out potential genes for further study whereby the genes: 1) 
were induced following agonist stimulation, 2) were unaffected by pre-treatment of 
antagonist alone in the absence of agonist and, 3) had their mRNA expression 
levels altered in the presence of both agonist and antagonist. Taking these criteria 
together allowed the selection of two candidate genes for further study in GM-
MDMs: CXCL5 and TGF-b2 (Figure 5.1).  
 
Stimulation of GM-MDM cells with 100 µM ATP positively induced mRNA 
expression of CXCL5 by 2.44 ± 0.47 fold (N=4 donors, P<0.05; Figure 5.2A). Pre-
treatment of antagonist PSB-12062 alone had no significant effect on the mRNA 
expression of CXCL5 in these cells, but in the presence of the agonist (100 µM 
ATP), PSB-12062 inhibited ATP-induced CXCL5 mRNA expression by 45.4 ± 1.32 
% (N=3 donors; P>0.05; Figure 5.2A). Similarly, pre-treatment of GM-MDM cells 
with 100 µM ATP positively induced mRNA expression of TGF-b2 by 2.37 ± 0.54 
fold (N=4 donors; P>0.05; Figure 5.2B) while PSB-12062 alone had no significant 
effect on TGFb2 mRNA expression. However, in the presence of agonist (100 µM 
ATP), PSB-12062 caused a significant up-regulation of the ATP-induced TGF-b2 
mRNA expression by 495.91 ± 375.03 % (N=3 donors; P>0.05; Figure 5.2B). 
Although the data did not yield a significant result due to large donor-to-donor 
variability and small sample size, the pattern of the PSB-12062 effect on ATP-
induced genes were consistent across the three independent samples. For this 
reason, these two genes were chosen to be studied in greater detail.  
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Figure 5.2. Effect of P2X4 antagonist, 10 µM PSB-12062, on mRNA transcript 
levels of two candidate genes arising from the RT2 profiler PCR array: A) 
CXCL5 (N = 3-5 donors) and B) TGF-b2 (N = 3-5 donors). Primary GM-MDM cells 
were treated with 10 µM PSB-12062 for 30 minutes followed by stimulation with 100 
µM ATP for 6 h. Fold change in mRNA expression is represented as normalized 
value to reference genes and vehicle control. Asterisks include significant changes 
towards control (* p<0.05, Student’s t-test).  
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5.3.1.4. Identifying genes induced by PSB-12062  
As a negative control, the effect of PSB-12062 (10 µM) in the absence of an 
agonist, was included in all experiments. As P2X4 activation requires ATP as an 
agonist to be present, the purpose of PSB-12062 stimulation alone was to eliminate 
any effect that may not be a true result of P2X4 inhibition. Supernatants from PSB-
12062 treatment alone were collected across various time points and various 
donors to test for toxicity using LDH assay. LDH quantification illustrated little or no 
toxicity induced by PSB-12062, up to 10 µM and 48 h, on GM-MDM cells (Table A1; 
Appendix). However, during this study, several things were not controlled for: 1) 
GM-MDM cells were cultured in the presence of 10% heat-inactivated autologous 
serum which may contain low levels of ATP (Gorman et al., 2007) and 2) GM-MDM 
cells may constitutively secrete ATP during the 6 h stimulation period and levels of 
ATP in supernatant was not quantified. Therefore, in the PSB-12062 stimulation 
alone samples, it is not possible to rule out the presence of low levels of ATP which 
can then activate purinergic receptors.  
 
Out of the 84 different genes screened, pre-treatment with PSB-12062 up-regulated 
the mRNA expression of 8 genes: CCL5, CXCL1, CXCL2, IL1a, IL1b, CXCL8, OSM 
and TNF (Figure 5.3A). Only 6 of the genes were significantly up-regulated: CCL5 
2.20 ± 0.57 fold (N=4; p<0.05), CXCL2 2.62 ± 0.44 fold (N=4; p<0.05), IL-1a 1.73 ± 
0.26 fold (N=4; p<0.05), IL-1b 4.30 ± 0.93 fold (N=4; p<0.05), CXCL8 7.00 ± 2.58 
(N=4; p<0.05) and OSM 2.90 ± 0.35 fold (N=4; p<0.05). Using STRING v9.1 
software, the protein-protein interaction network was also predicted for these genes 
to identify if they were closely related (Figure 5.3B). Based on the predicted protein 
network interaction, these 8 genes work very closely together in biological setting 
with all of them being produced by activated macrophages in response to 
inflammation (Beuscher et al., 1990, Owen and Mohamadzadeh, 2013). 
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Figure 5.3. Effect of P2X4 antagonist, 10 µM PSB-12062, on mRNA expression 
of various cytokines and chemokines. A) Fold change in mRNA transcript level 
was quantified using RT2 profiler mRNA array following treatment with 10 µM PSB-
12062 (N=4 donors). Data is normalized to housekeeping genes and vehicle 
control. B) Network of protein-protein interactions generated from genes in (A) using 
the software STRING v9.1. Asterisks include significant changes towards control (* 
p<0.05, Student’s t-test).  
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5.3.2. Role of P2X4 activation in ATP-induced TGF-b2 mRNA expression and 
protein secretion 
TGF-b proteins are distributed throughout the body and play a key role in almost 
every biological process such as regulating cell function, proliferation, differentiation 
and modulating the immune system (Taylor, 2009). To date, it is known that almost 
every cell in a human body can produce TGF-b and respond to it. In mammals, 
there are three TGF-b genes, each encoding for individual isoforms but functioning 
through the same signalling systems: TGF-b1, TGF-b2 and TGF-b3 (Derynck et al., 
1985, Derynck and Rhee, 1987, Massague, 2000). TGF-b signalling is initiated by 
the binding of the protein to two receptors known as type I and type II and is 
mediated by a family of effector proteins also known as Smads (Massague and 
Chen, 2000). Despite its huge importance within the immune system, there has 
been limited studies performed to explore the possibility that P2X4 may play a role 
in modulating the production of TGF-b. As TGF-b2 was identified as one of the 
candidate genes through the profiler PCR screen, this section of the thesis chapter 
will focus on the contribution of P2X4 activation in modulating level of TGF-b2 in 
human macrophages.  
 
5.3.2.1. Determining kinetics of ATP-induced TGF-b2 mRNA expression and 
protein secretion 
As the RT2 Profiler PCR screening was performed only at one-time point (6 h), it 
was important to identify the kinetics of ATP-induced TGF-b2 mRNA expression 
and secretion in GM-MDM cells. The effect of 100 µM ATP stimulation on GM-MDM 
cells were investigated at different time points: 6, 9, 18 and 24 h for mRNA 
quantification and 24, 32 and 48 h for protein quantification. As shown on Figure 
5.4, ATP significantly induced the mRNA expression of TGF-b2 at 6h (2.69 ± 0.16 
fold, N=4, P<0.05) and 18h (1.66 ± 0.19, N=4, P<0.05) but not at 9h (2.40 ± 0.79 
fold, N=4, P>0.05) and 24h (1.07 ± 0.26, N=4, P>0.05). The amount of TGF-b2 
protein secreted was also quantified using ELISA technique at various time points. 
Surprisingly, no TGF-b2 protein was detected at any of the time points studied. This 
was repeated on three independent donor samples with FBS being used as a 
positive control to ensure that the assay is working. Since no protein was detected, 
the effect of P2X4 on ATP-induced TGF-b2 level was only studied at the 
transcriptional level.   
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Figure 5.4. Time course study to investigate the kinetics of 100 µM ATP-
induced TGF-b2 mRNA expression. Kinetics of ATP-induced TGF-b2 mRNA 
expression was assessed across 4 time points (6, 9, 18 and 24h) across 4 
independent donors. Asterisks include significant changes towards control (** 
p<0.01, * p<0.05, Student’s t-test). 
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5.3.2.2. Effect of blocking P2X4 on ATP-induced TGF-b2 mRNA expression 
To study the importance of P2X4 activation on ATP-induced TGF-b2 mRNA 
expression, the effect of PSB-12062 was studied at various time points across 4 
independent donors. Figure 5.5A-D illustrated DDCT analysis from individual donors 
while Figure 5.5E illustrated an average data represented as ratio of fold change 
(DDCt ATP+PSB normalised to DDCt ATP) across the 4 independent donors. The 
average data is represented as a ratio of fold change due to the large donor-to-
donor variation readout. As can be seen from Figure 5.5, pre-treatment of GM-MDM 
cells resulted in a significant up regulation of ATP-induced mRNA expression of 
TGF-b2 at all time points. In three out of the four donors (Figure 5.5A, 5.5B and 
5.5D), the maximal effect of PSB-12062 on ATP-induced TGF-b2 mRNA expression 
was observed following 9 h stimulation with ATP while at higher time points (24 h), 
the effect was significantly reduced. Across 4 independent donors (Figure 5.5E), a 
significant up regulation in mRNA expression of TGF-b2 was observed at 6h (2.69 ± 
0.16 fold without PSB-12062 versus 9.45 ± 1.83 fold with PSB-12062, N=4 donors, 
P<0.05), 9h (2.40 ± 0.79 fold without PSB-12062 versus 12.84 ± 5.88 fold with PSB-
12062, N=4 donors, P<0.01) and 18h (1.66 ± 0.19 fold without PSB-12062 versus 
5.91 ± 0.60 fold with PSB-12062, N=4 donors, P<0.05). No significant effect was 
observed at 24h (1.07 ± 0.26 fold without PSB-12062 versus 6.48 ± 2.38 fold with 
PSB-12062, N=4 donors, P>0.05). These observations illustrated a possible role of 
P2X4 activation in negatively regulating TGF-b2 mRNA expression.  
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Figure 5.5. Time course study to investigate the effect P2X4 antagonist, 10 µM 
PSB-12062, on 100 µM ATP-induced TGF-b2 mRNA expression. A-D) Time 
course study was performed at four different time points: 6 h, 9 h, 18 h and 24 h in 
human primary GM-MDM cells obtained from four independent donors. Fold change 
in mRNA expression is represented as normalized value to reference genes and 
vehicle control. E) Average data to represent the effect of P2X4 antagonist, 10 µM 
PSB-12062 on various time points of ATP-induced CXCL5 mRNA expression, 
across 4 donors represented as ratio of fold change. Asterisks include significant 
changes towards control (** p<0.01, * p<0.05, Student’s t-test).   
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5.3.3. Role of P2X4 in ATP-induced CXCL5 mRNA expression and protein 
secretion 
CXCL5 is a pro-inflammatory chemokine playing a key role in regulating CXCR2-
dependent neutrophil trafficking. Although it has been reported that CXCL5 can be 
produced by various cells such as platelets, lung epithelial cells following severe 
infection and macrophage fraction of adipose tissue, it has not been reported if 
human monocyte-derived macrophages can secrete CXCL5 upon exposure to a 
DAMP signal such as ATP and if purinergic receptors may play a role in this. Like 
TGF-b2, CXCL5 was identified as one of the candidate genes for further study and 
this section of the chapter will focus on studying the importance of P2X4 and other 
purinergic receptors in the level of expression and secretion of ATP-induced CXCL5 
in human macrophages.  
 
5.3.3.1. Determining kinetics of ATP-induced CXCL5 mRNA expression and 
protein secretion 
Following the PCR screening, kinetics of ATP-induced CXCL5 mRNA and protein 
secretion was studied across various time points. For quantification of mRNA 
expression, 4 time points (6 h, 9 h, 18 h and 24 h) were assessed while for protein 
secretion quantification, 3 later time points (24 h, 32 h and 48 h) were assessed. 
Stimulation with ATP caused a time-dependent increase in mRNA expression of 
CXCL5 with maximal induction observed at 24 h (6 h: 6.57 ± 2.78 fold, N=4 donors, 
P>0.05; 9 h: 9.66 ± 2.16 fold, N=4 donors, P<0.05; 18 h: 18.75 ± 2.78 fold, N=4 
donors, P<0.01, and 24 h: 23.52 ± 5.00 fold, N=4 donors, P<0.05; Figure 5.6A). 
Similarly, stimulation of GM-MDM cells with ATP also resulted in a time-dependent 
increase in CXCL5 protein secretion with maximal secretion being observed at 48 h 
time point (24 h: 388.9 ± 125.4 pg/ml, N=9 donors; 32 h: 618.6 ± 139.0 pg/ml, N=7 
donors; 48 h: 686.9 ± 148.3 pg/ml; N=7 donors; Figure 5.6B).  
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Figure 5.6. Time course study to investigate the kinetics of 100 µM ATP-
induced CXCL5 level. A) 100 µM ATP-induced CXCL5 mRNA expression 
assessed across 4 time points (6 h, 9 h, 18 h and 24 h) across 4 independent 
donors. Data is represented as fold change of DDCT normalised to HKG and 
unstimulated control. B) 100 µM ATP-induced CXCL5 protein secretion across 4 
time points (24 h, 32 h and 48 h) across 7-9 independent donors. Data is 
represented as % secreted CXCL5 due to high variability between donors. Asterisks 
include significant changes towards control (*** p<0.001, ** p<0.01, * p<0.05, 
Student’s t-test).  
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5.3.3.2. Effect of blocking P2X4 on ATP-induced CXCL5 mRNA expression 
To study the importance of P2X4 activation on ATP-induced CXCL5 mRNA 
expression, the effect of PSB-12062 was tested across the different time points. 
Pre-treatment of GM-MDM cells with 10 µM PSB-12062 inhibited ATP-induced 
CXCL5 mRNA expression at lower time points (6 h and 9 h) across 4 independent 
donors (Figure 5.7A-D). However, at higher time points (18 h and 24 h), PSB-12062 
pre-treatment resulted in an increase of ATP-induced CXCL5 mRNA expression in 
3 out of the 4 donors (Figure 5.7A, B and D). The effect of PSB-12062 on ATP-
induced CXCL5 mRNA expression was quantified as average across the 4 donors 
and the data is represented as ratio of fold change between ATP + PSB-12062 
treatment versus ATP alone due to high donor-to-donor variability (Figure 5.7E). On 
average, pre-treatment of GM-MDM cells with PSB-12062 resulted in a significant 
inhibition of ATP-induced CXCL5 mRNA expression at 6 h (40.36 ± 4.86 %, N=4 
donors, P<0.01) and 9 h (34.77 ± 8.05 %, N=4 donors, P<0.05; Figure 5.7E) but not 
at 18 h and 24 h. This data illustrated that activation of P2X4 may play a modulatory 
role towards ATP-induced CXCL5 mRNA expression.  
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Figure 5.7. Time course study to investigate the effect P2X4 antagonist, 10 µM 
PSB-12062, on 100 µM ATP-induced CXCL5 mRNA expression. A-D) Time 
course study was performed at four different time points: 6 h, 9 h, 18 h and 24 h in 
human primary GM-MDM cells obtained from four independent donors. Fold change 
in mRNA expression is represented as normalized value to HKG and vehicle 
control. E) Average data across 4 donors represented as ratio of fold change. 
Asterisks include significant changes towards control (** p<0.01, * p<0.05, Student’s 
t-test).   
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5.3.3.3. Role of P2X4 activation on ATP-induced CXCL5 protein secretion 
To confirm if the effect of blocking P2X4 on ATP-induced CXCL5 mRNA expression 
can be mirrored at the protein level, ELISA technique was utilized to measure the 
amount of secreted CXCL5 protein in the supernatants collected at various time 
points. In the absence of agonist, pre-treatment of GM-MDM cells with PSB-12062 
alone had no significant effect towards the level of secreted CXCL5 when compared 
to unstimulated control (Figure 5.8B). However, in the presence of agonist (100 µM 
ATP), pre-treatment of GM-MDM cells with PSB-12062 resulted in significant 
inhibition of ATP-induced CXCL5 secretion at 32 h (22.91 ± 8.47 %, N=6 donors, 
P<0.05; Figure 5.8A and B) and 48 h (30.7 ± 6.3 %, N=9 donors, P<0.05; Figure 
5.8A and B) but not at 24 h. The effect of varying concentrations of PSB-12062 (1, 5 
and 10 µM) was also tested on 100 µM ATP-mediated CXCL5 secretion at one 
single time point of 48 h. Across three independent donors, PSB-12062 caused a 
significant reduction in ATP-mediated CXCL5 secretion in a dose dependent 
manner (1 µM PSB-12062: 12.0 ± 4.6 %, N=3 donors, P<0.05; 5 µM PSB-12062: 
27.4 ±7.2 %, N=3 donors, P<0.05; and 10 µM PSB-12062: 30.7 ± 6.3 %, N=9 
donors, P<0.001, Figure 5.9C).  
 
To further confirm the possible involvement of P2X4 towards the level of ATP-
induced CXCL5 secretion in human macrophages, the effect of selective P2X4 
positive allosteric modulator IVM was also studied at 48 h. In the absence of the 
agonist, IVM pre-treatment had no significant effect on CXCL5 secretion level when 
compared to unstimulated control. In the presence of agonist (100 µM ATP), pre-
treatment of GM-MDM cells with 3 µM IVM significantly augmented ATP-induced 
CXCL5 secretion (26.48 ± 10.70 % increase, N=6 donors, P<0.05; Figure 5.9D). 
Across the six donors investigated, all but one resulted in an increase in ATP-
induced CXCL5 secretion following IVM stimulation (Figure A5). Together, the effect 
of PSB-12062 and IVM suggests a possible role of P2X4R activation in the 
modulation of ATP-induced CXCL5 mRNA expression and secretion. 
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Figure 5.8. Role of P2X4 activation on 100 µM ATP-induced CXCL5 secretion. 
The importance of P2X4 activation on ATP-induced CXCL5 secretion in GM-MDM 
cells was studied using two pharmacological tools: A and B) selective antagonist 10 
µM PSB-12062 at 24 h (N=6 donors), 32 h (N=6 donors) and 48 h (N=9 donors), C) 
dose response of PSB-12062 (1 µM, 5 µM and 10 µM) at 48 h (N=3-9 donors), and 
D) positive allosteric modulator 3 µM IVM at 48 h (N=6 donors). In Figure B, light 
grey: unstimulated control, dark grey: PSB-12062 control, black: 100 µM ATP and 
red: 100 µM ATP + 10 µM PSB-12062. Asterisks include significant changes 
towards control (*** p<0.001, * p<0.05, Student’s t-test).  
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5.3.3.4. Effect of blocking P2X4 on ATP-induced CXCL5 protein synthesis 
Having established that P2X4 activation play a modulatory role towards ATP-
induced CXCL5 mRNA expression and secretion, it was important to identify if P2X4 
can potentially have an affect towards CXCL5 synthesis. This was studied across 3 
different time points (24 h, 32 h and 48 h) and the amount of synthesized CXCL5 
within the protein lysates were quantified by ELISA technique. As shown on Figure 
5.9, the amount of synthesized CXCL5 upon stimulation with ATP is maximal at 24 
h (495.98 ± 94.03 pg/ml, N=3 donors, P<0.05; Figure 5.9A) followed by a time-
dependent reduction, which seemed to plateau at 48 h (215.03 ± 18.97 pg/ml, N=5 
donors; P<0.01; Figure 5.9A). This observation could potentially be explained by the 
fact that at 48 h, the majority of the synthesized CXCL5 have been secreted (Figure 
5.6). Blocking of P2X4 activation had no significant effect on the level of ATP-
induced CXCL5 synthesis at 24 h and 32 h (Figure 5.9B and C, respectively) but 
caused a significant reduction at 48 h time point (41.78 ± 13.04 %, N=5 donors, 
P<0.05; Figure 5.9D).  
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Figure 5.9. Effect of blocking P2X4 activation on 100 µM ATP-induced CXCL5 
synthesis in human macrophages. A) Time course study of 100 µM ATP-induced 
CXCL5 synthesis, measured across 3 time points (24 h, 32 h and 48 h). B-D) Effect 
of 10 µM PSB-12062 on 100 µM ATP-induced CXCL5 synthesis was studied across 
3 different time points: B) 24 h (N=3 donors), C) 32 h (N=3 donors) and D) 48 h 
(N=5 donors). Asterisks include significant changes towards control (** p<0.01, * 
p<0.05, Student’s t-test). 
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5.3.3.5. Involvement of other purinergic receptors in ATP-induced CXCL5 
protein secretion 
The contribution of P2X4 receptor activation towards ATP-induced level of CXCL5 
was studied in previous sections of this chapter. The role of several other purinergic 
receptors (P2X7, P2Y11 and P2Y13) were also investigated. The effect of P2X7 
receptor activation was studied because it is highly expressed in immune cells and 
has been reported to be closely associated with P2X4 (Guo et al., 2007), while the 
effect of P2Y11 and P2Y13 was studied as these receptors has been shown to 
contribute to the magnitude of ATP-evoked Ca2+ response in GM-MDM cells 
(discussed in chapter 4). The effect of selective antagonists A438079 (P2X7), 
NF340 (P2Y11) and MRS2211 (P2Y13) on ATP-induced CXCL5 secretion were 
tested on GM-MDM cells only at one time point: 48 h. Pre-treatment of GM-MDM 
cells with each of the antagonists alone, in the absence of agonist, had no 
significant effect on the amount of endogenously secreted CXCL5. However, 
surprisingly, pre-treatment of GM-MDM cells with A438079 (Figure 5.10A and 
Figure A2; Appendix), NF340 (Figure 5.10B and Figure A3; Appendix) and 
MRS2211 (Figure 5.10C and Figure A4; Appendix) also had no significant effect on 
the ATP-induced CXCL5 secretion at 48 h, as quantified by ELISA.  
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Figure 5.10. Role of other purinergic receptors on 100 µM ATP-induced CXCL5 
secretion at 48h. The effect of selective antagonists for: A) P2X7 antagonist 
A438079 (5 µM; N=3 donors), B) P2Y11 antagonist NF340 (10 µM; N=3 donors) and 
C) P2Y13 antagonist MRS2211 (10 µM; N=5 donors), on 100 µM ATP-induced 
CXCL5 secretion in GM-MDM cells.   
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5.4. Summary  
In this chapter, the role of P2X4 and other purinergic receptors on ATP-induced 
cytokine and chemokine level was assessed. Stimulation of GM-MDM cells using 
ATP positively induced the mRNA expression of various genes that include CXCL2, 
CXCL5, IL12b, OSM, PPBP and TGF-b2. Using RT2 profiler PCR array to screen for 
84 different genes involved in the immune system, two candidate genes (TGF-b2 
and CXCL5) was selected for further study.  
 
The activation of P2X4 using 100 µM ATP caused a significant induction in the 
mRNA expression of TGF-b2 that peaked at 6 h. Blocking P2X4 activation using 
PSB-12062 resulted in a significant up-regulation of ATP-induced TGF-b2 mRNA 
expression at 6 h, 9 h and 18 h, illustrating a potential role of P2X4 in regulating the 
level of TGF-b2. This data corroborated a study by Kim et al. (2014) illustrating that 
lack of P2X4 receptor expression resulted in an increased in renal fibrosis and 
increased expression of TGF-b level in rodent model. Despite the significant effect 
seen at transcriptional level, the effect of PSB-12062 on mRNA expression did not 
translate to protein level as no TGF-b2 protein was detected in the supernatants. 
The data illustrated here indicated that despite having significant effect at the 
transcriptional level, the lack of evidence at the protein level makes interpretation 
very difficult. 
 
The second candidate gene studied in this chapter was CXCL5. Although CXCL5 
has been shown to be produced by various cells such as platelets and macrophage 
fraction of white adipose tissue (Chavey and Fajas, 2009), no study has reported 
the ability of human monocyte-derived macrophages to synthesize and secrete 
CXCL5 in response to a DAMP signal. The activation of P2X4 using ATP caused a 
significant induction in the mRNA expression of CXCL5 and protein secretion in a 
time-dependent manner that peaked at 24 h and 48 h, respectively. Pre-treatment 
of cells with PSB-12062 resulted in a significant inhibition of ATP-induced mRNA 
expression of CXCL5 at 6 h and 9 h. This was also translated at the protein level 
whereby 10 µM PSB-12062 treatment caused a significant inhibition of ATP-
induced CXCL5 protein secretion at 32 h and 48 h. Further study also revealed that 
at 48 h time point, PSB-12062 was able to cause a dose-dependent inhibition of 
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ATP-induced CXCL5 protein secretion while IVM was able to augment ATP-induced 
CXCL5 secretion. Further to this, blocking P2X4 activation also resulted in a 
reduction in ATP-induced CXCL5 synthesis at 48 h time point. Taken together, 
these observations illustrated that P2X4 activation modulates the expression, 
secretion and synthesis of ATP-induced CXCL5 chemokine. Finally, one interesting 
observation that was made in this study was that the activation of P2X7, P2Y11 and 
P2Y13 is not required for the secretion of ATP-induced CXCL5 chemokine at 48 h 
time point. As P2Y11 and P2Y13 activation plays a major role towards the peak 
magnitude of ATP-evoked Ca2+ response (described in Chapter 4), the findings in 
this chapter suggested that ATP-induced CXCL5 secretion is a process that may be 
independent of intracellular Ca2+ level.  
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Chapter 6: Discussion  
 
6.1 Overview 
Within the last decade, there has been a growing interest in identifying the role of 
the P2X4 receptor within the immune system. It is without a doubt that, compared to 
other subtypes of P2 receptors, research surrounding P2X4 has been significantly 
hampered due to the lack of commercially available selective antagonists and 
agonists. Targeting of other purinergic receptors such as P2X3, P2Y2 and P2Y12, 
have allowed the discovery and clinical use of several drugs for the treatment of 
conditions like chronic cough, dry eye disease and acute coronary syndrome, 
respectively (Jacobson et al., 2012, Lau et al., 2014). Elucidating the functional role 
of P2X4 in immune cells, such as macrophages, could therefore potentially allow the 
identification of new drug targets for the treatment of inflammatory conditions.  
 
Despite its recurring expression, the role of P2X4 in human macrophages is not well 
defined. Research in mouse macrophages, however, has revealed a regulatory role 
of P2X4 in facilitating P2X7 function. Examples of this include the involvement of 
P2X4 in the release of inflammatory mediators such as prostaglandin E2 (PGE2) 
(Ulmann et al., 2010), and P2X7-mediated autophagy (Kawano et al., 2012b). More 
recently, studies using a mouse macrophage cell line showed that P2X4 is 
responsible for regulating P2X7-mediated inflammation by facilitating the release of 
IL-1b (Kawano et al., 2012a). The interaction between P2X4 and P2X7 has also 
been shown to be important in determining macrophage phenotypic function and 
their ability to clear apoptotic cells following tissue injury (Gu et al., 2013). Despite 
these efforts, the functional roles for P2X4 in human macrophages remain elusive 
and this emphasizes the urgent need for research within this field. Pharmacological 
characterization and a functional role of P2X4 in human macrophages was 
investigated in this thesis using a combination of THP-1 differentiated macrophages 
(TDM) cell model and primary monocyte-derived macrophages (MDM).  
 
Several areas studied in this thesis include:   
A) The contribution of P2X4 towards ATP-evoked Ca2+ response in THP-1 
monocytes versus TDM cells (discussed in Chapter 3).  
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B) The contribution of P2X and P2Y receptors, with focus of P2X4, towards 
ATP-evoked Ca2+ response in primary MDM cells (discussed in Chapter 4). 
C) The role of P2X4 activation in cytokine/chemokine mRNA expression and 
secretion in human primary MDM cells (discussed in Chapter 5). 
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6.2 Key Findings 
 
6.2.1 THP-1 and TDM cell line model 
The first part of the discussion assessed findings generated from chapter 3 which 
focused on verifying pharmacological tools to characterize P2X4 contribution 
towards ATP-evoked intracellular Ca2+ response in THP-1 monocytes and TDM cell 
line model.  
 
THP-1 and TDM cell model express a diverse repertoire of P2XRs  
THP-1 and TDM cells are well established cell line models used for in vitro study of 
human monocytes and macrophages, respectively (Bosshart and Heinzelmann, 
2016, Daigneault et al., 2010, Genin et al., 2015, Qin, 2012). Prior to studying 
intracellular Ca2+ responses in these cells, the expression profile of P2X receptors in 
THP-1 and TDM cells at the mRNA and protein level was investigated. qRT-PCR 
analysis detected mRNA expression of P2X1, P2X4, P2X5, P2X6 and P2X7 in both 
cell types. mRNA expression of P2X2 was detected only in THP-1 cells while P2X3 
was absent in both cell types. Further analysis using non-quantitative RT-PCR 
illustrated that both THP-1 and TDM cells express the non-functional, exon 10-less 
P2X5, which are the predominant receptor isoform expressed in human subjects 
(Kotnis et al., 2010). In addition to this, qRT-PCR data illustrated that P2X1 and 
P2X2 are both down-regulated while P2X4 is up regulated in TDM cells when 
compared to THP-1 cells. No significant differences in mRNA expression were 
observed for P2X5, P2X6 and P2X7 in TDM cells compared to THP-1 cells. Further 
to this, immunocytochemistry was performed to detect protein expression in these 
cells. Using confocal imaging, protein expression of P2X1, P2X4, P2X5 and P2X7 
were all detected and appeared to have a punctate distribution in both cells. P2X2, 
P2X3 and P2X6 were not investigated due to the lack of available selective antibody. 
Although these cell lines are routinely used for the study of primary monocytes and 
macrophages, respectively, there are differences that may need to be considered. 
In this study, there was no significant difference in the mRNA expression of P2X7 in 
THP-1 cells vs. TDM cells. However, primary monocytes have shown up-regulation 
of P2X7 receptor mRNA upon differentiation to macrophages (Ferrari et al., 1999).  
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The detection of mRNA expression of P2X1, P2X4 and P2X7 in these cell lines fits 
with previous reports described within the literature (Into et al., 2002, Kaufmann et 
al., 2005, Li and Fountain, 2012, Wang et al., 2004). However, the differential 
relative mRNA expression of P2X1, P2X2 and P2X4 in the two cell types provide a 
novel finding. Similarly, there has been no prior literature reporting the expression of 
non-functional P2X5 in both THP-1 and TDM cells. Although P2X6 is detected in 
both cell types, it is unlikely to form a functional homotrimer (Barrera et al., 2005). 
Finally, the lack of P2X3 in these cells may be explained by the fact that they are 
predominantly distributed in sensory neurons and smooth muscles (Burnstock and 
Knight, 2004).  
 
ATP evoked an intracellular Ca2+ response in THP-1 and TDM cells  
Intracellular Ca2+ signaling is considered the most prominent signaling pathway 
responsible for various cellular processes like proliferation, apoptosis, differentiation 
and motility (Berridge, 1997, Glaser et al., 2013). The mobilization of Ca2+ in cells 
can be achieved through the activation of P2X and P2Y receptors by nucleotides 
such as ATP (Puchalowicz et al., 2014). Although the involvement of P2X4 in ATP-
evoked intracellular Ca2+ responses in various cell types have been reported 
previously (Glaser et al., 2013, Li and Fountain, 2012, Pubill et al., 2001, Light et al., 
2006), their contribution in THP-1 and TDM cells have not been well explored. To fill 
this gap, ATP dose response on THP-1 and TDM cells was initially performed in the 
presence of extracellular Ca2+ to identify a suitable concentration to maximally 
activate P2X4 in these cells. ATP elicited a concentration-dependent increase in 
intracellular Ca2+ level in both THP-1 and TDM cells that included a rapid peak 
response followed by a gradual return to steady-state elevated phase in THP-1 cells 
and back to the baseline in TDM cells. This intracellular Ca2+ profile is supportive of 
previous studies reported in other cell types (Hashioka et al., 2014, Nobile et al., 
2003, Yamamoto et al., 2000). In both THP-1 and TDM cells, 100 µM ATP caused 
maximum intracellular Ca2+ response and was chosen as the concentration used for 
the rest of the study. The strategy to use 100 µM ATP concentration was also 
supported by the fact that this concentration will maximally activate P2X4 (Li and 
Fountain, 2012) while not sufficient to activate P2X7 (Liang et al., 2015) (Chapter 3 
results). As P2X4 and P2X7 have been demonstrated in the literature to interact 
closely together, it was important to avoid an agonist concentration that activates 
P2X7 to allow characterization of P2X4 (Gu et al., 2013, Kawano et al., 2012b).  
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The side-by-side comparison of ATP-evoked intracellular Ca2+ responses showed a 
clear difference in Ca2+ profiles of the two cell types. The main differences include 
TDM cells having a smaller magnitude of ATP-evoked Ca2+ response as well as a 
significantly faster decay response. These are novel observations, which have not 
been described in literature previously. Although not investigated further in this 
study, several factors may underlie these differences. The first possible explanation 
is a differential expression of P2Y receptors in the two cell types, which can be 
investigated by qRT-PCR and immunocytochemistry studies. A comparison of the 
mRNA and protein level of P2YR has never been performed in THP-1 and TDM 
cells and would be an interesting study to undertake to clarify this matter. Secondly, 
TDM cells may have a higher expression of CD39 for a more efficient breakdown of 
ATP. Although CD39 is well accepted as the major NTPDase expressed by 
monocyte/macrophage system in their cell surface (Cohen et al., 2013, Dwyer et al., 
2007, Pulte et al., 2007), there has been no studies illustrating any differential 
expression in the two cell systems. Therefore, to clarify this matter, it may be 
necessary to perform a qRT-PCR analysis to see any differences in mRNA 
expression of CD39 in the two cell types. Further study to test the effect of selective 
inhibitors of CD39 (i.e. POM-1) (Bastid et al., 2015) to functionally assess this 
theory may also be necessary. Finally, it may be possible that TDM cells possess a 
better Ca2+ buffering capacity than THP-1 cells. Previous studies revealed that 
antibody/FcR generated phagocytosis in macrophages relies on an increase in 
cytosolic Ca2+ concentration (Diler et al., 2014, Lew et al., 1985). Since the process 
of phagocytosis relies on Ca2+ concentration in cells, it may be that professional 
phagocytes like macrophages are equipped to adapt to the changes in Ca2+ level 
better than cells that do not phagocytose (i.e. monocytes).  
 
P2X4 receptor activation, but not P2X1 or P2X7, contributes to U-73122- and 
Tg-resistant Ca2+ response in TDM cells  
ATP is a DAMP signal that can elicit a cellular response by activating both P2X and 
P2Y receptors in cells (Campwala and Fountain, 2013, Tanaka et al., 2014). As the 
main interest of this thesis is to study the contribution of P2X4 towards ATP-evoked 
Ca2+ response, pharmacological tools to block metabotropic P2Y receptor activity 
such as phospholipase C (PLC) inhibitor, U-73122, and SERCA pump inhibitor, Tg, 
were employed for intracellular Ca2+ measurements in THP-1 and TDM cells (Da 
Silva et al., 2008; Liu et al., 2000; Vial et al., 2004). An interesting revelation from 
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the intracellular Ca2+ measurements was that in THP-1 cells, a very small U-73122-
resistant Ca2+ response remained, while Tg completely abolished ATP-evoked 
intracellular Ca2+ responses. Meanwhile, in TDM cells, both U-73122- and Tg-
resistant Ca2+ response appeared more prominent and these responses were 
attenuated in the absence of extracellular Ca2+, suggesting that it is dependent on 
Ca2+ influx. For this reason, the contribution of P2X4 towards ATP-evoked Ca2+ 
response was investigated only in TDM cells.  
 
In TDM cells, treatment with P2X4 positive allosteric modulator, IVM, caused a 
significant potentiation towards the magnitude of both the U-73122- and Tg-
resistant Ca2+ response as well as a delay in the decay kinetics. These observations 
are consistent with studies by Norenberg et al. (2012) illustrating the effect of IVM 
on P2X4-mediated current. In addition to this, P2X4 antagonists, 5-BDBD and PSB-
12062, significantly inhibited the U-73122- and Tg-resistant Ca2+ response in TDM 
cells while P2X1 antagonist, Ro0437626, and P2X7 antagonist, A438079, did not 
appear to have any contribution towards the Ca2+ response. The contribution of 
P2X4 towards the ATP-evoked Ca2+ response in TDM cells were further confirmed 
through shRNA approach whereby P2X4 knockdown resulted in significant reduction 
of Tg-resistant Ca2+ response in TDM cells as well as reduced sensitivity towards 
IVM and PSB-12062. These results confirmed that P2X4 contributes partially to the 
Tg-resistant Ca2+ response in TDM cells and clarify that IVM and PSB-12062 are 
useful pharmacological tools for the study of P2X4. These novel findings are 
valuable as no studies in the past have reported the contribution of P2X4 towards 
ATP-evoked Ca2+ response in TDM cells, although work in THP-1 cells has been 
done (Li and Fountain, 2012). Additionally, as PSB-12062 is considered a new 
antagonist that has not been validated in many studies, these findings 
demonstrated additional evidence of its reliable use in future studies concerning 
P2X4. The reliable use of PSB-12062 can be reflected from three observations in 
this study so far: 1) the use of hP2X4 over-expressing cell line allowed the 
identification that PSB-12062 is more potent in blocking ATP-evoked Ca2+ response 
than 5-BDBD, 2) PSB-12062 blocked IVM-sensitive ATP-evoked Ca2+ response, 
and 3) P2X4 shRNA TDM cells illustrated reduced sensitivity towards PSB-12062 
and IVM.  
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Dependency of ATP-evoked Tg-resistant Ca2+ response on known modulators 
of P2X4 trafficking 
P2X4 in microglial and peripheral macrophages have been reported to be 
predominantly localized within lysosomal compartments, undergoing rapid 
constitutive recycling from the plasma membrane to intracellular compartments 
(Bobanovic et al., 2002, Qureshi et al., 2007, Royle et al., 2002, Toulme et al., 
2006). Activation of P2X4 regulates their trafficking to and from the plasma 
membrane in a Ca2+-dependent manner and studies by Stokes and Surprenant 
(2009) illustrated that plasma membrane expression of P2X4 is regulated by 
clathrin- and dynamin-dependent endocytosis. Data generated from intracellular 
Ca2+ measurements in TDM cells so far have illustrated that P2X4 contributes 
towards the ATP-evoked Tg-resistant Ca2+ response. To further clarify the 
contribution of P2X4, trafficking of lysosomal P2X4 towards the plasma membrane 
was targeted. To study this, dynamin-dependent endocytosis inhibitor (dynasore) 
and lysosomal exocytosis inhibitor (vacuolin-1) was employed.  
 
Stimulation of TDM cells with dynasore caused significant reduction in the 
magnitude of Tg-resistant Ca2+ response while significantly delaying decay 
response and increasing net calcium movement. These data were challenging to 
understand as it allowed two possible conclusions to be made. First, if P2X4 
contributed to the magnitude of the Tg-resistant Ca2+ response, the data illustrated 
that P2X4 expression at the cell surface is likely to be very low, as dynasore 
treatment did not result in potentiation of the Ca2+ response. This speculation fits 
with FACS analysis, which illustrated very low expression of cell surface P2X4 in 
TDM cells. Secondly, dynasore treatment resulted in the potentiation of net calcium 
movement as well as decay kinetics in the same manner as positive allosteric 
modulator IVM. IVM has been shown to act by preventing the internalization of P2X4 
from the plasma membrane (Toulme et al., 2006). This data, therefore, suggests 
that the ATP-evoked Tg-resistant decay response is dependent on dynamin 
resulting in build-up of P2X4 on the plasma membrane. This is supported by studies 
illustrating that dynasore can rapidly enhance translocation of intracellular P2X4 to 
the plasma membrane (Boumechache et al., 2009).  
 
Unfortunately, the observations described above were not confirmed by 
experimental findings using vacuolin-1. Inhibiting lysosomal exocytosis by vacuolin-
1 had no significant effect on the magnitude of both ATP-evoked Ca2+ response in 
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the presence and absence of Tg. However, vacuolin-1 had a significant, although 
small, inhibition towards the net calcium movement of ATP-evoked Ca2+ responses 
in TDM cells. This indicated that the Tg-resistant ATP-evoked Ca2+ response is 
likely to be independent of P2X4 trafficking from lysosomes to plasma membrane. 
Studies within the literature have described that lysosomal P2X4 are not just a 
reserve for regulating availability of P2X4 on the plasma membrane, instead they 
are specifically targeted to the acidic vesicles for unique lysosome-related functions, 
like lysosomal trafficking (Trang and Salter, 2012). It would undoubtedly be 
interesting to investigate if stimulation of TDM cells with dynasore or vacuolin-1 
could affect the protein expression of P2X4 within the cell surface membrane 
through flow cytometry analysis.  
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6.2.2 Human primary MDM cells 
The second part of the discussion assessed findings generated from chapter 4 and 
5 which focused on looking at the contribution of P2X4, and other P2 receptors, 
towards ATP-evoked intracellular Ca2+ response in primary monocyte-derived 
macrophages (MDM): GM-CSF differentiated (GM-MDM) and M-CSF differentiated 
(M-MDM). In addition to this, the role of P2X4 activation in ATP-induced cytokine 
secretion was also investigated.  
 
GM-MDM and M-MDM express various P2X and P2Y receptors at mRNA and 
protein level  
Monocyte-derived macrophages differentiated with colony stimulating factors GM-
CSF (GM-MDM) or M-CSF (M-MDM) are good in vitro models for the study of 
primary human macrophages (Fleetwood et al., 2005, Lacey et al., 2012). Within 
the literature, there is a tendency of using M-MDM as a model for tissue 
macrophages while GM-MDM as a model for dendritic cells (DCs) (Akagawa et al., 
1988, Verreck et al., 2004, Martinez et al., 2006). However, a comprehensive gene 
analysis study and bioinformatics analysis of their transcriptome revealed that GM-
MDM resembles macrophages more than DCs (Crozat et al., 2010, Lacey et al., 
2012, Robbins et al., 2008). While GM-MDM and M-MDM cells are often associated 
with pro-inflammatory M1 macrophages and anti-inflammatory M2 macrophages, 
respectively, no studies have been performed to identify any differences in P2 
receptor profiles within the two types of cells. Here, a side-by-side comparison of 
GM-MDM and M-MDM cells were studied to investigate which is a better model for 
the study of P2X4. 
 
qRT-PCR analysis illustrated that both GM-MDM and M-MDM cells express all 
P2XR apart from P2X2, P2X3 and P2X6, as well as all P2YR apart from P2Y12 and 
P2Y14. Non-quantitative RT-PCR also further illustrated that across N=3 donors, the 
P2X5 detected in human GM-MDM and M-MDM cells are non-functional which is 
supportive of findings by Kotnis et al. (2010). These observations corroborated 
various studies reported within the literature, particularly that in human alveolar 
macrophages which have been shown to express various P2 receptors but lacking 
P2X2, P2X3, P2X6 and P2Y12 receptors (Myrtek et al., 2008). qRT-PCR also 
revealed that although no significant differences were observed in the mRNA 
expression levels for P2XR in both GM-MDM and M-MDM cells, mRNA expression 
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of P2Y1 was found to be down-regulated while P2Y6 and P2Y11 were found to be 
up-regulated in M-MDM cells compared to GM-MDM cells. Immunocytochemistry 
study confirmed the expression of P2XR (P2X1, P2X4, P2X5 and P2X7) and P2YR 
(P2Y1, P2Y2, P2Y6 and P2Y13) at a protein level in both GM-MDM and M-MDM cells. 
These observations are novel findings reporting mRNA and protein expression of 
P2 receptors in human primary macrophage models. These observations would be 
beneficial when choosing a macrophage model to utilize for the study of specific P2 
receptors.  
 
ATP-evoked dose-dependent Ca2+ response in both GM-MDM and M-MDM 
cells  
In both GM-MDM and M-MDM cells, ATP evoked a dose-dependent increase in 
intracellular Ca2+ level in the presence and absence of extracellular Ca2+ with 
maximal response achieved at 100 µM agonist concentration. In the presence of 
100 µM ATP, the Ca2+ profile was significantly different in the two cell types, 
although this was not observed at lower ATP concentrations. In GM-MDM cells, 
responses were biphasic with an initial rapid peak of intracellular Ca2+ response, 
which decayed back to a baseline level. However, in M-MDM cells, a biphasic Ca2+ 
response was observed with an initial rapid peak of intracellular Ca2+ followed by a 
much slower decay response that plateaued to a sustained-elevated phase. This 
was a striking observation which could be explained either by differential expression 
of P2YR or ectonucleotidases (i.e. CD39 and CD73). The latter may be a plausible 
reasoning in support of previous studies reported in resident M1 and M2 
macrophages illustrating that M2 macrophages present increased CD39 and CD73 
expression, compared to M1 macrophages (Zanin et al., 2012). Increased CD39 
and CD73 will result in higher ATP and AMP hydrolysis, respectively, building up 
ADP levels in cells which may activate P2Y receptors in the macrophages. Although 
not further investigated in this study, it would be interesting to perform mRNA and 
protein studies to compare the expression of CD39 in GM-MDM vs. M-MDM cells.  
 
P2Y11 and P2Y13 activation are responsible for the amplitude of ATP-evoked 
intracellular Ca2+ in GM-MDM and M-MDM cells  
In the presence of 100 µM ATP, a prominent difference in the sustained phase of 
intracellular Ca2+ response was observed in M-MDM against GM-MDM cells. One of 
the key hypotheses for this difference is the differential expression of P2YR which 
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may be responsible for the slower decay phase of Ca2+ response, as have been 
described in several literatures (Govindan et al., 2010, Suplat-Wypych et al., 2010). 
The effect of P2Y1, P2Y2, P2Y6, P2Y11 and P2Y13 antagonists were tested on ATP-
evoked Ca2+ response in both cell types. Although ATP does not act as the main 
agonist for some of these P2YR, it is important to note that macrophages express 
CD39 enzymes, which allow the breakdown of ATP into ADP and AMP, which may 
then act on these receptors (Cohen et al., 2013, Dwyer et al., 2007).  
 
In GM-MDM cells, P2Y11 (NF340) and P2Y13 (MRS2211) antagonists both 
significantly inhibited the amplitude of the ATP-evoked Ca2+ response. When 
present together, NF340 and MRS2211 did not completely attenuate the ATP-
evoked intracellular Ca2+ response, but caused an even bigger inhibition than when 
present individually. None of the other P2YR antagonists had any effect on the 
ATP-evoked Ca2+ response in GM-MDM cells. In M-MDM cells, similar findings 
were observed. NF340 and MRS2211 caused a significant inhibition to ATP-evoked 
Ca2+ response while other P2YR had no significant effect. While P2Y13 appear to 
only influence the amplitude of ATP-evoked Ca2+ response in M-MDM cells, P2Y11 
appear to contribute significantly to both the amplitude as well as the sustained 
phase of the ATP-evoked Ca2+ response. This observation is supported by qRT-
PCR analysis illustrating an up-regulation of P2Y11 mRNA expression in M-MDM 
cells compared to GM-MDM cells, although additional work to quantify protein 
expression would be valuable and would provide further confirmation. This 
observation suggests that the activation of P2Y11 is responsible for the delayed 
sustained phase in ATP-evoked Ca2+ response in M-MDM cells. Although there has 
been no clear description of the P2 receptors involved in ATP-evoked Ca2+ 
response in human MDM cells, several studies have revealed that the contributions 
of P2 receptors vary significantly depending on cell types. In human airway 
epithelial cell models, P2Y receptors have been associated in eliciting a transient 
increase in intracellular Ca2+ level that is derived from intracellular stores while in rat 
glioma cells, P2Y receptors have been associated with sustained elevation of Ca2+ 
which occurs through the capacitive Ca2+ entrance mechanism typical for P2Y 
metabotropic receptors coupled to PLC (Suplat-Wypych et al., 2010, Zsembery et 
al., 2003). The latter may be supportive of the observation found in this thesis.  
 
The conclusion so far suggests that both P2Y11 and P2Y13 activation is required for 
the amplitude of the ATP-evoked Ca2+ response in both GM-MDM and M-MDM cells 
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and that P2Y11 contribute significantly to the decay response in M-MDM cells. 
These findings therefore provide novel evidence for the presence of functional 
P2Y11 and P2Y13 in human GM- and M-MDM cells as observed in their ability to 
evoke ATP Ca2+ response. Within the literature, the expression and functional 
characterization of P2 receptor subtypes in macrophages have been described in 
several cell lines. In all murine and rat macrophage cell lines, expression of multiple 
P2X and P2Y subtypes were seen although only P2Y1, P2Y2, P2Y4, P2X4 and P2X7 
receptors were demonstrated functionally through their ability in evoking ATP-
mediated intracellular Ca2+ response (Bar et al., 2008, Bowler et al., 2003, 
Coutinho-Silva et al., 2005). In human alveolar macrophages, only P2Y1, P2Y2, 
P2Y11 and P2X7 have been illustrated to exhibit functional responses in inducing 
intracellular Ca2+ elevation (Myrtek et al., 2008, Jacob et al., 2013). Although there 
are currently no defined roles of P2Y13 in human macrophages, a recent study 
revealed the potential role of P2Y11 activation in macrophage activation. Knockdown 
of P2Y11 significant suppressed polarization of macrophages towards M1-phenotype 
and IL-6 production (Sakaki et al., 2013b). 
 
P2X4 activation, but not P2X1 or P2X7, contributes to both the amplitude and 
sustained phase of ATP-evoked intracellular Ca2+ response in GM-MDM and 
M-MDM  
Intracellular Ca2+ measurements have illustrated the contribution of P2Y11 and 
P2Y13 towards ATP-evoked Ca2+ response in both GM-MDM and M-MDM cells. 
Here, the contribution of P2XR (P2X1, P2X4 and P2X7) towards ATP-evoked Ca2+ 
response was also investigated. The contribution of P2X5 towards ATP-evoked Ca2+ 
response was not investigated in GM-MDM and M-MDM cells since the detected 
isoform corresponds to non-functional receptor while P2X2, P2X3 and P2X6 was not 
investigated due to the absence of mRNA expression. In both GM-MDM and M-
MDM cells, P2X1 (Ro0437626) and P2X7 (A438079) selective antagonists had no 
significant inhibitory effect towards the ATP-evoked intracellular Ca2+ response 
suggesting its limited contribution. This may be explained by the fact that 100 µM 
ATP concentration is not sufficient to activate P2X7 (Chessell et al., 2005, Liang et 
al., 2015). This was also supported by ATP dose response performed on hP2X7 
overexpressing 1321N1 line that illustrated much higher ATP concentration is 
required for the activation of P2X7. This data therefore did not provide evidence for 
a functional P2X1 receptor, which corroborates with studies in human alveolar 
macrophages (Myrtek et al., 2008). To identify the presence of functional P2X7 by 
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assessment of ATP-evoked Ca2+ response, it may be necessary to employ a higher 
ATP concentration. However, as this thesis focuses on characterizing P2X4, it is of 
interest to maintain the use of 100 µM ATP concentration.  
 
The contribution of P2X4 activation towards ATP-evoked Ca2+ response was studied 
using a combination of three pharmacological tools: IVM, 5-BDBD and PSB-12062. 
IVM caused a significant potentiation to the amplitude of the ATP-evoked Ca2+ 
response in both GM-MDM and M-MDM cells but only delayed the sustained phase 
of decay response in GM-MDM cells. The effect of IVM on ATP-evoked Ca2+ 
response in GM-MDM cells corroborates previous studies illustrating the two 
hallmark effects of IVM on P2X4-mediated currents: 1) potentiation of current and 2) 
delay of decay kinetic (Norenberg et al., 2012). However, it is worth noting that IVM 
has previously been described to also potentiate the peak of P2X7-mediated 
current. However, the effect of IVM on delaying decay response is known to be 
specific to P2X4. Interestingly, in M-MDM cells, IVM only had a significant effect on 
the amplitude of the ATP-evoked Ca2+ response suggesting that there is potentially 
minimal contribution of P2X4 activation towards the sustained decay phase of the 
Ca2+ response or the possibility of IVM acting on P2X7 instead. The latter seemed 
unlikely as the agonist concentration used in these experiments is unlikely to be 
sufficient to activate P2X7 and A438079 had no effect on the ATP-evoked Ca2+ 
response (Chessell et al., 2005, Liang et al., 2015). The effect of P2X4 antagonists, 
5-BDBD and PSB-12062, was tested to provide further evidence of P2X4 
contribution. In GM-MDM cells, PSB-12062 significantly inhibited the magnitude and 
decay response of ATP-evoked Ca2+ response. Meanwhile, in the presence of IVM, 
PSB-12062 only inhibited the decay response. In M-MDM cells, PSB-12062 had a 
slightly different effect whereby it significantly inhibited only the magnitude of the 
ATP-evoked Ca2+ response in both presence and absence of IVM. 5-BDBD had a 
similar effect in both cell types whereby it caused an inhibition towards the 
amplitude of the ATP-evoked Ca2+ response. In the presence of IVM, 5-BDBD 
caused an inhibition towards both amplitude and decay response. These data 
altogether suggest that P2X4 is likely to contribute to both the amplitude and the 
second decay phase of the ATP-evoked Ca2+ response. Its contribution towards the 
second decay phase of the Ca2+ response may be supported by observations that 
while P2YR elicit a transient Ca2+ response derived from intracellular store, P2XR 
trigger a sustained Ca2+ response allowing Ca2+ influx from extracellular space 
(Zsembery et al., 2003).  
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P2X4 activation has a greater contribution to Ca2+ response in GM-MDM cells 
in comparison to M-MDM cells 
The experimental study involving the characterization of P2X4 in human primary 
monocyte-derived macrophages allowed the identification to which of the two MDM 
systems can serve as a better model to study functional P2X4. The two macrophage 
systems clearly displayed differences in morphology, P2 mRNA expression profiles 
and most importantly, ATP-evoked Ca2+ response features. There are currently no 
reports within the literature illustrating the contribution of P2X4 to ATP-evoked Ca2+ 
responses in both macrophage model. P2X4 has previously been speculated to be a 
pro-inflammatory receptor (Li and Fountain, 2012), it is therefore important to 
identify if pro-inflammatory M1 macrophages, GM-MDM, would serve as a better 
tool to study these receptors.  
 
As discussed previously, the utilization of P2X4 specific pharmacological tools 
allowed the revelation that P2X4 mainly contributed towards the decay phase of the 
ATP-evoked Ca2+ response, although it also had a small contribution towards the 
magnitude of the response. This was illustrated from Ca2+ measurements following 
the treatment of IVM, PSB-12062 and 5-BDBD. The use of PSB-12062 in the 
presence and absence of IVM illustrated that M-MDM cells are less sensitive 
towards the antagonist, compared to GM-MDM cells. The difference in sensitivities 
towards P2X4 antagonist may be due to the level of expression of P2X4 in the two 
cell types. Although qRT-PCR analysis illustrated no difference in P2X4 mRNA 
expression in GM-MDM and M-MDM cells, protein expression was found to be 
significantly different as quantified using FACS analysis. FACS studies illustrated 
that M-MDM cells expresses significantly lower amount of surface and total P2X4, 
compared to GM-MDM cells. There are currently no studies reporting the different 
level of protein expression of P2X4 in GM-MDM and M-MDM cells and this would 
provide valuable knowledge to researchers interested in the study of P2X4. 
Altogether, these findings illustrate that compared to M-MDM cells, GM-MDM cells 
provide a better model for the study of P2X4. In addition to this, if employed at 
reliable concentrations, PSB-12062 and IVM are valuable pharmacological tools 
that can be used for the characterization of P2X4.  
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ATP stimulation causes the induction of cytokine gene expression in GM-
MDMs 
To study the role of P2X4 activation in cytokine and chemokine secretion, an RT 
profiler array was performed to screen over 84 different genes of cytokines and 
chemokines that are associated with inflammatory responses. In the absence of 
extracellular agonist, ATP, GM-MDM cells constitutively expressed all the 
investigated genes apart from BMP4, CCL19, CXCL11, CXCL12, IFNG, IL12A, 
IL17A, IL2, TNFRS11B and XCL1. Following 6h stimulation with 100 µM ATP, 
several genes (CXCL2, CXCL5, IL-12b, OSM, PPBP and TGFb2) that have been 
associated with macrophages in the literature were found to be significantly up-
regulated. Apart from PPBP, these cytokines and chemokines have been 
demonstrated to be important inflammatory mediators that are expressed or 
secreted by human macrophages. 
 
- Tissue macrophages have been reported to synthesize CXCL2 in response 
to LPS stimulation. These are important chemokines for neutrophil 
recruitment during tissue inflammation (De Filippo et al., 2013). It has also 
been described that CXCL2 expression in macrophages is a process 
dependent on the NF-kb pathway (De Plaen et al., 2006). In addition to this, 
studies in mice revealed that injection of extracellular ATP intraperitoneally 
resulted in increased numbers of neutrophils within peritoneal cavity as well 
as increased levels of CXCL2 level in peritoneal lavage fluid (Kawamura et 
al., 2012). The increase of level of CXCL2 in mice has been demonstrated to 
be a process dependent on P2X7 and P2Y2 activation (Kawamura et al., 
2012). This finding is supportive of the finding within this thesis illustrating 
ATP induction of CXCL2 in human GM-MDM cells.  
- mRNA analysis in this thesis illustrated that ATP induced mRNA expression 
of IL-12b in GM-MDM cells. IL-12 is a cytokine produced primarily by APCs 
like macrophages and DCs (Ma et al., 2015) playing a role in activating NK 
cells and inducing the differentiation of naïve CD4 T lymphocytes. Our 
observation that ATP induced IL-12b expression in GM-MDM cells is 
contradictory to what was observed in a study involving peritoneal 
macrophages (Hasko et al., 2000). Pre-treatment with extracellular ATP was 
shown to reduce LPS-induced IL-12 production in macrophages as well as 
IL-12 (p35 and p40) mRNA expression.  
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- Oncostatin M (OSM) is an inflammatory cytokine belonging to IL-6 family 
produced by macrophages (Guihard et al., 2015). Within the literature to 
date, there are no studies reporting the ability of ATP stimulation to induce 
OSM mRNA expression in human macrophages and the data illustrated in 
this thesis may uncover OSM as a potential cytokine to investigate. Earlier 
investigation by Ganesh et al. (2012) illustrated that treatment of TDM cells 
with PGE2 resulted in a dose-dependent induction of anti-inflammatory OSM. 
This is an extremely interesting observation as P2X4 has been demonstrated 
to mediate PGE2 release by tissue resident macrophages to initiate 
inflammatory pain. Unfortunately, in the context of this thesis, OSM was not 
investigated further.  
 
It is without a doubt that one of the main limitations of this profiler array study is the 
use of only one time point to screen for changes in mRNA expression following ATP 
stimulation in GM-MDM cells. Different cytokines and chemokines genes have been 
shown to differ in their gene expression kinetics (Leyva-Illades et al., 2012, 
Sadahiro et al., 2007), however, it was not possible to screen for various time points 
due to difficulty in obtaining cell numbers. Altogether, IL-12b, OSM and CXCL2 are 
potentially interesting inflammatory mediators but were not pursued in the study of 
this thesis due to filtering criteria. In brief, as part of the filtering criteria, GM-MDM 
cells were stimulated with either PSB-12062 alone or in the presence of agonist 
ATP. Only genes that were unaffected by treatment with P2X4 antagonist, PSB-
12062, alone were investigated further and this yielded CXCL5 and TGF-b2 as 
potential candidates, which will be discussed more thoroughly within each section 
below.  
 
Blocking P2X4 increased ATP-induced TGF-b2 mRNA expression but not 
secretion 
One candidate gene that was investigated further from the RT2 profiler array study 
is one of the TGF-b isoforms, TGF-b2. Within the literature so far, there are several 
studies associating TGF-b and human macrophages although the involvement of 
purinergic receptors have not been explored in detail. TGF-b signaling is known to 
play a critical role in the promotion and polarization of anti-inflammatory M2 
macrophages (Roszer, 2015, Gong et al., 2012). It has been reported that 
inflammatory macrophages, such as those found in human and murine 
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atherosclerotic lesions, express TGF-b1 and its receptors and that macrophage 
specific TGF-b1 overexpression play a role in reducing and stabilizing 
atherosclerotic plaques in ApoE-deficient mice (Reifenberg et al., 2012). Although 
the predominant isoform being explored in literature is TGF-b1, TGF-b2 has also 
been associated with macrophages, although to a much smaller extent. Studies in 
human and murine intestinal tissue samples demonstrated that TGF-b2 suppresses 
macrophage cytokine production and mucosal inflammatory response (Maheshwari 
et al., 2011).  
 
Here, stimulation of GM-MDM cells with 100 µM ATP resulted in an increase in 
TGF-b2 mRNA expression, peaking at 6h. In the presence of P2X4 antagonist, PSB-
12062, ATP-induced TGF-b2 mRNA expression was significantly potentiated 
suggesting that P2X4 negatively regulate the mRNA expression level of TGF-b2. 
The effect of PSB-12062 on ATP-induced TGF-b2 mRNA expression mimic findings 
by a recent study illustrating that lack of P2X4 expression leads to increased renal 
fibrosis and increased expression of TGF-b (Kim et al., 2014). In addition to this, 
since P2X4 has previously been described as pro-inflammatory receptor, it may be 
speculated that blocking P2X4 resulted in increased expression of TGF-b,  a known 
regulator for anti-inflammatory M2 macrophage activation (Li and Fountain, 2012). 
However, it was a surprising finding that these significant changes of mRNA 
expression did not translate to protein level. In fact, no TGF-b2 protein was present 
at a detectable level within the preconditioned supernatant across 4 independent 
donors. Several explanations may justify this: 1) Poor protein stability or high 
degradation rate of TGF-b2 proteins due to post-translational modifications; 2) post-
transcriptional modifications of mRNA; 3) translation of mRNA is inhibited due to 
tight regulation within the cell causing no final synthesis of native protein; or 4) 
insufficient agonist concentration to allow the synthesis and secretion of protein. 
Although none of these theories have been confirmed, it has been reported that 
only a few primary cells and established cell lines secrete significant amounts of 
active TGF-b into culture medium under well-optimized conditions (Mazzieri et al., 
2000). Otherwise, little, if any, soluble active TGF-b is generated by most cultured 
cells and therefore, the absence of detectable levels of active TGF-b in medium is 
not surprising. Despite undetectable levels of TGF-b in supernatants, this does not 
necessarily imply a lack of TGF-b activation for two reasons: 1) in certain cases 
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TGF-b activation takes place at the cell surface therefore generating a high local 
concentration of active TGF-b (Sato et al., 1990, Dennis and Rifkin, 1991, Munger 
et al., 1999) and 2) active TGF-b may be cleared from supernatant by binding to cell 
surface receptor resulting in protein levels at undetectable levels (Mazzieri et al., 
2000). One potential solution for this would be to utilize a highly sensitive 
experimental tool to detect active TGF-b such as the use of reporter cells co-
cultured with activating cells (Crawford et al., 1998).  
 
Blocking P2X4 inhibited ATP-induced CXCL5 mRNA expression, protein 
secretion and synthesis  
Another candidate that was further investigated following the profiler array study 
was chemokine CXCL5. There are currently limited studies associating CXCL5 with 
human macrophages. A few examples include high level of expression and 
secretion of chemokine CXCL5 in the macrophage fraction of white adipose tissue 
(WAT) (Chavey and Fajas, 2009) and in monocyte-derived macrophages of normal 
donors that have been infected with HIV-1 (Guha et al., 2015). CXCL5 is a 
chemokine and adipokine that has been implicated in neutrophil recruitment and 
promotion of obesity by inhibiting insulin signaling (Sepuru et al., 2014). More recent 
studies by Li et al. (2016) showed that activation of the TLR9/MyD88/CXCL5 
signaling network by resident macrophages of the heart promote the recruitment of 
neutrophil and that CXCL5 functions to limit macrophage foam cell formation in 
conditions like atherosclerosis (Rousselle et al., 2013). Despite the link between 
CXCL5 and human macrophages, it is unknown if MDMs can synthesize and 
secrete CXCL5 following stimulation with a DAMP signal, ATP, and if P2X4, or any 
other P2 receptors, can contribute to this signaling pathway.  
 
Stimulation of GM-MDM cells with 100 µM ATP caused a time-dependent increase 
in mRNA expression and protein secretion of CXCL5. These are novel findings as 
to date, there has been no report illustrating the ability of GM-MDM cells to 
synthesize and secrete CXCL5 in response to stimulation with ATP. Blocking of 
P2X4 with PSB-12062 resulted in a significant reduction of ATP-induced CXCL5 
mRNA expression and protein secretion. To further confirm the involvement of P2X4 
in ATP-induced CXCL5 secretion, the dose response of PSB-12062 (1, 5 and 10 
µM) and IVM was tested. Lower concentrations of PSB-12062 (1 µM and 5 µM), 
which have been shown to be selective for P2X4 over P2X7, were able to still cause 
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a significant inhibition towards ATP-induced CXCL5 protein secretion. Reciprocally, 
treatment with IVM caused a significant potentiation towards ATP-induced CXCL5 
secretion in GM-MDM cells at 48h time point. The effect of PSB-12062 was also 
tested on ATP-induced synthesis of CXCL5 in GM-MDM cells. At 32h and 48h, 
blocking P2X4 caused a significant inhibition of ATP-induced CXCL5 synthesis. 
Taken together, the effect of IVM and PSB-12062 on ATP-induced CXCL5 
expression and secretion is promising and may suggest a role of P2X4 as a 
modulator of CXCL5 levels in human macrophages. These observations may 
corroborate with previous studies whereby in vitro treatment of HUVECs with 
atorvastatin significantly reduced IL-1b-induced CXCL5 levels in a dose-dependent 
manner (Zineh et al., 2008). Though no clear relationship has been associated 
between P2X4 and CXCL5, a study by Li and Fountain (2012)  illustrated 
suppression of P2X4 activity by fluvastatin in human monocytes through depletion of 
cholesterol levels. It may therefore be possible that the statin is affecting the level of 
CXCL5 indirectly through the P2X4 receptor. Despite the potentially interesting link, 
this was contradicted by a study illustrating that depletion of plasma membrane 
cholesterol did not adversely affect IL-1b secretion in response to ATP (Brough and 
Rothwell, 2007).  
 
Possible interactions of P2X4 and CXCL5 
CXCL5 has been shown to activate ERK, JNK and p38 MAPK signaling pathways, 
all of which are key players in tumour growth and metastasis (Dai et al., 2016). In 
the context of inflammatory diseases, CXCL5 have been shown to contribute to the 
pathologies of cardiovascular disease, pulmonary fibrosis and rheumatoid arthritis. 
Analysis of bronchoalveolar lavage fluid and lung tissue revealed elevated levels of 
CXCL5 were identified in patients with idiopathic pulmonary fibrosis (Strieter et al., 
2007). In the context of cardiovascular conditions, CXCL5 has been shown to offer 
an atheroprotective role by enhancing cholesterol efflux capacity in macrophages, 
thus regulating foam cell formation (Rousselle et al., 2013). In addition to this, 
treatment of HUVECs with atorvastatin in vitro resulted in the reduction of IL-1b-
induced CXCL5 in a dose-dependent manner (Zineh et al., 2008). Finally, an 
increase in CXCL5 levels have been detected in synovial fluid of patients suffering 
from rheumatoid arthritis (Koch et al., 1994). Rat adjuvant-induced arthritis (AIA) 
models for the study of arthritis showed elevated CXCL5 levels in their serum with 
progression of arthritis when compared to control animals. Pre-treatment of rats with 
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anti-CXCL5 antibody resulted in a significant reduction in severity of the disease 
(Halloran et al., 1999), suggesting that CXCL5 play an important role in the onset 
and progression of rheumatoid arthritis. Although the mechanism by which P2X4 
receptor activation modulates expression and secretion of CXCL5 in human MDM 
has not been investigated in this current study, several speculations can be made.  
 
First of all, studies by Song et al. (2013) illustrated that the pro-inflammatory 
chemokine CXCL5 was found to be rapidly upregulated by local presence of IL-1b 
and that its action was potentiated by MMP-2 and MMP-9, working synergistically to 
initiate neutrophil recruitment (Song et al., 2013). It is thought that the inflammatory 
cytokine IL-1b induces CXCL5 expression by the activation of NF-kB and CREB 
(Sun et al., 2008). Furthermore, evidence obtained from structural and functional 
studies revealed possible interactions of P2X4 and P2X7 and that P2X4 expression 
facilitated P2X7-dependent IL-1b release in mouse dendritic cells (Perez-Flores et 
al., 2015, Sakaki et al., 2013a). It may therefore be possible that P2X4 receptor 
activation modulates ATP-induced CXCL5 secretion by regulating IL-1b levels 
(Figure 6). As our data here illustrated that P2X7 activation had no significant effect 
on ATP-induced CXCL5 secretion, it may be interesting in future studies to identify if 
P2X4 can work independently.	
 
Secondly, the precursor of CXCL5 is made up of 114 amino acids which contain a 
signal peptide of 36 amino acids. The signal peptide can be cleaved to generate the 
mature protein containing 78 amino acids, hence the name ENA-78 (Walz et al., 
1997). Upon the generation of mature protein, human CXCL5 can act as a target for 
several proteases such as matrix metalloproteases (MMP-1, MMP-9, MMP-12 and 
MMP-25), which can cleave the N-terminal region resulting in either activation or 
inactivation of the chemokine (Van Den Steen et al., 2003, Dean et al., 2008, Starr 
et al., 2012). It is unknown whether P2X4 receptor can interact directly with CXCL5 
or interact with proteases responsible for the generation of the mature chemokine 
such as cysteine cathepsins (Repnik et al., 2015). Taking the P2X7 receptor as an 
example, it has been illustrated that their activation in macrophages in response to 
extracellular ATP results in the induction of NLRP3 inflammasome assembly and 
caspase-1-dependent processing and release of IL-1b (Brough and Rothwell, 2007, 
Gombault et al., 2012, Karmakar et al., 2016). This leads us to speculate that one 
route that P2X4 can modulate chemokine CXCL5 level is through their interaction 
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with proteases resulting in the modulation of CXCL5 processing and release in 
human macrophages. However, this is a speculation made in the assumption that 
the CXCL5 ELISA used throughout the study selectively detects and quantifies 
mature CXCL5. Although the ELISA kit employed in this study was tested and 
validated for the detection of mature CXCL5, it is unclear if it can also detect 
immature CXCL5. Therefore, to further study the mechanism of interaction between 
P2X4 and CXCL5, it may be interesting to utilize other biological assays such as 
western blots which will allow the distinction of the two forms of protein. Further 
studies will undoubtedly be required to unravel the mechanism by which P2X4 
regulates CXCL5 synthesis and secretion in human macrophages.  
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Figure 6. Suggested downstream signaling pathway of P2X4 activation 
following ATP stimulation in human macrophages. In green is the speculated 
downstream pathway following activation of P2X7 with 100 µM ATP as described in 
the literature. ATP activates P2X7 receptor which leads to the activation of NLRP3 
inflammasome and caspase-1 which can activate IL-1b. In red is the speculated 
downstream pathway following activation of P2X4 with 100 µM ATP as hypothesized 
from this research. ATP activates P2X4 receptor which leads to increase in 
intracellular Ca2+ level in the cell. P2X4 activation modulates the expression, 
secretion and synthesis of CXCL5 although the pathway involved has not been 
identified. On the other hand, P2X4 activation negatively modulates the gene 
expression of TGF-b2 as illustrated with the effect of selective antagonist PSB-
12062. Dashed lines represent possible interaction but with unknown pathway.  
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ATP-induced CXCL5 protein secretion is independent of intracellular Ca2+ 
level 
In addition to studying P2X4 contribution towards ATP-induced CXCL5 protein 
secretion, several other P2 receptors were investigated based on their contribution 
towards ATP-evoked Ca2+ response. The effect of P2Y11 (NF340) and P2Y13 
(MRS2211) antagonists were studied as they both significantly inhibited the 
amplitude of ATP-evoked Ca2+ response, while P2X7 antagonist (A438079) was 
studied mainly because P2X4 and P2X7 have been described to work in close 
relationship (Gu et al., 2013, Kawano et al., 2012a). Treatment of cells with 
A438079 had no significant effect towards ATP-induced CXCL5 secretion in GM-
MDM cells. This was a surprising observation as P2X4 has been closely associated 
with P2X7, especially in the context of cytokine secretion such as IL-1b. However, 
this is likely due to the fact that 100 µM ATP is not sufficient to cause the activation 
of P2X7..In addition to this, treatment of GM-MDM cells with NF340 and MRS2211 
had no significant effect on secretion of CXCL5 at 48h following ATP stimulation. 
These observations suggest that P2Y11 and P2Y13 are not responsible for the 
regulation of ATP-induced CXCL5 secretion in GM-MDM cells and that the 
secretion of CXCL5 may involve a pathway that is independent of intracellular Ca2+ 
level.  
 
This observation also leads us to speculate what the mode of action of P2X4 
antagonist (PSB-12062) is. In the literature so far, PSB-12062 has been described 
as an antagonist with an allosteric nature although its binding site has not been 
identified. The fact that CXCL5 secretion appears to be a process independent of 
intracellular Ca2+ level, it may be that PSB-12062 permeates through the membrane 
and acts intracellularly. Another plausible assumption would be that P2X4 is 
localized within intracellular compartments with CXCL5 and may interact directly, 
which can be investigated through co-staining of P2X4 and CXCL5. 
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6.3 Concluding Remarks  
The main purpose of this study was to characterize the contribution of P2X4 towards 
ATP-evoked Ca2+ responses in the TDM cell line and primary human MDM as well 
as elucidating a role of P2X4 activation towards cytokine and chemokine secretion 
in primary macrophages. In this study, TDM was used for the sole purpose of 
verifying the pharmacological tools commercially available for the characterization 
of P2X4-mediated Ca2+ influx in macrophages. Intracellular Ca2+ measurements in 
TDM cells highlighted both IVM and PSB-12062 as valuable tools for the study of 
P2X4 receptor. In addition to this, this thesis also allowed the demonstration that 
both P2XR and P2YR are responsible for ATP-evoked intracellular Ca2+ response in 
human GM-MDM and M-MDM cells. Although both MDM systems can prove to be 
useful tools for the study of different macrophage phenotype (i.e. pro- or anti-
inflammatory), P2X4 had a bigger contribution towards the ATP-evoked intracellular 
Ca2+ response in GM-MDM cells. Finally, the highlight of this study came with our 
observation that ATP, a DAMP signal, can induce the synthesis and secretion of 
chemokine CXCL5 in GM-MDM cells and that P2X4 modulates this process. 
Although additional work will undoubtedly be required to uncover the mechanism 
involved in P2X4-CXCL5 interaction in human macrophages, the current study has 
highlighted a novel role of P2X4 in human macrophages and its contribution towards 
chemokine secretion. 
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6.4 Future Directions  
This study has reflected the importance of P2X4 towards ATP-evoked Ca2+ 
response and CXCL5 secretion in human macrophages. However, many questions 
remain unexplored and further studies are undoubtedly required. It is without a 
doubt that the next step required to follow up this finding is identifying the 
mechanism involved in the regulation of CXCL5 synthesis and secretion by P2X4. It 
may be relevant to initially identify if there is a link between IL-1b and CXCL5 level 
in human macrophages. Further to this, it is unknown if P2X4 is working with other 
P2 receptors to modulate ATP-evoked CXCL5 synthesis and secretion. Here, the 
contributions of other receptors (P2X7, P2Y11 and P2Y13) were investigated allowing 
the conclusion that ATP-evoked CXCL5 secretion is potentially independent of 
intracellular Ca2+ level. It would be interesting to investigate the contributions of 
other ATP-activated P2 receptors such as P2Y2. Finally, one of the main limitations 
is that this study relied on the selectivity and specificity of antagonists and 
modulators and knocking down P2X4 in human primary macrophages would 
definitely provide further confirmation. Although challenging, successful transduction 
of lentiviral particles have been described in human macrophages (Leyva et al., 
2011, Zeng et al., 2006). 
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Appendix: Supplementary Data 
 
Supernatant sample Absorbance at 490nm (OD490) LDH activity (µU) 
Donor 32 24h unstim 0.194 13.42 
Donor 32 24h PSB-12062 0.199 18.00 
Donor 32 32h unstim 0.206 23.92 
Donor 32 32h PSB-12062 0.210 26.75 
Donor 32 48h unstim 0.201 19.25 
Donor 32 48h PSB-12062 0.198 16.75 
Donor 33 24h unstim 0.097 Negative value 
Donor 33 24h PSB-12062 0.128 Negative value 
Donor 33 32h unstim 0.101 Negative value 
Donor 33 32h PSB-12062 0.072 Negative value 
Donor 33 48h unstim 0.103 Negative value 
Donor 33 48h PSB-12062 0.121 Negative value 
Donor 34 24h unstim 0.180 Negative value 
Donor 34 24h PSB-12062 0.089 Negative value 
Donor 34 32h unstim 0.088 Negative value 
Donor 34 32h PSB-12062 0.094 Negative value 
Donor 34 48h unstim 0.089 Negative value 
Donor 34 48h PSB-12062 0.084 Negative value 
 
Table A1. Assessing toxicity of 10 µM P2X4 antagonist, PSB-12062, on 100 µM 
ATP-induced CXCL5 secretion at varying time points using LDH Cytotoxicity 
Assay. Data are represented as individual donors (N=3 donors) across varying time 
points (24h, 32h and 48h). The sensitivity of LDH Cytotoxicity Assay kit allowed the 
measurement of any LDH activity ranging from 31.25 – 1000 µU. Unstim refers to 
negative control where cells are treated with vehicle (0.5% DMSO), negative value 
refers to no LDH activity detected due to absorbance reading obtained at 490nm 
being found below the minimum read-out of the standard curve.  
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Figure A1. Gene stability ranking. Comparison of reference genes as evaluated 
using: A) DDCt method (N=5 donors), B) NormFinder (N=5 donors), C) GeNorm 
(N=5 donors), and D) Overall comprehensive gene stability ranking (N=5 donors). 
Assessment was performed using the RefFinder online database tool. As shown on 
here, housekeeping genes GAPDH and RPLP0 were shown to be the most stably 
expressed genes in primary human GM-MDM cells. Meanwhile, ACTB and HPRT1 
were found to be the least stably expressed genes by all methods. Therefore, for 
further gene expression studies in GM-MDM cells, GAPDH will be used as a 
reference gene to normalize all gene expression data. 
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Figure A2. Effect of 10 µM P2X7 antagonist, A438079, on 100 µM ATP-induced 
CXCL5 secretion. A – C) Effect of A438079 on ATP-induced CXCL5 secretion at 
48h time point for individual donors (N=3 donors). Data is normalized to amount of 
secreted CXCL5 in the presence of 100 µM ATP alone. Unstim represents cells in 
the presence of vehicle only, as background control.  
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Figure A3. Effect of 10 µM P2Y11 antagonist, NF340, on 100 µM ATP-induced 
CXCL5 secretion. A – C) Effect of NF340 on ATP-induced CXCL5 secretion at 48h 
time point for individual donors (N=4 donors). Data is normalized to amount of 
secreted CXCL5 in the presence of 100 µM ATP alone. Unstim represents cells in 
the presence of vehicle only, as background control.  
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Figure A4. Effect of 10 µM P2Y13 antagonist, MRS2211, on 100 µM ATP-
induced CXCL5 secretion. A – C) Effect of NF340 on ATP-induced CXCL5 
secretion at 48h time point for individual donors (N=5 donors). Data is normalized to 
amount of secreted CXCL5 in the presence of 100 µM ATP alone. Unstim 
represents cells in the presence of vehicle only, as background control.  
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Figure A5. Effect of 3 µM P2X4 positive allosteric modulator, IVM, on 100 µM 
ATP-induced CXCL5 secretion. A – C) Effect of NF340 on ATP-induced CXCL5 
secretion at 48h time point for individual donors (N=6 donors). Data is normalized to 
amount of secreted CXCL5 in the presence of 100 µM ATP alone. Unstim 
represents cells in the presence of vehicle only, as background control.  
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